

- <sup>9</sup>Berlin Institute of Health at Charité Universitätsmedizin Berlin, Center for Regenerative<br>30 Therapies (BCRT), Berlin, Germany.<br>31
- 30 Therapies (BCRT), Berlin, Germany.<br>31<br>32<br>33
- 
- 
- 32<br>33<br>34 --<br>33<br>34<br>35
- 34
- 35
- 34<br>35<br>36
- 35<br>35<br>36<br>37 36
- --<br>36<br>37<br>38 37
- --<br>37<br>38<br>39 --<br>38<br>39<br>40 38
- 39
- --<br>39<br>40<br>41 40
- --<br>40<br>41<br>42 --<br>41<br>42<br>43 41
- 42
- 42<br>43<br>44 43
- --<br>43<br>44<br>45 44<br>45<br>46 44
- --<br>45<br>46<br>47 45
- 46
- 46<br>47<br>48 --<br>47<br>48<br>49 47
- --<br>48<br>49<br>50 48
- 49
- --<br>49<br>50<br>51 --<br>50<br>51<br>52 50  $51$
- 51<br>52<br>53  $52$
- --<br>52<br>53 53<br>|
| 53

54 **Abstract**<br>55 The develo<br>56 melanoma p<br>57 involved in The development of brain metastases hallmarks disease progression in 20-40% of<br>56 melanoma patients and is a serious obstacle to therapy. Understanding the processes<br>57 involved in the development and maintenance of melano melanoma patients and is a serious obstacle to therapy. Understanding the processes<br>involved in the development and maintenance of melanoma brain metastases (MBM) is<br>critical for the discovery of novel therapeutic strategi involved in the development and maintenance of melanoma brain metastases (MBM) is<br>critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome<br>and methylome profiles of MBM showing high or l critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome<br>and methylome profiles of MBM showing high or low abundance of infiltrated Iba1<sup>high</sup> tumor-<br>associated microglia and macrophages and methylome profiles of MBM showing high or low abundance of infiltrated Iba1<sup>high</sup> and methylome profiles of MBM showing high or low abundance of infiltrated lba1<sup>nigh</sup> tumor-<br>50 associated microglia and macrophages (TAMs). Our survey identified potential prognostic<br>51 markers of favorable disease course associated microglia and macrophages (TAMs). Our survey identified potential prognostic<br>61 markers of favorable disease course and response to immune checkpoint inhibitor (ICi)<br>62 therapy, among them *APBB1IP* and the inte markers of favorable disease course and response to immune checkpoint inhibitor (ICi)<br>for therapy, among them *APBB1IP* and the interferon-responsive gene *ITGB7*. In MBM with high<br>ITGB7/APBB1IP levels, the accumulation of therapy, among them *APBB1IP* and the interferon-responsive gene *ITGB7*. In MBM with high<br>ITGB7/APBB1IP levels, the accumulation of TAMs correlated significantly with the immune<br>score. Signature-based deconvolution of MBM ITGB7/APBB1IP levels, the accumulation of TAMs correlated significantly with the immune<br>score. Signature-based deconvolution of MBM via single sample GSEA revealed enrichment<br>of interferon-response and immune signatures an score. Signature-based deconvolution of MBM via single sample GSEA revealed enrichment<br>of interferon-response and immune signatures and revealed inflammation, stress and MET<br>receptor signaling. MET receptor phosphorylation of interferon-response and immune signatures and revealed inflammation, stress and MET<br>receptor signaling. MET receptor phosphorylation/activation maybe elicited by inflammatory<br>processes in brain metastatic melanoma cells receptor signaling. MET receptor phosphorylation/activation maybe elicited by inflammatory<br>processes in brain metastatic melanoma cells via stroma cell-released HGF. We observed<br>phospho-MET<sup>Y1234/1235</sup> in a subset of MBM a processes in brain metastatic melanoma cells via stroma cell-released HGF. We observed<br>phospho-MET<sup>Y1234/1235</sup> in a subset of MBM and observed marked response of brain<br>metastasis-derived cell lines (BMCs) that lacked drug phospho-MET<sup>Y1234/1235</sup> phospho-MET<sup>Y1234/1235</sup> in a subset of MBM and observed marked response of brain<br>metastasis-derived cell lines (BMCs) that lacked druggable BRAF mutations or developed<br>resistance to BRAF inhibitors (BRAFi) *in vivo* to MET metastasis-derived cell lines (BMCs) that lacked druggable BRAF mutations or developed<br>resistance to BRAF inhibitors (BRAFi) *in vivo* to MET inhibitors PHA-665752 and ARQ197<br>(tivantinib). In summary, the activation of MET resistance to BRAF inhibitors (BRAFi) *in vivo* to MET inhibitors PHA-665752 and ARQ197<br>(tivantinib). In summary, the activation of MET receptor in brain colonizing melanoma cells by<br>stromal cell-released HGF may promote t (tivantinib). In summary, the activation of MET receptor in brain colonizing melanoma cells by<br>stromal cell-released HGF may promote tumor cells self-maintenance and expansion might<br>counteract ICi therapy. Therefore, thera stromal cell-released HGF may promote tumor cells self-maintenance and expansion might<br>counteract ICi therapy. Therefore, therapeutic targeting of MET possibly serves as promising<br>strategy to control intracranial progressi counteract ICi therapy. Therefore, therapeutic targeting of MET possibly serves as promising<br>strategy to control intracranial progressive disease and improve patient survival.<br>**Key words:** Melanoma, brain metastasis, TAMs, 574 strategy to control intracranial progressive disease and improve patient survival.<br>
75 **Key words:** Melanoma, brain metastasis, TAMs, interferon signaling, MET recep<br>
76

**75 Key words:** Melanoma, brain metastasis, TAMs, interferon signaling, MET receptor<br>76<br>77

- 
- 
- 

77<br>78<br>79 78<br>79 . .<br>79

79

 $\overline{3}$ 

80 **Introduction**<br>81 The interaction of<br>82 mainly comprising<br>83 oligodendrocytes The interaction of brain colonizing tumor cells with the tumor microenvironment (TME),<br>mainly comprising innate and adaptive immune cells, microglia, astrocytes, neurons and<br>oligodendrocytes crucially determines the develo mainly comprising innate and adaptive immune cells, microglia, astrocytes, neurons and<br>
83 oligodendrocytes crucially determines the developmental stages of brain metastases (BM).<br>
84 Brain metastases are observed in 20 – 83 oligodendrocytes crucially determines the developmental stages of brain metastases (BM).<br>84 Brain metastases are observed in  $20 - 40\%$  of melanoma patients during the course of<br>85 disease and micrometastases are evide Brain metastases are observed in  $20 - 40\%$  of melanoma patients during the course of<br>disease and micrometastases are evident in more than 75% of autopsied brains<sup>1</sup>. Hence,<br>only a subset of melanoma cells that entered th disease and micrometastases are evident in more than 75% of autopsied brains<sup>1</sup>. Hence, disease and micrometastases are evident in more than 75% of autopsied brains<sup>1</sup>. Hence,<br>86 only a subset of melanoma cells that entered the brain develop symptomatic and detectable<br>87 BM during the lifetime of melanoma pat only a subset of melanoma cells that entered the brain develop symptomatic and detectable<br>BM during the lifetime of melanoma patients. Unlike peripheral metastases, the emergence<br>of BM depends on a plethora of environmenta 87 BM during the lifetime of melanoma patients. Unlike peripheral metastases, the emergence<br>88 of BM depends on a plethora of environmental cues such as the spatiotemporal availability of<br>89 factors that are provided by ce of BM depends on a plethora of environmental cues such as the spatiotemporal availability of<br>factors that are provided by cells of the TME, supporting or repressing tumor cell growth<sup>2</sup>.<br>Moreover, single-cell RNA sequencin factors that are provided by cells of the TME, supporting or repressing tumor cell growth<sup>2</sup>. factors that are provided by cells of the TME, supporting or repressing tumor cell growth<sup>2</sup>.<br>
90 Moreover, single-cell RNA sequencing (scRNAseq) studies have confirmed regional<br>
91 heterogeneity of astrocytes<sup>3</sup>, oligode Moreover, single-cell RNA sequencing (scRNAseq) studies have confirmed regional<br>11 heterogeneity of astrocytes<sup>3</sup>, oligodendrocytes<sup>4</sup> and microglia<sup>5,6</sup> in healthy human brains.<br>12 Particularly, astrocytes and microglia heterogeneity of astrocytes<sup>3</sup>, oligodendrocytes<sup>4</sup> and microglia<sup>5,6</sup> heterogeneity of astrocytes<sup>3</sup>, oligodendrocytes<sup>4</sup> and microglia<sup>5,6</sup> in healthy human brains.<br>
Particularly, astrocytes and microglia adopt a reactive cell state<sup>7,8</sup> that accompanies<br>
secretion of pro- and anti-inflamma Particularly, astrocytes and microglia adopt a reactive cell state<sup>7,8</sup> Particularly, astrocytes and microglia adopt a reactive cell state<sup>7,8</sup> that accompanies<br>secretion of pro- and anti-inflammatory factors under pathological conditions<sup>9,10</sup>. It is<br>therefore possible that subfractions of as secretion of pro- and anti-inflammatory factors under pathological conditions<sup>9,10</sup> secretion of pro- and anti-inflammatory factors under pathological conditions<sup>9,10</sup>. It is<br>therefore possible that subfractions of astrocytes and microglia communicate and react with<br>tumor cells in different ways. Probably therefore possible that subfractions of astrocytes and microglia communicate and react with<br>tumor cells in different ways. Probably, neuroinflammation precedes colonization of the brain<br>by tumor cells. However, tumor cells tumor cells in different ways. Probably, neuroinflammation precedes colonization of the brain<br>by tumor cells. However, tumor cells invading the brain amplify inflammatory processes<br>mediated by astrocytes and infiltrating t by tumor cells. However, tumor cells invading the brain amplify inflammatory processes<br>mediated by astrocytes and infiltrating tumor-associated microglia and macrophages<br>(TAMs)<sup>11,12</sup>. Recently, signaling mediated by hepat mediated by astrocytes and infiltrating tumor-associated microglia and macrophages<br>
(TAMs)<sup>11,12</sup>. Recently, signaling mediated by hepatocyte growth factor (HGF) and the related<br>
receptor MET (c-MET, HGFR) was identified a  $(TAMs)^{11,12}$ . Recently, signaling mediated by hepatocyte growth factor (HGF) and the related (TAMs)<sup>11,12</sup>. Recently, signaling mediated by hepatocyte growth factor (HGF) and the related<br>receptor MET (c-MET, HGFR) was identified as the trigger of reactive microglia<sup>13</sup>. HGF is<br>thereby secreted by microglia in the receptor MET (c-MET, HGFR) was identified as the trigger of reactive microglia<sup>13</sup> receptor MET (c-MET, HGFR) was identified as the trigger of reactive microglia<sup>13</sup>. HGF is<br>thereby secreted by microglia in the context of trauma but also under normal conditions and<br>seems to play a special role in the gr thereby secreted by microglia in the context of trauma but also under normal conditions and<br>101 seems to play a special role in the growth and self-renewal of neural stem cells in the<br>102 subventricular zone (SVZ) of rat b seems to play a special role in the growth and self-renewal of neural stem cells in the<br>102 subventricular zone (SVZ) of rat brains<sup>14,15</sup>. Therefore, metastatic melanoma cells expressing<br>103 MET might scavenge HGF from th subventricular zone (SVZ) of rat brains $^{14,15}$ subventricular zone (SVZ) of rat brains<sup>14,15</sup>. Therefore, metastatic melanoma cells expressing<br>103 MET might scavenge HGF from the brain for activation of processes downstream of MET<br>104 mediating survival and proliferati MET might scavenge HGF from the brain for activation of processes downstream of MET<br>104 mediating survival and proliferation.<br>105 Here, we used transcriptome and methylome profiling to unravel the epigenetic and<br>106 transc

104 mediating survival and proliferation.<br>105 Here, we used transcriptome and<br>106 transcriptomic landscapes of MBM 105 Here, we used transcriptome and methylome profiling to unravel the epigenetic and<br>106 transcriptomic landscapes of MBM that featured infiltration of TAMs with emphasis on the<br>4 106 transcriptomic landscapes of MBM that featured infiltration of TAMs with emphasis on the<br>4

potential role of microglia in the activation of the HGF/MET receptor signaling pathway. The<br>108 MET receptor inhibitors PHA-665752 and tivantinib (ARQ197) effectively blocked the growth<br>109 of brain metastases derived cel 108 MET receptor inhibitors PHA-665752 and tivantinib (ARQ197) effectively blocked the growth<br>109 of brain metastases derived cells (BMCs). Hence, targeting MET receptor signaling might<br>110 serve as a potent therapeutic ta 109 of brain metastases derived cells (BMCs). Hence, targeting MET receptor signaling might<br>110 serve as a potent therapeutic target for brain metastases lacking druggable BRAF<sup>V600</sup><br>111 mutations.<br>112 **Results** serve as a potent therapeutic target for brain metastases lacking druggable BRAF $^{V600}$ 110<br>111<br>112<br>113 111 mutations.<br>112 **Results**<br>113 **A microgli**<br>114 Microglia a

112 **Results**<br>113 **A microgli**<br>114 Microglia a<br>115 (CNS) tha **A microglia-specific gene cluster discriminates MBM**<br>114 Microglia are a unique population of antigen-presenting cells in the central nervous system<br>115 (CNS) that are capable of clearing the brain of microbes, dead cells Microglia are a unique population of antigen-presenting cells in the central nervous system<br>115 (CNS) that are capable of clearing the brain of microbes, dead cells and protein<br>116 aggregates<sup>16</sup>. Besides, microglia play a (CNS) that are capable of clearing the brain of microbes, dead cells and protein<br>116 aggregates<sup>16</sup>. Besides, microglia play a crucial role during injury repair and display an<br>117 exceptional role in immune surveillance an aggregates<sup>16</sup>. Besides, microglia play a crucial role during injury repair and display an aggregates<sup>16</sup>. Besides, microglia play a crucial role during injury repair and display an<br>117 exceptional role in immune surveillance and tumor clearance<sup>17,18</sup>. Although the role of tumor-<br>118 associated microglia and ma exceptional role in immune surveillance and tumor clearance<sup>17,18</sup> Exceptional role in immune surveillance and tumor clearance<sup>17,18</sup>. Although the role of tumor-<br>associated microglia and macrophages (TAMs) in primary brain tumors such as<br>glioblastoma<sup>19-22</sup> has been intensively studied, associated microglia and macrophages (TAMs) in primary brain tumors such as<br>119 glioblastoma<sup>19-22</sup> has been intensively studied, their role in the progression of brain<br>120 metastases remains poorly understood.<br>121 We perf glioblastoma<sup>19-22</sup>

qlioblastoma<sup>19-22</sup> has been intensively studied, their role in the progression of brain<br>120 metastases remains poorly understood.<br>121 We performed immunohistochemistry (IHC) of our MBM cohort (Supplementary table 1<br>122 a metastases remains poorly understood.<br>121 We performed immunohistochemistry<br>122 and<sup>23</sup>) to determine the levels of activa<br>123 well-established marker, reactive micro 121 We performed immunohistochemistry (IHC) of our MBM cohort (Supplementary table 1<br>122 and<sup>23</sup>) to determine the levels of activated, Iba1<sup>high</sup> TAMs. Although Iba1/AIF1 serves as a<br>123 well-established marker, reactive and<sup>23</sup>) to determine the levels of activated, Iba1<sup>high</sup> and<sup>23</sup>) to determine the levels of activated,  $Iba1<sup>n</sup>yn$  TAMs. Although  $Iba1/AlF1$  serves as a<br>123 well-established marker, reactive microglia cannot be distinguished from brain infiltrated<br>124 macrophages<sup>24</sup>. Initial well-established marker, reactive microglia cannot be distinguished from brain infiltrated<br>124 macrophages<sup>24</sup>. Initial studies of MBM revealed that lba1/AIF1 levels classified tumors into<br>125 highly and lowly TAM infiltra macrophages $^{\mathsf{24}}$ macrophages<sup>24</sup>. Initial studies of MBM revealed that  $\frac{1}{A}$  levels classified tumors into<br>
highly and lowly TAM infiltrated (Figure 1a, Supplementary figure 1a). Moreover, we<br>
observed overlapping patterns of infiltra highly and lowly TAM infiltrated (Figure 1a, Supplementary figure 1a). Moreover, we<br>126 observed overlapping patterns of infiltration of Iba1<sup>high</sup> TAMs and CD3<sup>+</sup> T cells (Figure 1b). As<br>127 CD3 only provided information observed overlapping patterns of infiltration of  $Iba1<sup>high</sup> TAMs$  and  $CD3<sup>+</sup> T$  cells (Figure 1b). As the observed overlapping patterns of infiltration of  $\text{lba1}^{\text{ngh}}$  TAMs and CD3<sup>+</sup> T cells (Figure 1b). As<br>127 CD3 only provided information about levels of T cell infiltration, we used the ESTIMATE<br>128 algorithm<sup>25</sup> t 127 CD3 only provided information about levels of T cell infiltration, we used the ESTIMATE<br>128 algorithm<sup>25</sup> to gain insight into the overall degree of immune cell infiltration of MBM. In line<br>129 with our previous obser algorithm<sup>25</sup> algorithm<sup>25</sup> to gain insight into the overall degree of immune cell infiltration of MBM. In line<br>129 with our previous observation, tumors with intensive TAM and T cell infiltration exhibited a<br>130 high immune score (Pts with our previous observation, tumors with intensive TAM and T cell infiltration exhibited a<br>130 high immune score (Pts 3, 4, 10, 12) whereas MBM with low levels of Iba1<sup>high</sup>/ CD3<sup>+</sup> cell<br>131 infiltration (Pts 1, 2) or lo high immune score (Pts 3, 4, 10, 12) whereas MBM with low levels of Iba1<sup>high</sup>/ CD3<sup>+</sup> high immune score (Pts 3, 4, 10, 12) whereas MBM with low levels of Iba1<sup>nign</sup>/ CD3<sup>+</sup> cell<br>131 infiltration (Pts 1, 2) or low expression of Iba1/AIF1 (Supplementary figures 1b, c) showed<br>132 low immune scores (Figure 1c). 131 infiltration (Pts 1, 2) or low expression of Iba1/AIF1 (Supplementary figures 1b, c) showed<br>132 low immune scores (Figure 1c). As expected, brain metastases derived cell lines (BMCs)<br>133 with absence of immune cells fe 132 low immune scores (Figure 1c). As expected, brain metastases derived cell lines (BMCs)<br>133 with absence of immune cells featured lowest scores (Supplementary figures 1b, c). The<br>133 states of immune cells featured lowe 133 with absence of immune cells featured lowest scores (Supplementary figures 1b, c). The<br>5

brain has long been considered a sanctuary where tumor cells can grow undisturbed and<br>protected from attack by immune cells. Therefore, we next investigated expression levels of<br>lba1/AIF1 in brain (MBM) and extracranial me protected from attack by immune cells. Therefore, we next investigated expression levels of<br>136 Iba1/AIF1 in brain (MBM) and extracranial metastases (EM). We observed AIF1 expression<br>137 in both as well as a high correlati Iba1/AIF1 in brain (MBM) and extracranial metastases (EM). We observed AIF1 expression<br>in both as well as a high correlation with immune score (Figure 1d), suggesting a relationship<br>between levels of infiltration of TAMs a 137 in both as well as a high correlation with immune score (Figure 1d), suggesting a relationship<br>
138 between levels of infiltration of TAMs and immune cells not only in the brain. As high levels of<br>
139 immune cell/T c between levels of infiltration of TAMs and immune cells not only in the brain. As high levels of<br>
immune cell/T cell infiltration are generally associated with good prognosis<sup>26</sup>, we determined<br>
the probability of survival immune cell/T cell infiltration are generally associated with good prognosis<sup>26</sup> 139 immune cell/T cell infiltration are generally associated with good prognosis<sup>26</sup>, we determined<br>140 the probability of survival related to Iba1/AIF1 expression of patient's with (study<br>141 EGAS00001003672) and without 140 the probability of survival related to Iba1/AIF1 expression of patient's with (study<br>141 EGAS00001003672) and without (TCGA-SKCM) MBM. We observed beneficial effects of<br>142 high Iba1/AIF1 levels in the TCGA cohort (HR= 141 EGAS00001003672) and without (TCGA-SKCM) MBM. We observed beneficial effects of<br>
142 high Iba1/AIF1 levels in the TCGA cohort (HR=0.46 (0.35 – 0.62), logrank p=1.3e-07)<br>
143 (Figures 1e, f), however, Iba1/AIF1 level ha 142 high Iba1/AIF1 levels in the TCGA cohort (HR=0.46 (0.35 – 0.62), logrank p=1.3e-07)<br>
143 (Figures 1e, f), however, Iba1/AIF1 level had no beneficial effects on the survival of MBM<br>
144 patients. Since no data on TAM-i 143 (Figures 1e, f), however, Iba1/AIF1 level had no beneficial effects on the survival of MBM<br>144 patients. Since no data on TAM-infiltrated MBM are available, we performed comparative<br>145 methylome and transcriptome pro patients. Since no data on TAM-infiltrated MBM are available, we performed comparative<br>
145 methylome and transcriptome profiling of  $Iba1^{high}$  (n=5-10) and  $Iba1^{low}$  (n=2-6) tumors and<br>
146 identified a set of 417 different methylome and transcriptome profiling of Iba1<sup>high</sup> (n=5-10) and Iba1<sup>low</sup> methylome and transcriptome profiling of  $\text{lba1}^{\text{hign}}$  (n=5-10) and  $\text{lba1}^{\text{low}}$  (n=2-6) tumors and<br>146 identified a set of 417 differentially methylated genomic regions (DMRs) that corresponded to<br>147 294 MBM expre identified a set of 417 differentially methylated genomic regions (DMRs) that corresponded to<br>147 294 MBM expressed genes (Figure 1g) a core set of markers (n=31) sufficient to split tumors<br>148 (Figure 1h; Supplementary ta 294 MBM expressed genes (Figure 1g) a core set of markers (n=31) sufficient to split tumors<br>148 (Figure 1h; Supplementary tables 2, 3). Among them, we identified the integrin family<br>149 member and gut-homing receptor ITGB7 148 (Figure 1h; Supplementary tables 2, 3). Among them, we identified the integrin family<br>149 member and gut-homing receptor ITGB7 -which we described in our previous study as a<br>150 distinguishing mark between BRAF and NRA member and gut-homing receptor ITGB7 -which we described in our previous study as a<br>150 distinguishing mark between BRAF and NRAS mutant MBM<sup>23</sup> - and *APBB1IP* (amyloid b<br>151 precursor protein-binding family b member 1 in distinguishing mark between BRAF and NRAS mutant MBM $^{23}$ distinguishing mark between BRAF and NRAS mutant MBM<sup>23</sup> - and *APBB1IP* (amyloid b<br>151 precursor protein-binding family b member 1 interacting protein). Both are associated with<br>152 better prognosis in patients with color precursor protein-binding family b member 1 interacting protein). Both are associated with<br>152 better prognosis in patients with colorectal cancer<sup>27,28</sup> and clustered with known TAM-<br>153 associated genes such as *P2RY12* better prognosis in patients with colorectal cancer<sup>27,28</sup> better prognosis in patients with colorectal cancer<sup>27,28</sup> and clustered with known TAM-<br>153 associated genes such as *P2RY12* and *AIF1* (Figure 1h). Remarkably, all clustered tumors<br>154 were associated with a high immune associated genes such as *P2RY12* and *AIF1* (Figure 1h). Remarkably, all clustered tumors<br>154 were associated with a high immune score. A correlation analysis of clustered genes<br>155 revealed a high degree of correlation a were associated with a high immune score. A correlation analysis of clustered genes<br>155 revealed a high degree of correlation among each other (Figure 1i) and association with<br>156 hepatocyte growth factor (HGF) that was re revealed a high degree of correlation among each other (Figure 1i) and association with<br>156 hepatocyte growth factor (HGF) that was recently connected with microglia activation<sup>13</sup>.<br>157 However, only some of the identified hepatocyte growth factor (HGF) that was recently connected with microglia activation<sup>13</sup> hepatocyte growth factor (HGF) that was recently connected with microglia activation<sup>13</sup>.<br>157 However, only some of the identified markers within the gene cluster were specifically<br>158 expressed in microglia but not in bra However, only some of the identified markers within the gene cluster were specifically<br>158 expressed in microglia but not in brain infiltrating macrophages or other brain cells such as<br>159 *APBB1IP* (Figure 1j). The latter expressed in microglia but not in brain infiltrating macrophages or other brain cells such as<br>
159 APBB1IP (Figure 1j). The latter gene which has been identified as a conserved microglial<br>
160 gene<sup>29</sup> and binding partner *APBB1IP* (Figure 1j). The latter gene which has been identified as a conserved microglial<br>160 gene<sup>29</sup> and binding partner of amyloid precursor protein (APP), Tau, 14-3-3g, and glycogen<br>161 synthase kinase 3 b (GSK3 b) wa gene<sup>29</sup> qene<sup>29</sup> and binding partner of amyloid precursor protein (APP), Tau, 14-3-3g, and glycogen<br>161 synthase kinase 3 b (GSK3 b) was associated with actin dynamics and retinoic acid<br>6 161 synthase kinase 3 b (GSK3 b) was associated with actin dynamics and retinoic acid

signaling<sup>30,31</sup>. Expression of APBB1IP was significantly (MBM: R=0.86, p<2.2e-16) correlated signaling<sup>30,31</sup>. Expression of APBB1IP was significantly (MBM: R=0.86, p<2.2e-16) correlated<br>163 with immune score (Figure 1k) and survival of melanoma patients (Supplementary figures<br>164 1d-e). Moreover, our survey ident with immune score (Figure 1k) and survival of melanoma patients (Supplementary figures<br>164 1d-e). Moreover, our survey identified a differentially methylated side (Supplementary table<br>165 4) within the promoter of PD-L2 (P 164 1d-e). Moreover, our survey identified a differentially methylated side (Supplementary table<br>165 4) within the promoter of PD-L2 (PDCD1LG2) that may predict progression-free survival in<br>166 melanoma patients receiving 4) within the promoter of PD-L2 (PDCD1LG2) that may predict progression-free survival in<br>166 melanoma patients receiving anti-PD-1 immunotherapy<sup>32</sup>. PD-L2 expression was associated<br>167 with favorable survival (p=0.020) of melanoma patients receiving anti-PD-1 immunotherapy $^{32}$ melanoma patients receiving anti-PD-1 immunotherapy<sup>32</sup>. PD-L2 expression was associated<br>with favorable survival (p=0.020) of patients with MBM (Supplementary figure 1f). We found<br>additional genes among our cluster that we with favorable survival (p=0.020) of patients with MBM (Supplementary figure 1f). We found<br>additional genes among our cluster that were expressed in TAMs and significantly<br>associated with immune score (Supplementary figure additional genes among our cluster that were expressed in TAMs and significantly<br>169 associated with immune score (Supplementary figures 1g-n).<br>170 Expression of ITGB7 serves as indicator of immune cell infiltration

associated with immune score (Supplementary figures 1g-n).<br>170<br>171 Expression of ITGB7 serves as indicator of immune cell in<br>172 Recent studies have shown that ITGB7 plays a critical role in 170<br>171<br>172<br>173 **Expression of ITGB7 serves as indicator of immune cell infiltration**<br>172 Recent studies have shown that ITGB7 plays a critical role in the recruit<br>173 intestine and that downregulation of ITGB7 is important in protecting 172 Recent studies have shown that ITGB7 plays a critical role in the recruitment of T cells to the<br>173 intestine and that downregulation of ITGB7 is important in protecting intestinal tumors from<br>174 attack by activated intestine and that downregulation of ITGB7 is important in protecting intestinal tumors from<br>174 attack by activated T cells<sup>27,33</sup>. Hence, we sought to investigate *ITGB7* in more detail. Mining<br>175 of publicly available attack by activated T cells $^{27,33}$ attack by activated T cells<sup>27,33</sup>. Hence, we sought to investigate *ITGB7* in more detail. Mining<br>175 of publicly available immune cell data (studies GSE146771<sup>34</sup>, DICE database<sup>35</sup>) revealed<br>176 expression of *ITGB7* ac of publicly available immune cell data (studies GSE146771 $^{34}$ , DICE database $^{35}$ of publicly available immune cell data (studies GSE146771<sup>34</sup>, DICE database<sup>35</sup>) revealed<br>expression of *ITGB7* across different immune cell stages including naïve and memory<br>subsets of T cells, B cells and NK cells (Figu 176 expression of *ITGB7* across different immune cell stages including naïve and memory<br>177 subsets of T cells, B cells and NK cells (Figure 2a and Supplementary figure 2a). We found<br>178 that *ITGB7* was rather expressed subsets of T cells, B cells and NK cells (Figure 2a and Supplementary figure 2a). We found<br>that *ITGB7* was rather expressed in MBM with infiltration of immune cells and particularly<br>within immune cell dense areas (Supplem that *ITGB7* was rather expressed in MBM with infiltration of immune cells and particularly<br>
179 within immune cell dense areas (Supplementary figure 2b). Co-staining revealed<br>
180 accumulation of CD3<sup>+</sup> T cells as well as within immune cell dense areas (Supplementary figure 2b). Co-staining revealed<br>accumulation of CD3<sup>+</sup> T cells as well as of Iba1<sup>high</sup> TAMs (Figure 2b). Ranking of MBM<br>regarding levels of *ITGB7* expression showed co-occur accumulation of CD3<sup>+</sup> T cells as well as of Iba1<sup>high</sup> accumulation of CD3<sup>+</sup> T cells as well as of Iba1<sup>nigh</sup> TAMs (Figure 2b). Ranking of MBM<br>181 regarding levels of *ITGB7* expression showed co-occurrence in the expression of CD4,<br>182 CD274, Sushi Domain Containing 3 (SUSD3 181 regarding levels of *ITGB7* expression showed co-occurrence in the expression of CD4,<br>
182 CD274, Sushi Domain Containing 3 (SUSD3) and *ITGB7* level (Figure 2c) and validated a<br>
183 possible, previously observed<sup>23</sup> c 182 CD274, Sushi Domain Containing 3 (SUSD3) and *ITGB7* level (Figure 2c) and validated a<br>183 possible, previously observed<sup>23</sup> correlation of *ITGB7* and SUSD3. Moreover *ITGB7*, SUSD3<br>184 and *APBB1IP* showed expression possible, previously observed<sup>23</sup> possible, previously observed<sup>23</sup> correlation of *ITGB7* and SUSD3. Moreover *ITGB7*, SUSD3<br>and *APBB1IP* showed expression across different immune cell types except for monocytes<br>and NK cells (Supplementary figures 2c-f). and *APBB1IP* showed expression across different immune cell types except for monocytes<br>
and NK cells (Supplementary figures 2c-f). Global (850k) methylome profiling uncovered four<br>
propertic regulation sites of *ITGB7* (S and NK cells (Supplementary figures 2c-f). Global (850k) methylome profiling uncovered four<br>186 epigenetic regulation sites of *ITGB7* (Supplementary table 4) with two sites that were<br>187 associated with expression levels epigenetic regulation sites of *ITGB7* (Supplementary table 4) with two sites that were<br>associated with expression levels and immune score (Figures 2d, left and center panel,<br>Supplementary figure 3a), located in a proximal associated with expression levels and immune score (Figures 2d, left and center panel,<br>188 Supplementary figure 3a), located in a proximal enhancer-like region (probe cg26689077) or<br>189 near by the promotor of ITGB7 (probe 188 Supplementary figure 3a), located in a proximal enhancer-like region (probe cg26689077) or<br>189 near by the promotor of ITGB7 (probe cg01033299). The latter site was also identified in the<br>189 189 near by the promotor of ITGB7 (probe cg01033299). The latter site was also identified in the

190 TCGA-SKCM cohort. The sites did not correlate with the BRAF mutation status of MBM<br>191 (Figures 2d, right panel) in contrast to additional two sides that were found within intergenic<br>192 regions including an CpG island 191 (Figures 2d, right panel) in contrast to additional two sides that were found within intergenic<br>192 regions including an CpG island located between exons 4 and 5 (probes cg11510999 and<br>193 cg18320160; Supplementary fig

regions including an CpG island located between exons 4 and 5 (probes cg11510999 and<br>cg18320160; Supplementary figures 3b-e).<br>Hence, methylome profiling of MBM identified two DMRs within the *ITGB7* gene that might<br>serve a cg18320160; Supplementary figures 3b-e).<br>194 Hence, methylome profiling of MBM identit<br>195 serve as indicators of the degree of immune

194 Hence, methylome profiling of MBM identified two DMRs within the *ITGB7* gene that might<br>195 serve as indicators of the degree of immune cell infiltration.<br>196 A recent study demonstrated that MBM feature a lower T cel serve as indicators of the degree of immune cell infiltration.<br>196 A recent study demonstrated that MBM feature a lowe<br>197 extracranial metastases, however response rates to Ip<br>198 Assuming that ITGB7 expression might be c 206 A recent study demonstrated that MBM feature a lower T cell content than matched<br>2197 extracranial metastases, however response rates to ICi of both were comparable<sup>36</sup>.<br>2198 Assuming that ITGB7 expression might be cru extracranial metastases, however response rates to ICi of both were comparable<sup>36</sup> extracranial metastases, however response rates to ICi of both were comparable<sup>36</sup>.<br>198 Assuming that ITGB7 expression might be crucial for T cell recruitment, we ascertained<br>199 *ITGB7* levels in MBM (n=79) and EM (n=59; 198 Assuming that ITGB7 expression might be crucial for T cell recruitment, we ascertained<br>
199 ITGB7 levels in MBM (n=79) and EM (n=59; study EGAS00001003672). We observed that<br>
17GB7 was expressed in both metastatic subt *ITGB7* levels in MBM (n=79) and EM (n=59; study EGAS00001003672). We observed that<br>
17GB7 was expressed in both metastatic subtypes and was significantly correlated (MBM:<br>
17GB7 was expressed in both metastatic subtypes a *ITGB7* was expressed in both metastatic subtypes and was significantly correlated (MBM:<br>201 R=0.51, p=1.8e-06; EM: R=0.69, p=1.1e-09) with the tumor's immune scores (Figure 2e). As<br>202 we suggest that *ITGB7* expression m 201 R=0.51, p=1.8e-06; EM: R=0.69, p=1.1e-09) with the tumor's immune scores (Figure 2e). As<br>202 we suggest that *ITGB7* expression might indicate the degree of immune cell infiltration and<br>203 possibly serve as indicator we suggest that *ITGB7* expression might indicate the degree of immune cell infiltration and<br>
203 possibly serve as indicator of response to ICi, we next performed correlation analysis of<br>
204 *ITGB7* and known markers of 203 possibly serve as indicator of response to ICi, we next performed correlation analysis of<br>204 *ITGB7* and known markers of T cells and B cells. We observed a high concordance with<br>205 immune cell-related but not tumor *ITGB7* and known markers of T cells and B cells. We observed a high concordance with<br>
205 immune cell-related but not tumor cell-related genes (*NGFR, MITF, MLANA, SLC45A2*) and<br>
206 correlation with expression of *PDCD1L* 205 immune cell-related but not tumor cell-related genes (*NGFR, MITF, MLANA, SLC45A2*) and<br>206 correlation with expression of *PDCD1LG2* (PD-L2) and *SUSD3*, irrespective of the side of<br>207 metastasis (Figures 2f, g). In 206 correlation with expression of *PDCD1LG2* (PD-L2) and *SUSD3*, irrespective of the side of<br>207 metastasis (Figures 2f, g). In line with previous observations, *ITGB7* was expressed in<br>208 primary and metastatic tumors 207 metastasis (Figures 2f, g). In line with previous observations, *ITGB7* was expressed in<br>208 primary and metastatic tumors (TCGA-SKCM) and like SUSD3 was associated with favored<br>209 survival (Figure 2i). In summary, ou 208 primary and metastatic tumors (TCGA-SKCM) and like SUSD3 was associated with favored<br>209 survival (Figure 2i). In summary, our survey identified a set of markers that are potentially<br>210 associated with the level of TA 209 survival (Figure 2i). In summary, our survey identified a set of markers that are potentially<br>210 associated with the level of TAM/immune cell infiltration, particularly *ITGB7* might serve as a<br>211 marker for a favora 210 associated with the level of TAM/immune cell infiltration, particularly *ITGB7* might serve as a<br>211 marker for a favorable course of the disease.<br>212

211 marker for a favorable course of the disease.<br>212<br>213 **A signature-based deconvolution revea** 212<br>213<br>214 213 **A signature-based deconvolution revealed MET receptor signaling in microglia-**214 **enriched MBM** 

215 Our previous survey identified a set of markers that potentially characterize a molecular<br>216 subset of MBM, likely showing a favorable course and response to ICi therapy<sup>37,38</sup>. To further<br>217 characterize this set of subset of MBM, likely showing a favorable course and response to ICi therapy $^{37,38}$ subset of MBM, likely showing a favorable course and response to ICi therapy<sup>37,38</sup>. To further<br>217 characterize this set of tumors, we performed single-sample Gene set Enrichment-Analysis<br>218 (SSGSEA) using defined immune characterize this set of tumors, we performed single-sample Gene set Enrichment-Analysis<br>218 (ssGSEA) using defined immune-related and gene signatures specifying signaling processes<br>219 such as MET receptor or STAT3 signal 218 (ssGSEA) using defined immune-related and gene signatures specifying signaling processes<br>219 such as MET receptor or STAT3 signaling among others that are reported to be involved in<br>220 immune-response mechanisms (Supp such as MET receptor or STAT3 signaling among others that are reported to be involved in<br>
220 immune-response mechanisms (Supplementary table 5). We observed that MBM featuring a<br>
221 high immune score showed activation of 220 immune-response mechanisms (Supplementary table 5). We observed that MBM featuring a<br>221 high immune score showed activation of MET and STAT3 signaling, increased tumor<br>222 inflammation, stress and senescence (SenMayo<sup></sup> high immune score showed activation of MET and STAT3 signaling, increased tumor<br>222 inflammation, stress and senescence (SenMayo<sup>39</sup>) (Figure 3a). Moreover, deconvolution<br>223 revealed the presence of reactive microglia, as inflammation, stress and senescence (SenMayo<sup>39</sup>) (Figure 3a). Moreover, deconvolution inflammation, stress and senescence (SenMayo<sup>39</sup>) (Figure 3a). Moreover, deconvolution<br>
223 revealed the presence of reactive microglia, astrocytes and immune cell subsets, among<br>
224 them stem cell-like CD8<sup>+</sup> T cells (T 223 revealed the presence of reactive microglia, astrocytes and immune cell subsets, among<br>224 them stem cell-like CD8<sup>+</sup> T cells (TCF7)<sup>40</sup> in tumors, absent in BMCs. CD8<sup>+</sup> (TCF7) T cells<br>225 are necessary for long-term them stem cell-like CD8<sup>+</sup> T cells (TCF7)<sup>40</sup> in tumors, absent in BMCs. CD8<sup>+</sup> 224 them stem cell-like CD8<sup>+</sup> T cells (TCF7)<sup>40</sup> in tumors, absent in BMCs. CD8<sup>+</sup> (TCF7) T cells<br>
225 are necessary for long-term maintenance of T cell responses and predicted positive clinical<br>
226 outcome<sup>41,42</sup>. Sign 225 are necessary for long-term maintenance of T cell responses and predicted positive clinical<br>226 outcome<sup>41,42</sup>. Signatures clearly discriminated MBM and BMCs and reinforced the differences<br>227 of Iba1<sup>high</sup> (Pts 3, 4) outcome<sup>41,42</sup>. Signatures clearly discriminated MBM and BMCs and reinforced the differences outcome<sup>41,42</sup>. Signatures clearly discriminated MBM and BMCs and reinforced the differences<br>227 of Iba1<sup>high</sup> (Pts 3, 4) and Iba1<sup>low/neg</sup> (Pts 1, 2) tumors. We therefore suggest that the activation<br>228 of MET- or STAT3-m of Iba1<sup>high</sup> (Pts 3, 4) and Iba1<sup>low/neg</sup> of Iba1<sup>nigh</sup> (Pts 3, 4) and Iba1<sup>16w/neg</sup> (Pts 1, 2) tumors. We therefore suggest that the activation<br>228 of MET- or STAT3-mediated signaling processes or those related to stress/senescence or<br>229 inflammation strongly de 228 of MET- or STAT3-mediated signaling processes or those related to stress/senescence or<br>
229 inflammation strongly depend on the composition of the tumor microenvironment, likely<br>
230 determining the response to therape inflammation strongly depend on the composition of the tumor microenvironment, likely<br>230 determining the response to therapeutic interventions. Although infiltration of TAMs is not<br>231 evident in all MBM, microglia infilt 230 determining the response to therapeutic interventions. Although infiltration of TAMs is not<br>231 evident in all MBM, microglia infiltration seems to be an early occurring process observed<br>232 ~21d after intracranial in evident in all MBM, microglia infiltration seems to be an early occurring process observed<br>
232 ~21d after intracranial injection of BMCs into brains of immune compromised Crl:CD1-<br>
233 Foxn1<sup>nu</sup> mice<sup>23</sup> (Figure 3b). More  $\sim$ 21d after intracranial injection of BMCs into brains of immune compromised Crl:CD1-<br>
233 Foxn1<sup>nu</sup> mice<sup>23</sup> (Figure 3b). Moreover, we observed activation of Stat3 signaling in tumor<br>
234 adjacent cells (Figure 3b), su Foxn1<sup>nu</sup> mice<sup>23</sup> Foxn1<sup>nu</sup> mice<sup>23</sup> (Figure 3b). Moreover, we observed activation of Stat3 signaling in tumor<br>
adjacent cells (Figure 3b), suggesting that brain microenvironmental cells are activated after<br>
a short time of tumor-stroma in 234 adjacent cells (Figure 3b), suggesting that brain microenvironmental cells are activated after<br>235 a short time of tumor-stroma interaction and establish an inflammatory environment. We<br>236 performed ssGSEA and applied 235 a short time of tumor-stroma interaction and establish an inflammatory environment. We<br>236 performed ssGSEA and applied the above mentioned signatures and observed a<br>237 comparable pattern of enrichment in a more compr performed ssGSEA and applied the above mentioned signatures and observed a<br>237 comparable pattern of enrichment in a more comprehensive and independent set of MBM<br>238 (study EGAS00001003672<sup>43</sup>, n=79 MBM) (Supplementary fi (study EGAS00001003672 $43$ , n=79 MBM) (Supplementary figure 4a).

comparable pattern of enrichment in a more comprehensive and independent set of MBM<br>
(study EGAS00001003672<sup>43</sup>, n=79 MBM) (Supplementary figure 4a).<br>
HGF or scatter factor (SF) is the only identified ligand of MET, plays 238 (study EGAS00001003672<sup>43</sup>, n=79 MBM) (Supplementary figure 4a).<br>
239 HGF or scatter factor (SF) is the only identified ligand of MET, pla<br>
240 neural development, regulating growth and survival of neurons<sup>15,4</sup><br>
241 239 HGF or scatter factor (SF) is the only identified ligand of MET, plays a pivotal role during<br>240 neural development, regulating growth and survival of neurons<sup>15,44</sup> and likely serves as<br>241 inducer of reactive microgl neural development, regulating growth and survival of neurons<sup>15,44</sup> neural development, regulating growth and survival of neurons<sup>15,44</sup> and likely serves as<br>241 inducer of reactive microglia by an autocrine loop in response to trauma or<br>242 neurodegenerative disorders<sup>13</sup>. Therefore, MET 241 inducer of reactive microglia by an autocrine loop in response to trauma or<br>242 neurodegenerative-disorders<sup>13</sup>. Therefore, MET-expressing, brain-colonizing-melanoma-cells<br>9 neurodegenerative disorders<sup>13</sup> neurodegenerative disorders<sup>13</sup>. Therefore, MET expressing, brain colonizing melanoma cells<br>9<br>9

may benefit and take advantage of the HGF-controlled systems naturally occurring in the<br>244 brain. We observed HGF expression among tumors of different data sets comprising MBM,<br>245 EM and primary tumors (studies EGAS00001 244 brain. We observed HGF expression among tumors of different data sets comprising MBM,<br>245 EM and primary tumors (studies EGAS00001005976; TCGA-SKCM; EGAS00001003672)<br>246 with no significant difference of HGF levels in 245 EM and primary tumors (studies EGAS00001005976; TCGA-SKCM; EGAS00001003672)<br>246 with no significant difference of HGF levels in tumor subsets (Figures 3d, e). Investigation of<br>247 immune cell and brain cell data (DICE with no significant difference of HGF levels in tumor subsets (Figures 3d, e). Investigation of<br>
247 immune cell and brain cell data (DICE database<sup>35</sup> and study GSE73721<sup>45</sup>) revealed high<br>
248 expression of HGF in monocy immune cell and brain cell data (DICE database $^{35}$  and study GSE73721 $^{45}$ 247 immune cell and brain cell data (DICE database<sup>35</sup> and study GSE73721<sup>45</sup>) revealed high<br>248 expression of HGF in monocytes and astrocytes (Figures 3f, g), suggesting a potential role of<br>249 different stroma cell popul expression of HGF in monocytes and astrocytes (Figures 3f, g), suggesting a potential role of<br>249 different stroma cell populations for activating HGF/MET signaling in brain-infiltrating tumor<br>250 cells. Assuming that the different stroma cell populations for activating HGF/MET signaling in brain-infiltrating tumor<br>
250 cells. Assuming that the degree of microglia infiltration determines signaling processes in<br>
251 MBM cells, we explored ex cells. Assuming that the degree of microglia infiltration determines signaling processes in<br>251 MBM cells, we explored expression levels of MET signaling-associated genes in tumors with<br>252 high and low level of infiltrate 251 MBM cells, we explored expression levels of MET signaling-associated genes in tumors with<br>
252 high and low level of infiltrated TAMs and found levels of HGF, PIK3CG, PTK2B, STAT3 and<br>
253 MAP4K1 significantly correl 252 high and low level of infiltrated TAMs and found levels of HGF, PIK3CG, PTK2B, STAT3 and<br>253 MAP4K1 significantly correlated with microglia score (Supplementary figure 4c-e) that was<br>254 defined as average expression 253 MAP4K1 significantly correlated with microglia score (Supplementary figure 4c-e) that was<br>254 defined as average expression level or β-value of microglia markers *APBB1IP, SYK, HCK*<br>255 and *P2RY12* (Supplementary tab

254 defined as average expression level or β-value of microglia markers *APBB1IP, SYK, HCK*<br>255 and *P2RY12* (Supplementary table 6).<br>256 HGF might be released by immune cells as well as homeostatic and reactive microglia 255 and *P2RY12* (Supplementary table 6).<br>256 HGF might be released by immune c<br>257 astrocytes. We surveyed the Seattle A<br>258 in the Allen brain atlas database (http 256 HGF might be released by immune cells as well as homeostatic and reactive microglia or<br>257 astrocytes. We surveyed the Seattle Alzheimer's Disease Brain Atlas which is implemented<br>258 in the Allen brain atlas database astrocytes. We surveyed the Seattle Alzheimer's Disease Brain Atlas which is implemented<br>258 in the Allen brain atlas database (https://portal.brain-map.org/) and observed that dementia<br>259 fostered expansion of microglia in the Allen brain atlas database (https://portal.brain-map.org/) and observed that dementia<br>
259 fostered expansion of microglia with increased expression of HGF (Figure 3h, center and<br>
260 right panels). Reactive microgl 259 fostered expansion of microglia with increased expression of HGF (Figure 3h, center and<br>260 right panels). Reactive microglia and immune cell released HGF might hence be responsible<br>261 for activation of growth factor/ right panels). Reactive microglia and immune cell released HGF might hence be responsible<br>261 for activation of growth factor/survival signaling in adjacent tumor cells. In line with previous<br>262 studies, we observed a sig 261 for activation of growth factor/survival signaling in adjacent tumor cells. In line with previous<br>262 studies, we observed a significant correlation of HGF expression with immune score in brain<br>263 (BM, R=0.49, p=5.3e-262 studies, we observed a significant correlation of HGF expression with immune score in brain<br>263 (BM, R=0.49, p=5.3e-06) and extracranial metastases (EM, R=0.41, p=1.5e-03), (Figure 3i).<br>264 Expression and activation of

263 (BM, R=0.49, p=5.3e-06) and extracranial metastases (EM, R=0.41, p=1.5e-03), (Figure 3i).<br>264<br>265 Expression and activation of MET receptor classifies a molecular subset of MBM<br>266 Understanding the molecular mechanism 264<br>265<br>266<br>267 **Expression and activation of MET receptor classifies a molecular subset of MBM**<br>266 Understanding the molecular mechanisms that establish cellular dependencies and<br>267 control the development and maintenance of brain meta Understanding the molecular mechanisms that establish cellular dependencies and thus<br>
control the development and maintenance of brain metastases is critical for their therapeutic<br>
manipulation. Recently, we identified tha control the development and maintenance of brain metastases is critical for their therapeutic<br>
268 manipulation. Recently, we identified that the expression of Ecad and NGFR sufficiently<br>
269 discriminated molecular subset manipulation. Recently, we identified that the expression of Ecad and NGFR sufficiently<br>
269 discriminated molecular subsets of MBM<sup>23</sup>. These subsets likely distinctly interact with<br>
270 microenvironmental cells and respo discriminated molecular subsets of MBM<sup>23</sup> discriminated molecular subsets of MBM<sup>23</sup>. These subsets likely distinctly interact with<br>270 microenvironmental cells and respond to therapeutics (Figure 4a). To identify potential<br>10 270 microenvironmental cells and respond to therapeutics (Figure 4a). To identify potential

druggable targets, we surveyed the pan-MBM, NGFR and Ecad-specific gene sets for cell<br>272 surface receptors that may serve as crucial key factors that control tumor cell maintenance<br>273 and expansion and identified 24 rece 272 surface receptors that may serve as crucial key factors that control tumor cell maintenance<br>273 and expansion and identified 24 receptors that distinguished Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors<br>274 (Figure 4b). Particularly ADIP and expansion and identified 24 receptors that distinguished Ecad<sup>+</sup> and NGFR<sup>+</sup> and expansion and identified 24 receptors that distinguished Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors<br>274 (Figure 4b). Particularly ADIPOR1 (adiponectin receptor 1, p=1.9e-02), SIRPA (signal<br>275 regulatory protein alpha, p=1.1e-05) and 274 (Figure 4b). Particularly ADIPOR1 (adiponectin receptor 1, p=1.9e-02), SIRPA (signal<br>275 regulatory protein alpha, p=1.1e-05) and PLXNC1 (plexin C1) showed significantly increased<br>276 expression in Ecad<sup>+</sup> MBM and EM b expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c).<br>
276 expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c).<br>
277 In addition, Ecad<sup>+</sup> MBM featured increase expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c). expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c).<br>
277 In addition, Ecad<sup>+</sup> MBM featured increased levels of MET receptor in (p=1.4e-04). MET was<br>
278 significantly (p=2.7e-05) higher exp In addition,  $Ecad^+$  MBM featured increased levels of MET receptor in  $(p=1.4e-04)$ . MET was 277 In addition, Ecad<sup>+</sup> MBM featured increased levels of MET receptor in (p=1.4e-04). MET was<br>278 significantly (p=2.7e-05) higher expressed in MBM than EM (Figure 4d, left and center<br>279 panels). The MET tyrosine kinase 278 significantly (p=2.7e-05) higher expressed in MBM than EM (Figure 4d, left and center<br>279 panels). The MET tyrosine kinase receptor pathway serves as a potent survival and<br>280 maintenance factor for MBM and might be a panels). The MET tyrosine kinase receptor pathway serves as a potent survival and<br>280 maintenance factor for MBM and might be a promising therapeutic target<sup>46</sup>. MET expression<br>281 was associated with increased cell cycle maintenance factor for MBM and might be a promising therapeutic target<sup>46</sup> maintenance factor for MBM and might be a promising therapeutic target<sup>46</sup>. MET expression<br>281 was associated with increased cell cycle progression and proliferation (Figure 4d, right panel)<br>282 and defined yet another sub was associated with increased cell cycle progression and proliferation (Figure 4d, right panel)<br>282 and defined yet another subset of MBM (Figure 4e). Next we assessed whether expressed<br>283 MET indeed participated in activ 282 and defined yet another subset of MBM (Figure 4e). Next we assessed whether expressed<br>283 MET indeed participated in active signaling processes. Phosphorylation of MET at tyrosine<br>284 residues 1234/1235 (pMET<sup>Y1234/123</sup> 283 MET indeed participated in active signaling processes. Phosphorylation of MET at tyrosine<br>284 residues 1234/1235 (pMET<sup>Y1234/1235</sup>) is critical for kinase activation and initiation of<br>285 downstream processes and was e residues 1234/1235 (pMET<sup>Y1234/1235</sup> residues 1234/1235 (pMET<sup> $Y1234/1235$ </sup>) is critical for kinase activation and initiation of<br>285 downstream processes and was evident in nearly all MET<sup>high</sup> MBM investigated, independent<br>286 of the BRAF mutation status (F downstream processes and was evident in nearly all MET<sup>high</sup> downstream processes and was evident in nearly all MET<sup>nigh</sup> MBM investigated, independent<br>
286 of the BRAF mutation status (Figures 4f, g). MET receptor alterations are evident in 9 % of all<br>
287 SKCM melanoma cases, inc 286 of the BRAF mutation status (Figures 4f, g). MET receptor alterations are evident in 9 % of all<br>287 SKCM melanoma cases, including amplification as observed in 1.13 – 17.2% or 11% of<br>288 melanoma (TCGA-SKCM, study by R 287 SKCM melanoma cases, including amplification as observed in 1.13 – 17.2% or 11% of<br>288 melanoma (TCGA-SKCM, study by Ramani et al.<sup>47</sup>). However, targeted DNA sequencing<br>289 (TargetSeq) and fluorescence in-situ hybridi melanoma (TCGA-SKCM, study by Ramani et al.<sup>47</sup> melanoma (TCGA-SKCM, study by Ramani et al.<sup>47</sup>). However, targeted DNA sequencing<br>289 (TargetSeq) and fluorescence in-situ hybridization (FISH) revealed absence of MET<br>290 activating mutations and a tendential MET amplifi 289 (TargetSeq) and fluorescence in-situ hybridization (FISH) revealed absence of MET activating mutations and a tendential MET amplification in only one case (Pat 5, Supplementary figure 5a, b). However, all but one tumor activating mutations and a tendential MET amplification in only one case (Pat 5,<br>291 Supplementary figure 5a, b). However, all but one tumor (Pat 14) showed high polysomy. As<br>292 we assume that environmental cells foster a 291 Supplementary figure 5a, b). However, all but one tumor (Pat 14) showed high polysomy. As<br>292 we assume that environmental cells foster activation of MET receptor signaling in a subset of<br>293 tumor cells, we performed we assume that environmental cells foster activation of MET receptor signaling in a subset of<br>
293 tumor cells, we performed co-IHC for pMET<sup>Y1234/1235</sup> and Iba1. We observed pMET<sup>Y1234/1235</sup><br>
294 positive tumor cells in c tumor cells, we performed co-IHC for pMET<sup>Y1234/1235</sup> and Iba1. We observed pMET<sup>Y1234/1235</sup> 293<br>294<br>295<br>296 positive tumor cells in close proximity to Iba1<sup>high</sup> TAMs (Figure 4h), though MET receptor was positive tumor cells in close proximity to Iba1<sup>nigh</sup> TAMs (Figure 4h), though MET receptor was<br>
295 not activated in Iba1<sup>high</sup> microglia that resided in adjacent normal tissue (Supplementary<br>
296 figure 5c, upper panel) not activated in Iba1<sup>high</sup> microglia that resided in adjacent normal tissue (Supplementary not activated in Iba1<sup>nigh</sup> microglia that resided in adjacent normal tissue (Supplementary<br>196 figure 5c, upper panel). However, MET receptor activation was also evident in scattered<br>197 tumor cells in the absence of adja figure 5c, upper panel). However, MET receptor activation was also evident in scattered<br>tumor cells in the absence of adjacent Iba1<sup>high</sup> TAMs (Supplementary figure 5c, lower panel)<br>suggesting paracrine mechanisms or addit tumor cells in the absence of adjacent Iba1<sup>high</sup> tumor cells in the absence of adjacent Iba1<sup>nigh</sup> TAMs (Supplementary figure 5c, lower panel)<br>298 suggesting paracrine mechanisms or additional sources of HGF such as immune cells or<br>11 298 suggesting paracrine mechanisms or additional sources of HGF such as immune cells or<br>11

astrocytes. Considering that HGF levels, like those of other growth factors provided by<br>300 stromal cells, might depend on spatial factors, we examined the Allan Brain Atlas database<br>301 and found that HGF is comparably ex 300 stromal cells, might depend on spatial factors, we examined the Allan Brain Atlas database<br>301 and found that HGF is comparably expressed in different brain sections (frontal lobe (FL),<br>302 parietal lobe (PL), temporal 301 and found that HGF is comparably expressed in different brain sections (frontal lobe (FL),<br>302 parietal lobe (PL), temporal lobe (TL), occipital lobe (OL)) but is lowly abundant in the<br>303 brainstem (pons) (supplementa 302 parietal lobe (PL), temporal lobe (TL), occipital lobe (OL)) but is lowly abundant in the<br>303 brainstem (pons) (supplemental Figure 5d). The spatially dependent expression of growth<br>304 factors in the brain may therefo 303 brainstem (pons) (supplemental Figure 5d). The spatially dependent expression of growth<br>304 factors in the brain may therefore determine the dependencies of the tumor cells.<br>305 **Interferon signaling determines respons** 

# 304 factors in the brain may therefore determine the dependencies of the tumor cells.<br>305<br>**Interferon signaling determines response of MBM to immune checkpoir**<br>307 **therapy** 305<br>306<br>307<br>308

306 **Interferon signaling determines response of MBM to immune checkpoint inhibitor**<br>307 **therapy**<br>308 Interferon-gamma signaling has been identified as an important mechanism for upregulation<br>309 of PD-L1 on melanoma cell 307 **therapy**<br>308 Interferor<br>309 of PD-L1<br>310 recent s Interferon-gamma signaling has been identified as an important mechanism for upregulation<br>309 of PD-L1 on melanoma cells and escape from immune recognition. On the other hand,<br>310 recent studies uncovered that high interf 309 of PD-L1 on melanoma cells and escape from immune recognition. On the other hand,<br>310 recent studies uncovered that high interferon-gamma-related gene expression signature<br>311 scores (IFN-y score) were associated with Frecent studies uncovered that high interferon-gamma-related gene expression signature<br>311 scores (IFN-γ score) were associated with low risk of melanoma relapse from neoadjuvant<br>312 ipilimumab plus nivolumab therapy<sup>48,</sup> ipilimumab plus nivolumab therapy $48,49$ .

scores (IFN-γ score) were associated with low risk of melanoma relapse from neoadjuvant<br>ipilimumab plus nivolumab therapy<sup>48,49</sup>.<br>313 In our recent study, we observed significant enrichment of interferon and inflammatory<br> ipilimumab plus nivolumab therapy<sup>48,49</sup>.<br>313 In our recent study, we observed sign<br>314 response ("Hallmark", MsigDB<sup>50</sup>) sign<br>315 lymphocytes (TIL<sup>high</sup>)<sup>23</sup> that have bee 313 In our recent study, we observed significant enrichment of interferon and inflammatory<br>314 response ("Hallmark", MsigDB<sup>50</sup>) signatures in MBM with high level of tumor infiltrating<br>315 lymphocytes (TIL<sup>high</sup>)<sup>23</sup> that response ("Hallmark", MsigDB<sup>50</sup> 314 response ("Hallmark", MsigDB<sup>50</sup>) signatures in MBM with high level of tumor infiltrating<br>315 lymphocytes (TIL<sup>high</sup>)<sup>23</sup> that have been attributed with favored survival in a pre-clinical<br>316 melanoma model<sup>49</sup>. We fou lymphocytes (TIL<sup>high</sup>)<sup>23</sup> 315 lymphocytes  $(TIL^{ngn})^{23}$  that have been attributed with favored survival in a pre-clinical<br>316 melanoma model<sup>49</sup>. We found overlapping expression of *ITGB7*, *SUSD3* and *HGF* and<br>317 Hallmark interferon-response gen melanoma model<sup>49</sup>. We found overlapping expression of *ITGB7*, SUSD3 and HGF and melanoma model<sup>49</sup>. We found overlapping expression of *ITGB7*, *SUSD3* and *HGF* and<br>317 Hallmark interferon-response genes, separating MBM of our cohort and MBM of study<br>518 EGAS00001003672 (Figure 4i, Supplementary figu 317 Hallmark interferon-response genes, separating MBM of our cohort and MBM of study<br>318 EGAS00001003672 (Figure 4i, Supplementary figure 6a). Expression of *ITGB7* significantly<br>319 correlated with levels of interferon r 318 EGAS00001003672 (Figure 4i, Supplementary figure 6a). Expression of *ITGB7* significantly<br>319 correlated with levels of interferon regulatory factor 1 (IRF1) and IRF8 in MBM (BM) and<br>320 extracranial metastases (EM) of 319 correlated with levels of interferon regulatory factor 1 (IRF1) and IRF8 in MBM (BM) and<br>320 extracranial metastases (EM) of study EGAS00001003672 (Supplementary figure 6b-d).<br>321 Moreover, we observed high correlation extracranial metastases (EM) of study EGAS00001003672 (Supplementary figure 6b-d).<br>321 Moreover, we observed high correlation of levels of *HGF*, *IRF1* and *IRF8* in MBM<br>322 (Supplementary figure 6e). As microglia serve a 321 Moreover, we observed high correlation of levels of *HGF*, *IRF1* and *IRF8* in MBM<br>322 (Supplementary figure 6e). As microglia serve as a source of soluble receptor ligands such<br>323 as Hgf, we next surveyed data of in 322 (Supplementary figure 6e). As microglia serve as a source of soluble receptor ligands such<br>323 as Hgf, we next surveyed data of interferon-gamma treated (1 U/mL IFNy, 24h) murine<br>324 microglia cells (BV2, GSE132739). 323 as Hgf, we next surveyed data of interferon-gamma treated (1 U/mL IFNy, 24h) murine<br>324 microglia cells (BV2, GSE132739). Indeed, we found significant upregulation of *Itgb7* (p =<br>325 2.9e-03) and *Hgf* (p=4.4e-02) bu 324 microglia cells (BV2, GSE132739). Indeed, we found significant upregulation of *Itgb7* (p =<br>325 2.9e-03) and *Hgf* (p=4.4e-02) but downregulation of *Susd3* (p=4.0e-02) in BV2 cells<br>326 (Supplementary figure 6f). For c 325 2.9e-03) and *Hgf* (p=4.4e-02) but downregulation of *Susd3* (p=4.0e-02) in BV2 cells 326 (Supplementary figure 6f). For control, we investigated levels of known interferon-responsive<br>12<br>12

genes that were significantly increased 24h after interferon treatment, *Mx1* (p=1.2e-02), PD-<br>328 L1/Cd274 (p=3.6e-02), *Irf1* (p=3.1e-02) Cxcl9 (p=4.0e-03) and *Aif1* (p=3.9e-04)<br>329 (Supplementary figure 6g). In order t 11/*Cd274* (p=3.6e-02), *Irf1* (p=3.1e-02) *Cxcl9* (p=4.0e-03) and *Aif1* (p=3.9e-04)<br>329 (Supplementary figure 6g). In order to classify MBM of our study into anti-PD-L1 responsible<br>330 and non-responsible and for linking (Supplementary figure 6g). In order to classify MBM of our study into anti-PD-L1 responsible<br>and non-responsible and for linking *ITGB7*, *SUSD3* and *HGF* with therapy response, we<br>performed ssGSEA and applied interferon and non-responsible and for linking *ITGB7*, *SUSD3* and *HGF* with therapy response, we<br>performed ssGSEA and applied interferon responsive and additional immune response gene<br>signatures (of study GSE186344<sup>51</sup>). Our surve 331 performed ssGSEA and applied interferon responsive and additional immune response gene<br>332 signatures (of study GSE186344<sup>51</sup>). Our survey validated that *ITGB7*, *SUSD3* and *HGF* were<br>333 highly expressed in MBM that signatures (of study GSE186344<sup>51</sup> signatures (of study GSE186344<sup>51</sup>). Our survey validated that *ITGB7*, *SUSD3* and *HGF* were<br>highly expressed in MBM that featured enrichment of interferon responsive genes/signatures<br>(Pts. 3-6, 12; Supplementary figure highly expressed in MBM that featured enrichment of interferon responsive genes/signatures<br>334 (Pts. 3-6, 12; Supplementary figure 6h).<br>335 Hence, we suggest that *ITGB7*, SUSD3 and HGF like PD-L1 are among the interferon-

934 (Pts. 3-6, 12; Supplementary figure 6h).<br>335<br>336 Hence, we suggest that *ITGB7*, SUSL<br>337 regulated genes triggered by immune ce 335<br>336<br>337<br>338 336 Hence, we suggest that *ITGB7*, *SUSD3* and *HGF* like *PD-L1* are among the interferon-<br>regulated genes triggered by immune cell-released interferon-gamma and may be involved in<br>immune response mechanisms of MBM.<br>339 337 regulated genes triggered by immune cell-released interferon-gamma and may be involved in<br>338 immune response mechanisms of MBM.<br>339 The targeting of MET receptor serves as a promising strategy to control MBM growth

338 immune response mechanisms of MBM.<br>339<br>340 **The targeting of MET receptor serves** :<br>341 Although a subset of MBM exhibit immu 339<br>340<br>341<br>342 **The targeting of MET receptor serves as a promising strategy to control MBM growth**<br>341 Although a subset of MBM exhibit immune cell subset enrichment and interferon respons<br>342 signatures and respond to ICi therapy, MET-341 Although a subset of MBM exhibit immune cell subset enrichment and interferon response<br>342 signatures and respond to ICi therapy, MET-expressing brain metastatic melanoma cells<br>343 may benefit from HGF released by stro signatures and respond to ICi therapy, MET-expressing brain metastatic melanoma cells<br>343 may benefit from HGF released by stromal cells to drive progression. Hence, activation of<br>344 MET signaling may depend on the degree 343 may benefit from HGF released by stromal cells to drive progression. Hence, activation of<br>344 MET signaling may depend on the degree of tumor-stroma interaction, possibly<br>345 counteracting the beneficial impact of immu 344 MET signaling may depend on the degree of tumor-stroma interaction, possibly<br>345 counteracting the beneficial impact of immune checkpoint inhibition (ICi). Resistance-<br>346 mediating processes include the phosphorylatio counteracting the beneficial impact of immune checkpoint inhibition (ICi). Resistance-<br>mediating processes include the phosphorylation of ribosomal protein S6 (pS6), which is<br>downstream of MET and mTOR signaling<sup>52</sup> and wa mediating processes include the phosphorylation of ribosomal protein S6 (pS6), which is<br>347 downstream of MET and mTOR signaling<sup>52</sup> and was observed in progressive BRAFi-resistant<br>348 melanomas<sup>53,54</sup>.<br>349 We assessed pS6 downstream of MET and mTOR signaling $^{52}$ melanomas $53,54$ .

downstream of MET and mTOR signaling<sup>52</sup> and was observed in progressive BRAFi-resistant<br>348 melanomas<sup>53,54</sup>.<br>349 We assessed pS6 phosphorylation of serine residues 235/236 and found co-occurrence of<br>350 activated MET rec 348 melanomas<sup>53,54</sup>.<br>349 We assessed p<sup>o</sup><br>350 activated MET<br>351 Supplementary We assessed pS6 phosphorylation of serine residues 235/236 and found co-occurrence of<br>activated MET receptor and of pS6<sup>235/236</sup> in MITF positive tumors (Figure 5a and<br>351 Supplementary figures 7a, b). Moreover, pS6 phosph activated MET receptor and of  $pS6^{235/236}$ activated MET receptor and of  $pS6^{235/236}$  in MITF positive tumors (Figure 5a and<br>351 Supplementary figures 7a, b). Moreover, pS6 phosphorylation was evident in a BRAF<sup>wt</sup><br>352 (T2002) and mutated (V600E, BMC53) cell lin Supplementary figures 7a, b). Moreover, pS6 phosphorylation was evident in a BRAF<sup>wt</sup> 351<br>352<br>353<br>354 352 (T2002) and mutated (V600E, BMC53) cell lines probably suggesting a general activation of<br>353 pS6 signaling irrespective of the presence of mutated BRAF (Figure 5b). As MET signaling<br>354 might serve as mediator of a re 953 pS6 signaling irrespective of the presence of mutated BRAF (Figure 5b). As MET signaling<br>354 might serve as mediator of a resistance-mediating program, we assessed the efficacies of<br>354 might serve as mediator of a res 354 might serve as mediator of a resistance-mediating program, we assessed the efficacies of<br>13

the ATP-competitive inhibitor PHA-665752 and the non-ATP-competitive, clinical phase I/II<br>356 MET receptor inhibitor (METi) tivantinib (ARQ197) in BMCs that showed variable levels of<br>357 MET expression (Figure 5c and Suppl 356 MET receptor inhibitor (METi) tivantinib (ARQ197) in BMCs that showed variable levels of<br>357 MET expression (Figure 5c and Supplementary figure 7c). ARQ197 failed to improve the<br>358 outcome and overall survival of pati 357 MET expression (Figure 5c and Supplementary figure 7c). ARQ197 failed to improve the<br>358 outcome and overall survival of patients with hepatocellular carcinoma<sup>55</sup> but may potentially<br>359 be effective in melanoma patie outcome and overall survival of patients with hepatocellular carcinoma<sup>55</sup> outcome and overall survival of patients with hepatocellular carcinoma<sup>55</sup> but may potentially<br>359 be effective in melanoma patients. The initial testing revealed a general response of BMCs<br>360 (BMC1-M1, BMC53), T2002 cell 359 be effective in melanoma patients. The initial testing revealed a general response of BMCs<br>360 (BMC1-M1, BMC53), T2002 cells and conventional cell lines (A375, A2058, MeWo) to both<br>361 inhibitors irrespective of the BR 360 (BMC1-M1, BMC53), T2002 cells and conventional cell lines (A375, A2058, MeWo) to both<br>361 inhibitors irrespective of the BRAF mutation status (Figures 5d, e). As we observed a<br>362 mutually exclusive rather than co-expr inhibitors irrespective of the BRAF mutation status (Figures 5d, e). As we observed a<br>362 mutually exclusive rather than co-expression of MET receptor and NGFR (nerve growth<br>363 factor receptor), we tested whether the mani mutually exclusive rather than co-expression of MET receptor and NGFR (nerve growth<br>363 factor receptor), we tested whether the manipulation of NGFR levels might affect the<br>364 response to PHA-665752 (PHA). We observed tha 363 factor receptor), we tested whether the manipulation of NGFR levels might affect the<br>364 response to PHA-665752 (PHA). We observed that overexpression of NGFR in A375 cells<br>365 (A375<sup>NGFR</sup>) sensitized to METi compared response to PHA-665752 (PHA). We observed that overexpression of NGFR in A375 cells<br>365 (A375<sup>NGFR</sup>) sensitized to METi compared to RFP expressing control (A375<sup>RFP</sup>) or MeWo cells<br>366 (Figure 5f). Next, we asked whether M (A375<sup>NGFR</sup>) sensitized to METi compared to RFP expressing control (A375<sup>RFP</sup>  $(A375^{NGFK})$  sensitized to METi compared to RFP expressing control  $(A375^{KFF})$  or MeWo cells<br>366 (Figure 5f). Next, we asked whether METi targeting may serve as alternative therapeutic<br>367 strategy for BRAFi resistant (BMC 366 (Figure 5f). Next, we asked whether METi targeting may serve as alternative therapeutic<br>367 strategy for BRAFi resistant (BMC4) or cells with non-BRAF<sup>V600</sup> mutations (BMC2) showing<br>368 only moderate or no response to strategy for BRAFi resistant (BMC4) or cells with non-BRAF<sup>V600</sup> 367 strategy for BRAFi resistant (BMC4) or cells with non-BRAF<sup>V600</sup> mutations (BMC2) showing<br>368 only moderate or no response to dabrafenib (Figure 5g) as indicated by  $IC_{50}$  values (BMC4,<br>369  $IC_{50} = 226.4$  nM and BMC2 368 only moderate or no response to dabrafenib (Figure 5g) as indicated by  $IC_{50}$  values (BMC4,<br>369  $IC_{50} = 226.4$  nM and BMC2,  $IC_{50} = 3029.5$  nM). The broad range (1nM – 10µM) testing of<br>370 tivantinib in BMCs, T2002 a  $IC_{50} = 226.4$  nM and BMC2,  $IC_{50} = 3029.5$  nM). The broad range (1nM – 10µM) testing of<br>370 tivantinib in BMCs, T2002 and conventional melanoma cells and PHA in BMCs revealed that<br>371 all cell lines responded to both MET ivantinib in BMCs, T2002 and conventional melanoma cells and PHA in BMCs revealed that<br>371 all cell lines responded to both METi, irrespective of the mutation status. However, we<br>372 observed that the non-(brain) metastati 371 all cell lines responded to both METi, irrespective of the mutation status. However, we<br>372 observed that the non-(brain) metastatic cell lines A375, A2058, and T2002 were more<br>373 sensitive to treatment with tivantin 372 observed that the non-(brain) metastatic cell lines A375, A2058, and T2002 were more<br>
sensitive to treatment with tivantinib than BMCs (Figures h-j, Supplementary figure 7d). The<br>
median IC<sub>50</sub> value of BMCs was ~600 373 sensitive to treatment with tivantinib than BMCs (Figures h-j, Supplementary figure 7d). The<br>374 median IC<sub>50</sub> value of BMCs was ~600 nM (range: 406.5 – 800.1). Cell lines lacking BRAF<br>375 and NRAS mutations (MeWo, T2 374 median IC<sub>50</sub> value of BMCs was ~600 nM (range: 406.5 – 800.1). Cell lines lacking BRAF<br>375 and NRAS mutations (MeWo, T2002) showed highest responses to tivantinib (Figure 5k).<br>376 In summary, brain metastatic as conv

and NRAS mutations (MeWo, T2002) showed highest responses to tivantinib (Figure 5k).<br>376<br>In summary, brain metastatic as conventional melanoma cell lines responded to MI<br>378 suggesting that targeting of MET signaling might 376<br>377<br>378<br>379 377 In summary, brain metastatic as conventional melanoma cell lines responded to METi,<br>378 suggesting that targeting of MET signaling might be a promising tool for the treatment of non-<br>379 BRAF<sup>V600</sup> and BRAF<sup>V600</sup> muta suggesting that targeting of MET signaling might be a promising tool for the treatment of non-<br>BRAF<sup>V600</sup> and BRAF<sup>V600</sup> mutated MBM that acquired resistance to BRAFi or for combinatorial<br>of METi and ICi in NRAS mutated tu  $\mathsf{BRAF}^{\mathsf{V600}}$  and  $\mathsf{BRAF}^{\mathsf{V600}}$ 379 BRAF<sup>V600</sup> and BRAF<sup>V600</sup> mutated MBM that acquired resistance to BRAFi or for combinatorial<br>380 of METi and ICi in NRAS mutated tumors.<br>381<br>382 380 of METi and ICi in NRAS mutated tumors.<br>381<br>382

- 
- 381<br>382

14

383 **Discussion**<br>384 The spatiotemp<br>385 determined by<br>386 macrophages, a The spatiotemporal development of primary and secondary brain tumors is strongly<br>385 determined by the crosstalk of tumor and brain micronenvironmental cells, particularly<br>386 macrophages, astrocytes and microglia<sup>56</sup> and determined by the crosstalk of tumor and brain micronenvironmental cells, particularly<br>
macrophages, astrocytes and microglia<sup>56</sup> and the consequential activation of inflammatory<br>
processes<sup>57</sup>. Although the neuro-inflamma macrophages, astrocytes and microglia<sup>56</sup> macrophages, astrocytes and microglia<sup>56</sup> and the consequential activation of inflammatory<br>387 processes<sup>57</sup>. Although the neuro-inflammatory processes that are activated alongside<br>388 development and progression of primar processes<sup>57</sup> processes<sup>57</sup>. Although the neuro-inflammatory processes that are activated alongside<br>388 development and progression of primary brain tumors such as glioblastoma have been<br>389 intensively studied, the mechanisms that acco development and progression of primary brain tumors such as glioblastoma have been<br>intensively studied, the mechanisms that accompany emergence of brain metastases on the<br>other side are not well investigated.<br>391 Here, we

intensively studied, the mechanisms that accompany emergence of brain metastases on the<br>390 other side are not well investigated.<br>391 Here, we used combined transcriptome and methylome profiling to unravel the molecular<br>39 390 other side are not well investigated.<br>391 Here, we used combined transcrip<br>392 features of MBM of different prog<br>393 associated macrophages/microglia 391 Here, we used combined transcriptome and methylome profiling to unravel the molecular<br>392 features of MBM of different progression stages showing high and low level of tumor-<br>393 associated macrophages/microglia (TAMs) features of MBM of different progression stages showing high and low level of tumor-<br>associated macrophages/microglia (TAMs) infiltration, irrespective of the phenotype (Ecad,<br>NGFR). Generally, TAMs foster development and associated macrophages/microglia (TAMs) infiltration, irrespective of the phenotype (Ecad,<br>394 NGFR). Generally, TAMs foster development and progression of primary brain tumors<sup>58,59</sup>,<br>395 however their functional role in NGFR). Generally, TAMs foster development and progression of primary brain tumors<sup>58,59</sup> NGFR). Generally, TAMs foster development and progression of primary brain tumors<sup>58,99</sup>,<br>395 however their functional role in MBM may be different. We observed that MBM containing a<br>396 high proportion of TAMs were assoc 395 however their functional role in MBM may be different. We observed that MBM containing a<br>396 high proportion of TAMs were associated with a high immune score and infiltration of CD3<sup>+</sup> T<br>397 cells. The profiling of Iba high proportion of TAMs were associated with a high immune score and infiltration of  $CD3<sup>+</sup>$ high proportion of TAMs were associated with a high immune score and infiltration of CD3<sup>+</sup> T<br>cells. The profiling of Iba1/AIF1<sup>high</sup> tumors revealed a cluster of genes, among them *ITGB7*,<br>*APBB1IP* as *SUSD3* and *PD-L2* cells. The profiling of Iba1/AIF1<sup>high</sup> cells. The profiling of Iba1/AIF1<sup>nigh</sup> tumors revealed a cluster of genes, among them *ITGB7*,<br>398 APBB1IP as SUSD3 and PD-L2, that were widely expressed among immune cell subtypes<br>399 and previously associated with incre *APBB1IP* as *SUSD3* and *PD-L2*, that were widely expressed among immune cell subtypes<br>and previously associated with increased immune T cell infiltration<sup>23,27,28,33</sup> and favored<br>400 outcome. Previous mouse studies demon and previously associated with increased immune T cell infiltration $^{23,27,28,33}$ and previously associated with increased immune T cell infiltration<sup>23,27,28,33</sup> and favored<br>399 outcome. Previous mouse studies demonstrated a pivotal role of ITGB7 for intestinal T cell<br>301 recruitment and correlated lo outcome. Previous mouse studies demonstrated a pivotal role of ITGB7 for intestinal T cell<br>401 recruitment and correlated low levels of Itgb7 with colorectal cancer progression and<br>402 maintenance of intestinal stem cells recruitment and correlated low levels of Itgb7 with colorectal cancer progression and<br>
402 maintenance of intestinal stem cells via Ecad-mediated interaction<sup>27,33</sup>. However, we<br>
403 observed strong protein expression of I maintenance of intestinal stem cells via Ecad-mediated interaction $^{27,33}$ maintenance of intestinal stem cells via Ecad-mediated interaction<sup>27,33</sup>. However, we<br>observed strong protein expression of ITGB7 in immune cells adjacent to tumor cells of<br>Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors, suggesting a broader dos deserved strong protein expression of ITGB7 in immune cells adjacent to tumor cells of<br>404 Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors, suggesting a broader function of ITGB7 in different subtypes of<br>405 metastases and cancers. Enhance Ecad<sup>+</sup> and NGFR<sup>+</sup> Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors, suggesting a broader function of ITGB7 in different subtypes of<br>405 metastases and cancers. Enhanced expression of ITGB7 might be a prerequisite for immune<br>406 cell invasion. Therefore, epigenet metastases and cancers. Enhanced expression of ITGB7 might be a prerequisite for immune<br>cell invasion. Therefore, epigenetic marks that correlate with the expression of ITGB7 and<br>other genes mentioned above may be of progn cell invasion. Therefore, epigenetic marks that correlate with the expression of ITGB7 and<br>407 other genes mentioned above may be of prognostic importance, and the expression of these<br>408 markers could determine the pathwa other genes mentioned above may be of prognostic importance, and the expression of these<br>
markers could determine the pathways of intracranial progression.<br>
15 408 markers could determine the pathways of intracranial progression.<br>
The pathways of intracranial progression.<br>
The pathways of intracranial progression.

As previously described for the Ecad<sup>+</sup> and NGFR<sup>+</sup> As previously described for the Ecad<sup>+</sup> and NGFR<sup>+</sup> subtypes of MBM, whether tumors are<br>410 enriched or depleted in TAMs and immune cell subsets is critical and may determine<br>411 response to therapeutic intervention. The s enriched or depleted in TAMs and immune cell subsets is critical and may determine<br>411 response to therapeutic intervention. The subsequent ssGSEA-based characterization of<br>412 MBM of studies performed by us and others rev 411 response to therapeutic intervention. The subsequent ssGSEA-based characterization of<br>412 MBM of studies performed by us and others revealed molecular programs fostering or<br>413 accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subt MBM of studies performed by us and others revealed molecular programs fostering or<br>accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subtype. TAM<sup>+</sup>/TIL<sup>+</sup> tumors featured activation of MET<br>and STAT3 signaling, increased stress respons accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subtype. TAM<sup>+</sup>/TIL<sup>+</sup> accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subtype. TAM<sup>+</sup>/TIL<sup>+</sup> tumors featured activation of MET<br>and STAT3 signaling, increased stress response, tumor inflammation, senescence and<br>activation of microglia and astrocytes but al and STAT3 signaling, increased stress response, tumor inflammation, senescence and<br>activation of microglia and astrocytes but also activated interferon signaling. STAT3<br>activation in tumor-adjacent astrocytes in response t activation of microglia and astrocytes but also activated interferon signaling. STAT3<br>activation in tumor-adjacent astrocytes in response to brain damage or tumor cells is well-<br>investigated process<sup>60,61</sup> and was rapidly activation in tumor-adjacent astrocytes in response to brain damage or tumor cells is well-<br>investigated process<sup>60,61</sup> and was rapidly induced in response to brain infiltrating BMCs.<br>Hence, enrichment of STAT3 signature investigated process<sup>60,61</sup> investigated process<sup>60,61</sup> and was rapidly induced in response to brain infiltrating BMCs.<br>418 Hence, enrichment of STAT3 signature genes was likely attributed to tumor-adjacent<br>419 astrocytes and infiltrated immune cell Hence, enrichment of STAT3 signature genes was likely attributed to tumor-adjacent<br>astrocytes and infiltrated immune cells<sup>62</sup>.<br>420<br>The HGF/MET receptor signaling plays a pivotal role during brain development and neuroastrocytes and infiltrated immune cells<sup>62</sup>.

astrocytes and infiltrated immune cells<sup>62</sup>.<br>420<br>421 The HGF/MET receptor signaling plays a pivotal role dur<br>422 regeneration, homeostasis of microglia and neurons<sup>14,44</sup> 422<br>423 The HGF/MET receptor signaling plays a pivotal role during brain development and neuro-<br>regeneration, homeostasis of microglia and neurons<sup>14,44</sup> but is also involved in microglia<br>activation in response to trauma<sup>13,44,63</sup> regeneration, homeostasis of microglia and neurons<sup>14,44</sup> but is also involved in microglia<br>activation in response to trauma<sup>13,44,63</sup>. Brain infiltrating melanoma cells hence may engage<br>the HGF/MET signaling of brain cel activation in response to trauma $^{13,44,63}$ the HGF/MET signaling of brain cells and utilize for regulation of survival and proliferation.<br>425 We observed expression of MET receptor in the subset of E-cadherin (Ecad) expressing<br>426 tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> the HGF/MET signaling of brain cells and utilize for regulation of survival and proliferation.<br>425 We observed expression of MET receptor in the subset of E-cadherin (Ecad) expressing<br>426 tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> We observed expression of MET receptor in the subset of E-cadherin (Ecad) expressing<br>
426 tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> but not NGFR<sup>+</sup> cells may depend on HGF/MET signaling. As<br>
427 we observed that HGF is expressed tumors $^{23}$ , suggesting that Ecad $^{\ast}$  but not NGFR $^{\ast}$ tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> but not NGFR<sup>+</sup> cells may depend on HGF/MET signaling. As<br>
427 we observed that HGF is expressed by immune cell subsets and homeostatic or reactive<br>
428 astrocytes and microglia, we inve we observed that HGF is expressed by immune cell subsets and homeostatic or reactive<br>astrocytes and microglia, we investigated the level of activated/phosphorylated MET receptor<br>in TAM-adjacent tumor cells. We found that t astrocytes and microglia, we investigated the level of activated/phosphorylated MET receptor<br>in TAM-adjacent tumor cells. We found that tumor cells but not Iba1<sup>high</sup> TAMs that resided in<br>tumor cell-free adjacent stroma sh in TAM-adjacent tumor cells. We found that tumor cells but not Iba1<sup>high</sup> in TAM-adjacent tumor cells. We found that tumor cells but not  $\text{Iba1}^{\text{high}}$  TAMs that resided in<br>tumor cell-free adjacent stroma showed activation of MET, however MET was also activated<br>in the absence of adjacent micro tumor cell-free adjacent stroma showed activation of MET, however MET was also activated<br>in the absence of adjacent microglia in some tumor cells, suggesting a paracrine effect of<br>HGF. In line with our previous study<sup>23</sup>, 431 in the absence of adjacent microglia in some tumor cells, suggesting a paracrine effect of<br>432 HGF. In line with our previous study<sup>23</sup>, we observed enrichment of interferon-response<br>433 signatures in the subset of TI HGF. In line with our previous study<sup>23</sup>, we observed enrichment of interferon-response  $\text{HGF. In line with our previous study}^{\text{23}}$ , we observed enrichment of interferon-response<br>signatures in the subset of TIL<sup>high</sup>/immune score (IS)<sup>high</sup> tumors. We observed enrichment of<br>interferon-response genes in MBM with high levels of IT signatures in the subset of TIL<sup>high</sup>/immune score (IS)<sup>high</sup> signatures in the subset of TIL<sup>nigh</sup>/immune score (IS)<sup>nigh</sup> tumors. We observed enrichment of<br>interferon-response genes in MBM with high levels of ITGB7 expression and observed<br>significant response of Itgb7 and Hgf amon interferon-response genes in MBM with high levels of ITGB7 expression and observed<br>significant response of Itgb7 and Hgf among known interferon-inducible genes such as<br> $Cd274^{64}$  and Mx1<sup>65</sup> in interferon-gamma treated B 435 significant response of Itgb7 and Hgf among known interferon-inducible genes such as<br>436  $\text{Cd274}^{\text{64}}$  and Mx1<sup>65</sup> in interferon-gamma treated BV2 murine microglia cells (unpublished<br> $16$ Cd274 $^{64}$  and Mx1 $^{65}$ 436 Cd274 $^{64}$  and Mx1 $^{65}$  in interferon-gamma treated BV2 murine microglia cells (unpublished<br>16

study GSE132739). Hence, T cell-provided interferon-gamma might not only induce<br>438 expression of Cd274/PD-L1 but may also activate expression of HGF and ITGB7. Therefore,<br>439 autocrine MET receptor signaling might be trig expression of Cd274/PD-L1 but may also activate expression of HGF and ITGB7. Therefore,<br>autocrine MET receptor signaling might be triggered in response to immune cell released<br>interferon-gamma and/or paracrine activation o autocrine MET receptor signaling might be triggered in response to immune cell released<br>interferon-gamma and/or paracrine activation of MET signaling may occur via (INFG-<br>activated) reactive glia-released HGF.<br>Qur study br

interferon-gamma and/or paracrine activation of MET signaling may occur via (INFG-<br>activated) reactive glia-released HGF.<br>Qur study bridges the gap between the immune cell phenotype of MBM and the activation of<br>potentially activated) reactive glia-released HGF.<br>442 Our study bridges the gap between the<br>443 potentially therapeutic counteracting<br>444 immune cells thus represents a double Our study bridges the gap between the immune cell phenotype of MBM and the activation of<br>potentially therapeutic counteracting signaling pathways. The infiltration of TAMs and<br>immune cells thus represents a double-sided sw potentially therapeutic counteracting signaling pathways. The infiltration of TAMs and<br>
immune cells thus represents a double-sided sword and on the one hand is associated with<br>
an effective response to immune checkpoint i immune cells thus represents a double-sided sword and on the one hand is associated with<br>an effective response to immune checkpoint inhibitors, but on the other hand can support the<br>growth of MET expressing tumor cells via

an effective response to immune checkpoint inhibitors, but on the other hand can support the<br>growth of MET expressing tumor cells via secreted factors such as HGF.<br>Therefore, we finally assessed the potential role of small growth of MET expressing tumor cells via secreted factors such as HGF.<br>447 Therefore, we finally assessed the potential role of small molecule inhibit<br>448 (METi) for targeting of MBM that lack druggable BRAF<sup>V600</sup> mutation Therefore, we finally assessed the potential role of small molecule inhibitors of MET receptor<br>
(METi) for targeting of MBM that lack druggable BRAF<sup>V600</sup> mutations or developed refractory<br>
disease. To this end, we took ad (METi) for targeting of MBM that lack druggable BRAF $V600$ (METi) for targeting of MBM that lack druggable BRAF<sup>v600</sup> mutations or developed refractory<br>disease. To this end, we took advantage of well-characterized BMCs serving as *in vitro*<br>model systems. We observed that the ATPdisease. To this end, we took advantage of well-characterized BMCs serving as *in vitro*<br>model systems. We observed that the ATP-competitive inhibitor PHA-665752 and the non-<br>ATP-competitive, clinical phase II inhibitor AR model systems. We observed that the ATP-competitive inhibitor PHA-665752 and the non-<br>451 ATP-competitive, clinical phase II inhibitor ARQ197 (tivantinib) elicited response in BMCs<br>452 and conventional melanoma cell lines ATP-competitive, clinical phase II inhibitor ARQ197 (tivantinib) elicited response in BMCs<br>and conventional melanoma cell lines irrespective of the BRAF/NRAS mutation status.<br>However, although being effective at doses of and conventional melanoma cell lines irrespective of the BRAF/NRAS mutation status.<br>453 However, although being effective at doses of 100 – 200 nM in MeWo and A375 cells,<br>454 ARQ197 showed a median IC<sub>50</sub> value of ~1  $\mu$ However, although being effective at doses of 100 – 200 nM in MeWo and A375 cells,<br>454 ARQ197 showed a median  $IC_{50}$  value of ~1 µM in BMCs, suggesting a general difference<br>455 among brain metastatic and long-term mainta ARQ197 showed a median  $IC_{50}$  value of ~1  $µM$  in BMCs, suggesting a general difference<br>455 among brain metastatic and long-term maintained conventional cell lines established from<br>456 either non metastatic (A375) or loc

among brain metastatic and long-term maintained conventional cell lines established from<br>456 either non metastatic (A375) or locally metastatic (MeWo) cells.<br>457 In summary, we have shown that MET receptor signaling is act either non metastatic (A375) or locally metastatic (MeWo) cells.<br>457 In summary, we have shown that MET receptor signaling is<br>458 conferring a survival/growth benefit independent of BRAF/N<br>459 activation may occu In summary, we have shown that MET receptor signaling is active in a subset of MBM,<br>conferring a survival/growth benefit independent of BRAF/NRAS mutation status. MET<br>activation may occur in response to HGF released by TAM conferring a survival/growth benefit independent of BRAF/NRAS mutation status. MET<br>activation may occur in response to HGF released by TAM/immune cells and could<br>counteract therapeutic interventions. Furthermore, we sugges activation may occur in response to HGF released by TAM/immune cells and could<br>460 counteract therapeutic interventions. Furthermore, we suggest interferon-induced expression<br>461 of HGF in tumor cells triggered by interfer counteract therapeutic interventions. Furthermore, we suggest interferon-induced expression<br>461 of HGF in tumor cells triggered by interferon-gamma provided by stromal cells mediates<br>462 autocrine activation of MET-signali 461 of HGF in tumor cells triggered by interferon-gamma provided by stromal cells mediates<br>462 autocrine activation of MET-signaling tumor cells (Figure 6). In addition, we demonstrated<br>463 that methylome profiling of MBM autocrine activation of MET-signaling tumor cells (Figure 6). In addition, we demonstrated<br>that methylome profiling of MBM has high potential to identify gene regulatory sites that may<br>17 that methylome profiling of MBM has high potential to identify gene regulatory sites that may<br>17<br>17

predict favorable progression of intracranial disease. In the present study, we identified<br>epigenetic regulatory sites in a group of genes comprising ITGB7, APBB1IP, SUSD3 and<br>PD-L2 (PDCD1LG2). epigenetic regulatory sites in a group of genes comprising *ITGB7*, *APBB1IP*, *SUSD3* and<br>466 PD-L2 (*PDCD1LG2*).<br>467

# 466 PD-L2 (*PDCD1LG2*).<br>467<br>468 **Limitations of the st**

467<br>468<br>469<br>470 **Limitations of the study**<br>469 The present study is not v<br>470 is activated in tumor cells<br>471 evidence that growth of e The present study is not without limitations. Although we suggested that HGF/MET signaling<br>is activated in tumor cells in close proximity to infiltrated microglia, we have not provided<br>evidence that growth of established b 470 is activated in tumor cells in close proximity to infiltrated microglia, we have not provided<br>471 evidence that growth of established brain tumors and phosphorylation of MET decreases in<br>472 response to METi. Moreover, evidence that growth of established brain tumors and phosphorylation of MET decreases in<br>
1472 response to METi. Moreover, whether METi are capable of passing the blood-brain barrier<br>
1473 and not affect normal homeostatic 472 response to METi. Moreover, whether METi are capable of passing the blood-brain barrier<br>and not affect normal homeostatic processes e.g. those crucial for neuron survival needs to<br>be investigated.<br>475 and not affect normal homeostatic processes e.g. those crucial for neuron survival needs to<br>
474 be investigated.<br>
475<br> **Mathada** 474 be investigated.<br>475<br>476 **Methods** 

# 475<br>476<br>477

476 **Methods**<br>477 **Patient coheral**<br>478 All procedure<br>479 **respective** in **Patient cohorts**<br>
478 All procedures po<br>
479 respective institu<br>
480 later amendmen All procedures performed in this study were in accordance with the ethical standards of the<br>
479 respective institutional research committees and with the 1964 Helsinki declaration and its<br>
480 later amendments or comparab respective institutional research committees and with the 1964 Helsinki declaration and its<br>480 later amendments or comparable ethical standards. All patients gave written informed<br>481 consent for the collection and scient 480 later amendments or comparable ethical standards. All patients gave written informed<br>481 consent for the collection and scientific use of tumor material which was collected at the<br>482 Biobank of the Charité – Comprehen consent for the collection and scientific use of tumor material which was collected at the<br>482 Biobank of the Charité – Comprehensive Cancer Center (CCCC). The study was approved<br>483 by the Ethics Committee of the Charité 482 Biobank of the Charité – Comprehensive Cancer Center (CCCC). The study was approved<br>by the Ethics Committee of the Charité (EA1/152/10; EA1/107/17; EA4/028/18 and<br>484 EA1/107/17 and EA1/075/19) and Universitätsmedizin 483 by the Ethics Committee of the Charité (EA1/152/10; EA1/107/17; EA4/028/18 and<br>484 EA1/107/17 and EA1/075/19) and Universitätsmedizin Greifswald (BB 001/23).<br>485 **Cultivation of MBM-derived and conventional melanoma ce** 

484 EA1/107/17 and EA1/075/19) and Universitätsmedizin Greifswald (BB 001/23).<br>485 **Cultivation of MBM-derived and conventional melanoma cell lines**<br>487 All cell lines were cultured as previously reported<sup>23</sup>. Briefly, all 485<br>486<br>487<br>488 **Cultivation of MBM-derived and conventional melanoma cell lines**<br>487 All cell lines were cultured as previously reported<sup>23</sup>. Briefly, all brain m<br>488 lines (BMCs) and conventional melanoma cell lines were kept at 37<sup>c</sup><br>4 All cell lines were cultured as previously reported<sup>23</sup> All cell lines were cultured as previously reported<sup>23</sup>. Briefly, all brain metastases-derived cell<br>
1488 lines (BMCs) and conventional melanoma cell lines were kept at  $37^{\circ}$ C/ 5% CO<sub>2</sub> and 95%<br>
1489 humidity in cell c 488 lines (BMCs) and conventional melanoma cell lines were kept at  $37^{\circ}$ C/ 5% CO<sub>2</sub> and 95%<br>humidity in cell culture medium (DMEM, 4.5 g/L glucose, stabilized glutamine/GlutaMax,<br>18 489 humidity in cell culture medium (DMEM, 4.5 g/L glucose, stabilized glutamine/GlutaMax,<br>18<br>18

490 pyruvate, Gibco/ThermoFisher) supplemented with 10% fetal bovine (FBS, Gibco) serum and<br>491 1% penicillin/streptomycin (P/S) (Gibco/ThermoFisher) and routinely passaged. BMCs were<br>492 established from intraoperative tu 1% penicillin/streptomycin (P/S) (Gibco/ThermoFisher) and routinely passaged. BMCs were<br>established from intraoperative tumors as previously reported<sup>23</sup>.<br>493<br>**Live cell imaging-based drug sensitivity assays** established from intraoperative tumors as previously reported $^{23}$ .

established from intraoperative tumors as previously reported<sup>23</sup>.<br>493<br>**Live cell imaging-based drug sensitivity assays**<br>Drug treatments were performed 24 h after seeding of 2,500-493<br>494<br>495<br>496 **Live cell imaging-based drug sensitivity assays**<br>495 Drug treatments were performed 24 h after seedin<br>496 medium. The response of BMCs and conventional<br>497 665752 or ARQ197 (all purchased from Selleckc Drug treatments were performed 24 h after seeding of 2,500-5,000 cells/96-well in 100 µl<br>
496 medium. The response of BMCs and conventional melanoma cell lines to dabrafenib, PHA-<br>
497 665752 or ARQ197 (all purchased from medium. The response of BMCs and conventional melanoma cell lines to dabrafenib, PHA-<br>497 665752 or ARQ197 (all purchased from Selleckchem) in a range of 1nM-10µM of eight<br>498 technical replicates was determined by live ce 665752 or ARQ197 (all purchased from Selleckchem) in a range of 1nM-10μM of eight<br>technical replicates was determined by live cell imaging. Images were taken every three<br>hours using a 10x objective and the general label-f technical replicates was determined by live cell imaging. Images were taken every three<br>hours using a 10x objective and the general label-free mode, two pictures of eight technical<br>replicates per condition were taken. Drug hours using a 10x objective and the general label-free mode, two pictures of eight technical<br>
soo replicates per condition were taken. Drug response was assessed by changes in the cellular<br>
density over time. The cell dens replicates per condition were taken. Drug response was assessed by changes in the cellular<br>501 density over time. The cell density was determined by a confluence mask tool as part of the<br>502 Incucyte S3 software. IC50 valu density over time. The cell density was determined by a confluence mask tool as part of the<br>502 Incucyte S3 software. IC50 values were calculated by curve-fitting (https://search.r-<br>503 project.org/CRAN/refmans/REAT/html/c 502 IncucyteS3 software. IC50 values were calculated by curve-fitting (https://search.r-<br>503 project.org/CRAN/refmans/REAT/html/curvefit.html) based on confluence measurements at<br>504 day 3.<br>**In vivo experiments** project.org/CRAN/refmans/REAT/html/curvefit.html) based on confluence measurements at<br>504 day 3.<br>**In vivo experiments**<br>506 All animal experiments were performed in accordance with the German Animal Protection

504 day 3.<br>505 **In viv**<br>506 All an<br>507 Law u 505 **In vivo experiments**<br>506 All animal experimen<br>507 Law under the permis<br>508 Social Affairs (LaGes 506 All animal experiments were performed in accordance with the German Animal Protection<br>507 Law under the permission number G0130/20 obtained via the Berlin Ministry of Health and<br>508 Social Affairs (LaGeSo). ARRIVE 2.0 507 Law under the permission number G0130/20 obtained via the Berlin Ministry of Health and<br>508 Social Affairs (LaGeSo). ARRIVE 2.0 Guidelines were strictly followed and performed as<br>509 previously reported<sup>23</sup>. Briefly, 2 Social Affairs (LaGeSo). ARRIVE 2.0 Guidelines were strictly followed and performed as<br>
previously reported<sup>23</sup>. Briefly, 2.5x10<sup>4</sup> BMC1-M4 and BMC2 cells were stereotactically<br>
inoculated into brains of female Crl:CD1-Fox previously reported<sup>23</sup>. Briefly,  $2.5x10^4$  BMC1-M4 and BMC2 cells were stereotactically previously reported<sup>23</sup>. Briefly, 2.5x10<sup>4</sup> BMC1-M4 and BMC2 cells were stereotactically<br>510 inoculated into brains of female Crl:CD1-Foxn1<sup>nu</sup> nude mice (8-9 weeks of age, 24-26g,<br>511 Charles River Laboratories) were wit inoculated into brains of female Crl:CD1-Foxn1<sup>nu</sup> 510 inoculated into brains of female Crl:CD1-Foxn1<sup>nu</sup> nude mice (8-9 weeks of age, 24-26g,<br>511 Charles River Laboratories) were with using a 1µl Hamilton syringe and a stereotactic frame<br>512 as described previously<sup>66</sup>. S11 Charles River Laboratories) were with using a 1µl Hamilton syringe and a stereotactic frame<br>
512 as described previously<sup>66</sup>. Tumor growth was tracked by MRI and animals were sacrificed by<br>
513 perfusion with 4% PFA i as described previously<sup>66</sup> 512 as described previously<sup>66</sup>. Tumor growth was tracked by MRI and animals were sacrificed by<br>513 perfusion with 4% PFA in deep anesthesia after tumors reached a volume of 20 mm<sup>3</sup>.<br>514 Following, whole brains were remo 513 perfusion with 4% PFA in deep anesthesia after tumors reached a volume of 20 mm<sup>3</sup>.<br>514 Following, whole brains were removed, dehydrated, paraffin embedded and sections of 2 μm<br>515 were used for downstream analyses.<br>5 514 Following, whole brains were removed, dehydrated, paraffin embedded and sections of 2 µm<br>515 were used for downstream analyses.<br>516<br>517 515 were used for downstream analyses.<br>516<br>517

516<br>517

**RNA isolation and sequencing**<br>519 **Isolation of total RNA from snaplical previously reported<sup>23</sup>. Briefly, 10<br>521 TruSeq Stranded total RNA Sa** 519 Isolation of total RNA from snap frozen tumors and RNA sequencing was performed as<br>520 previously reported<sup>23</sup>. Briefly, 100 ng of total RNA was used for library preparation with<br>521 TruSeq Stranded total RNA Sample previously reported<sup>23</sup> previously reported<sup>23</sup>. Briefly, 100 ng of total RNA was used for library preparation with<br>521 TruSeq Stranded total RNA Sample Preparation-Kit and Ribo-Zero Gold Kit (Illumina).<br>522 Paired-end (2x100 bp) sequencing of R 521 TruSeq Stranded total RNA Sample Preparation-Kit and Ribo-Zero Gold Kit (Illumina).<br>522 Paired-end (2x100 bp) sequencing of RNA libraries with integrity numbers (RIN) ≥7 was<br>523 performed on NovaSeq6000 platform at Ce 522 Paired-end (2x100 bp) sequencing of RNA libraries with integrity numbers (RIN) ≥7 was<br>523 performed on NovaSeq6000 platform at Cegat GmbH, Tuebingen (Germany). Following<br>524 demultiplexing of sequenced reads and adap performed on NovaSeq6000 platform at Cegat GmbH, Tuebingen (Germany). Following<br>524 demultiplexing of sequenced reads and adapter trimming<sup>67</sup>, FASTQ files were obtained. Raw<br>525 counts of protein-coding genes were normali demultiplexing of sequenced reads and adapter trimming $^{67}$ demultiplexing of sequenced reads and adapter trimming<sup>o</sup>', FASTQ files were obtained. Raw<br>
s25 counts of protein-coding genes were normalized using the DESeq2<br>
(https://bioconductor.org/packages/ release/bioc/html/DESeq2. 525 counts of protein-coding genes were normalized using the DESeq2<br>526 (https://bioconductor.org/packages/ release/bioc/html/DESeq2.html) package<sup>68</sup>. Differential<br>527 expression of genes between groups was determined aft (https://bioconductor.org/packages/ release/bioc/html/DESeq2.html) package<sup>68</sup>. Differential (https://bioconductor.org/packages/ release/bioc/html/DESeq2.html) package<sup>68</sup>. Differential<br>527 expression of genes between groups was determined after fitting models of negative<br>528 binomial distributions to the raw coun expression of genes between groups was determined after fitting models of negative<br>528 binomial distributions to the raw counts. Raw p-values were FDR (false discovery rate)-<br>529 adjusted for multiple testing and a value b 528 binomial distributions to the raw counts. Raw p-values were FDR (false discovery rate)-<br>529 adjusted for multiple testing and a value below 0.05 for the adjusted p-values were used to<br>530 determine significant differen 529 adjusted for multiple testing and a value below 0.05 for the adjusted p-values were used to<br>530 determine significant differentially expressed genes.<br>531 **Gene-set enrichment GSEA/Single-sample GSEA/Scores** 

determine significant differentially expressed genes.<br>531 **Gene-set enrichment GSEA/Single-sample GSEA**<br>533 **GSEA** was performed using the most current B 531<br>532<br>533<br>534 Gene-set enrichment GSEA/Single-sample GSEA/Scores<br>533 GSEA was performed using the most current BROAD<br>634 (http://www.broadinstitute.org/gsea/downloads.jsp) and gene<br>535 signature database MsigDB<sup>50,69</sup>, v7.4. In addition GSEA was performed using the most current BROAD javaGSEA standalone version<br>534 (http://www.broadinstitute.org/gsea/downloads.jsp) and gene signatures of the molecular<br>535 signature database MsigDB<sup>50,69</sup>, v7.4. In additio (http://www.broadinstitute.org/gsea/downloads.jsp) and gene signatures of the molecular<br>signature database MsigDB<sup>50,69</sup>, v7.4. In addition, we performed GSVA/ssGSEA using R<br>packages GSVA<sup>70</sup>, GSRI, GSVAdata and org.Hs.eg. signature database MsigDB<sup>50,69</sup> signature database MsigDB<sup>50,69</sup>, v7.4. In addition, we performed GSVA/ssGSEA using R<br>packages GSVA<sup>70</sup>, GSRI, GSVAdata and org.Hs.eg.db and a customized collection of gene<br>signatures including the signatures provided by packages GSVA<sup>70</sup> packages GSVA<sup>70</sup>, GSRI, GSVAdata and org.Hs.eg.db and a customized collection of gene<br>signatures including the signatures provided by Biermann et al.<sup>71</sup> and own signatures as<br>defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup>, micro signatures including the signatures provided by Biermann et al.<sup>71</sup> and own signatures as signatures including the signatures provided by Biermann et al.<sup>71</sup> and own signatures as<br>
defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup>, microglia or TME core genes (this study). All gene<br>
signatures are shown in Supplementary defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup> defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup>, microglia or TME core genes (this study). All gene<br>signatures are shown in Supplementary table 5. Microglia scores were defined as the mean<br> $\beta$ -value of probes cg24400465 (APBB1IP), signatures are shown in Supplementary table 5. Microglia scores were defined as the mean<br>540 β-value of probes cg24400465 (APBB1IP), cg05128364 (SYK), cg21704050 (P2RY12) and<br>541 cg03498995 (HCK) or expression levels (log 540 β-value of probes cg24400465 (APBB1IP), cg05128364 (SYK), cg21704050 (P2RY12) and<br>541 cg03498995 (HCK) or expression levels (log2 FPKM) of these markers. The proliferation<br>542 index in Figure 4d was defined as mean ex 541 cg03498995 (HCK) or expression levels (log2 FPKM) of these markers. The proliferation<br>index in Figure 4d was defined as mean expression level of the cell cycle regulators PCNA,<br>MKI67, CCNB1 and CCNB2.<br>544 542 index in Figure 4d was defined as mean expression level of the cell cycle regulators PCNA,<br>543 MKI67, CCNB1 and CCNB2.<br>544<br>545 543 MKI67, CCNB1 and CCNB2.<br>544<br>545<br>-

544<br>545

20

Fluorescence in situ hybridization (FISH)<br>547 FISH analysis was performed on 4 µm secti<br>548 dehydrated and incubated in pre-treatment s<br>549 Samples were treated with pepsin solution f FISH analysis was performed on 4 µm sections of FFPE blocks. Slides were deparaffinized,<br>548 dehydrated and incubated in pre-treatment solution (Dako, Denmark) for 10 min at 95–99°C.<br>549 Samples were treated with pepsin so 549 Samples were treated with pepsin solution for 6 min at 37°C. For hybridization, a Vysis MET<br>550 SpectrumRed/ Vysis CEP 7 (D7Z1) SpectrumGreen Probe (Abbott, Chicago, USA) was<br>551 used. Incubation took place overnight a Samples were treated with pepsin solution for 6 min at 37°C. For hybridization, a Vysis MET<br>550 SpectrumRed/ Vysis CEP 7 (D7Z1) SpectrumGreen Probe (Abbott, Chicago, USA) was<br>551 used. Incubation took place overnight at 37 SpectrumRed/ Vysis CEP 7 (D7Z1) SpectrumGreen Probe (Abbott, Chicago, USA) was<br>551 used. Incubation took place overnight at 37°C, followed by counterstaining with 4,6-<br>552 diamidino-2-phenylindole (DAPI). For each case, si used. Incubation took place overnight at 37°C, followed by counterstaining with 4,6-<br>552 diamidino-2-phenylindole (DAPI). For each case, signals were counted in 50 non-overlapping<br>553 tumor cells using a fluorescence micro diamidino-2-phenylindole (DAPI). For each case, signals were counted in 50 non-overlapping<br>553 tumor cells using a fluorescence microscope (BX63 Automated Fluorescence Microscope,<br>554 Olympus Corporation, Tokyo, Japan). Co tumor cells using a fluorescence microscope (BX63 Automated Fluorescence Microscope,<br>554 Olympus Corporation, Tokyo, Japan). Computer-based documentation and image analysis<br>555 was performed with the SoloWeb imaging system S54 Olympus Corporation, Tokyo, Japan). Computer-based documentation and image analysis<br>
555 was performed with the SoloWeb imaging system (BioView Ltd, Israel). MET high-level<br>
556 amplification (MET FISH+) was defined a ss5 was performed with the SoloWeb imaging system (BioView Ltd, Israel). MET high-level<br>556 amplification (MET FISH+) was defined as (a) MET/CEN7 ratio ≥2.0, (b) average MET copy<br>557 number/cell ≥ 6 or (c) ≥10% of tumor c 556 amplification (MET FISH+) was defined as (a) MET/CEN7 ratio ≥2.0, (b) average MET copy<br>557 number/cell ≥ 6 or (c) ≥10% of tumor cells with ≥15 MET copies/cell as described in<br>558 Schildhaus et al<sup>72</sup>.<br>559 557 number/cell ≥ 6 or (c) ≥10% of tumor cells with ≥15 MET copies/cell as described in<br>558 Schildhaus et al<sup>72</sup>.<br>559 Schildhaus et al<sup>72</sup>. 558 Schildhaus et al<sup>72</sup>.<br>559<br>560 **Quantitative real-t** 

559<br>560<br>561<br>562 **Quantitative real-time RT-PCR**<br>561 RNA isolation from frozen cell<br>562 Germany) and, following the ma<br>563 carried out on a Step one plus P RNA isolation from frozen cell pellets was performed with the RNeasy Mini Kit (Qiagen,<br>562 Germany) and, following the manufacturers protocol as previously reported<sup>23</sup>.qRT-PCR was<br>563 carried out on a Step one plus PCR cy Germany) and, following the manufacturers protocol as previously reported<sup>23</sup> 562 Germany) and, following the manufacturers protocol as previously reported<sup>23</sup>.qRT-PCR was<br>563 carried out on a Step one plus PCR cycler (Applied Biosystems, Germany) for 30–40 cycles.<br>564 Primers were designed for 55 563 carried out on a Step one plus PCR cycler (Applied Biosystems, Germany) for 30–40 cycles.<br>564 Primers were designed for 55–60°C annealing temperatures. Relative expression levels were<br>565 calculated with the ΔΔCT met 564 Primers were designed for 55–60°C annealing temperatures. Relative expression levels were<br>565 calculated with the ΔΔCT method<sup>73</sup>, normalized to β-actin. Primer sequences are shown in<br>566 Supplementary table 7.<br>567 calculated with the  $\Delta\Delta\text{CT}$  method<sup>73</sup> 565 calculated with the ΔΔCT method<sup>73</sup>, normalized to β-actin. Primer sequences are shown in<br>566 Supplementary table 7.<br>567 **Immunohistochemistry (IHC)/Immunofluorescence (IF)** 

566 Supplementary table 7.<br>567<br>568 **Immunohistochemistr**<br>569 Automated immunohis 567<br>568<br>569<br>570 Immunohistochemistry (IHC)/Immunofluorescence (IF)<br>569 Automated immunohistochemical staining was performed on formalin-fixed, paraffin-<br>570 embedded (FFPE) tissue sections using the BenchMark Ultra (Ventana) autostainer. Automated immunohistochemical staining was performed on formalin-fixed, paraffin-<br>570 embedded (FFPE) tissue sections using the BenchMark Ultra (Ventana) autostainer. The<br>571 following primary antibodies were used: CD3 (a embedded (FFPE) tissue sections using the BenchMark Ultra (Ventana) autostainer. The<br>571 following primary antibodies were used: CD3 (anti-CD3ε, Agilent, catalog number:<br>572 #A045201-2, rabbit, dilution: 1:100), pMET (pho 571 following primary antibodies were used: CD3 (anti-CD3ε, Agilent, catalog number:<br>572 #A045201-2, rabbit, dilution: 1:100), pMET (phospho-MET, Tyr1234/1235, Cell signaling,<br>21 572 #A045201-2, rabbit, dilution: 1:100), pMET (phospho-MET, Tyr1234/1235, Cell signaling,

catalog number: #3077, rabbit, dilution: 1:100), pS6 (phospho-S6 ribosomal protein<br>574 Ser235/236, Cell signaling, catalog number: #2211, rabbit, dilution: 1:100), IBA1 (IBA1/AIF-1,<br>575 ionized calcium-binding adaptor mole Ser235/236, Cell signaling, catalog number: #2211, rabbit, dilution: 1:100), IBA1 (IBA1/AIF-1,<br>
ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number: #17198, rabbit,<br>
dilution: 1:100), ITGB7 (Integrin ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number: #17198, rabbit,<br>576 dilution: 1:100), ITGB7 (Integrin beta 7, Thermo Fisher, catalog number: #BS-1051R, rabbit,<br>577 dilution: 1:100) and pSTAT3 (p dilution: 1:100), ITGB7 (Integrin beta 7, Thermo Fisher, catalog number: #BS-1051R, rabbit,<br>dilution: 1:100) and pSTAT3 (phospho-STAT3, Tyr705, Cell signaling, catalog number:<br>#9145, rabbit, dilution: 1:100) and MITF (clon dilution: 1:100) and pSTAT3 (phospho-STAT3, Tyr705, Cell signaling, catalog number:<br>
#9145, rabbit, dilution: 1:100) and MITF (clones C5 $\square$ + $\square$ D5, Zytomed, catalog number:<br>
Z2161MP, mouse, dilution: 1:100). Primary antib #9145, rabbit, dilution: 1:100) and MITF (clones C5□+□D5, Zytomed, catalog number:<br>579 Z2161MP, mouse, dilution: 1:100). Primary antibodies were applied and developed using the<br>580 iVIEW DAB Detection Kit (Ventana Medical Z2161MP, mouse, dilution: 1:100). Primary antibodies were applied and developed using the<br>580 iVIEW DAB Detection Kit (Ventana Medical Systems) or the ultraView Universal Alkaline<br>581 Phosphatase Red Detection Kit (Ventana iVIEW DAB Detection Kit (Ventana Medical Systems) or the ultraView Universal Alkaline<br>581 Phosphatase Red Detection Kit (Ventana Medical Systems). All slides were counterstained<br>582 with hematoxylin for 8 minutes. IF of mo 581 Phosphatase Red Detection Kit (Ventana Medical Systems). All slides were counterstained<br>582 with hematoxylin for 8 minutes. IF of mouse brain sections was performed with IBA1<br>583 (IBA1/AIF-1, ionized calcium-binding ad with hematoxylin for 8 minutes. IF of mouse brain sections was performed with IBA1<br>583 (IBA1/AIF-1, ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number:<br>584 #17198, rabbit, dilution: 1:100), KBA.62, 583 (IBA1/AIF-1, ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number:<br>584 #17198, rabbit, dilution: 1:100), KBA.62, NovusBiologicals, catalog number: NBP2-45285,<br>585 mAb mouse, 1:100; GFAP-AlexaFluor 584 #17198, rabbit, dilution: 1:100), KBA.62, NovusBiologicals, catalog number: NBP2-45285,<br>585 mAb mouse, 1:100; GFAP-AlexaFluor594, BioLegend, catalog number: 644708, mAb<br>586 mouse.<br>587 585 mAb mouse, 1:100; GFAP-AlexaFluor594, BioLegend, catalog number: 644708, mAb<br>586 mouse.<br>587<br>588 **Data availability** 

# 586 mouse.<br>587<br>588 **Data a**<br>589 Whole

587<br>588<br>589<br>590 588 **Data availability**<br>589 Whole transcriptome<br>590 Phenome Archive<br>591 EGAS00001005976 Whole transcriptome and methylome data were deposited in the European Genome-<br>590 Phenome Archive (EGA), under accession numbers EGAS00001005975,<br>591 EGAS00001005976 (https://ega-archive.org/studies/). The data are availab 590 Phenome Archive (EGA), under accession numbers EGAS00001005975,<br>591 EGAS00001005976 (https://ega-archive.org/studies/). The data are available under<br>592 controlled access. Supplementary tables of our recent study have 591 EGAS00001005976 (https://ega-archive.org/studies/). The data are available under<br>592 controlled access. Supplementary tables of our recent study have been deposited at Zenodo<br>593 (https://doi.org/10.5281/zenodo.1000688 controlled access. Supplementary tables of our recent study have been deposited at Zenodo<br>
(https://doi.org/10.5281/zenodo.10006881). Supplementary tables of our previous study<br>
containing a full list of patient's characte 593 (https://doi.org/10.5281/zenodo.10006881). Supplementary tables of our previous study<br>594 containing a full list of patient s characteristics (Supplementary table 1) have been deposited<br>595 at Zenodo (https://zenodo.or 594 containing a full list of patient´s characteristics (Supplementary table 1) have been deposited<br>at Zenodo (https://zenodo.org/record/7013097 and https://doi.org/10.5281/zenodo.7249214).<br>596 595 at Zenodo (https://zenodo.org/record/7013097 and https://doi.org/10.5281/zenodo.7249214).<br>596<br>596

 $22<sub>2</sub>$ 



# 606<br>607<br>608 606 **Competing interests**<br>607 The authors declare no confl<br>608 **Funding**

607 The authors declare no conflicting interests.<br>608 <br>610 JR is an alumnus of the BIH-Charité Clini 609<br>610<br>611 609 **Funding**<br>610 JR is an al<br>611 Universitäts<br>612 Consortium Fiame JR is an alumnus of the BIH-Charité Clinical Scientist Program funded by the Charité –<br>611 Universitätsmedizin Berlin and the Berlin Institute of Health. We thank the German Cancer<br>612 Consortium (DKTK), Partner site 611 Universitätsmedizin Berlin and the Berlin Institute of Health. We thank the German Cancer<br>612 Consortium (DKTK), Partner site Berlin for technical support. AV received funding by the<br>613 ÖAW (DOC Fellowship: DOC/26523) 612 Consortium (DKTK), Partner site Berlin for technical support. AV received funding by the<br>613 ÖAW (DOC Fellowship: DOC/26523).<br>614 **Acknowledgments** 613 OAW (DOC Fellowship: DOC/26523).<br>614<br>615 **Acknowledgments**<br>616 We gratefully thank Cathrin Müller for (

614<br>615<br>616<br>617 615 **Acknowledgments**<br>616 We gratefully thank Cathri<br>617<br>618 616 We gratefully thank Cathrin Müller for excellent technical assistance.<br>617<br>618<br>619

- 618<br>619
- 
- 
- 619<br>620<br>621 ---<br>620<br>621<br>622 621
- 622

- 
- **623 References**<br> **624 1** Redmer, 1<br> **625** matter. M<br> **626 2** Srinivasan<br> **627** of brair<br> **628** doi:10.109<br> **620 2** Helt M For the gist of the matter. Mol Cancer 17, 106, doi:10.1186/s12943-018-0854-5 (2018).<br>
625 matter. Mol Cancer 17, 106, doi:10.1186/s12943-018-0854-5 (2018).<br>
626 2 Srinivasan, E. S., Deshpande, K., Neman, J., Winkler, F. & 626 2 Srinivasan, E. S., Deshpande, K., Neman, J., Winkler, F. & Khasraw, M<br>627 of brain metastases from solid tumors. Neurooncol<br>628 doi:10.1093/noajnl/vdab121 (2021).<br>629 3 Holt, M. G. Astrocyte heterogeneity and intera 627 of brain metastases from solid tumors. Neurooncol Adv 3, v121-v132,<br>628 doi:10.1093/noajnl/vdab121 (2021).<br>629 3 Holt, M. G. Astrocyte heterogeneity and interactions with local neural circuits. *Essays*<br>630 *Biochem* 6
- 628 doi:10.1093/noajnl/vdab121 (2021).<br>629 3 Holt, M. G. Astrocyte heterogeneity and interactions with local neural circuits. *Essays*<br>630 *Biochem* **67**, 93-106, doi:10.1042/ebc20220136 (2023).<br>631 4 Bilscher, M. M. et al 629 3 Holt, M. G. Astrocyte heterogenei<br>630 *Biochem* 67, 93-106, doi:10.1042/ebo<br>631 4 Hilscher, M. M. *et al.* Spatial and term<br>632 oligodendrocyte subtypes. *BMC Biolo*<br>633 5 Li, Y. *et al.* Decoding the temporal a<br>634
- 
- 629 3 Holt, M. G. Astrocyte heterogeneity and interactions with local neural circuits. Essays 631 4 Hilscher, M. M. *et al.* Spatial and temporal heterogene<br>632 oligodendrocyte subtypes. *BMC Biology* 20, 122, doi:10.<br>633 5 Li, Y. *et al.* Decoding the temporal and regional specifical human brain. *Cell stem cell* 632 oligodendrocyte subtypes. *BMC Biology* 20, 122, doi:10.1186/s12915-022-01325-z (2022).<br>633 5 Li, Y. *et al.* Decoding the temporal and regional specification of microglia in the developing<br>634 human brain. *Cell stem* 633 5 Li, Y. *et al.* Decoding the temporal and regional specification of microglia in the develop<br>634 human brain. *Cell stem cell* **29**, 620-634 e626, doi:10.1016/j.stem.2022.02.004 (2022).<br>635 Tan, Y.-L., Yuan, Y. & Ti
- 634 bunnels and regional specification of interogram the developing<br>634 human brain. Cell stem cell 29, 620-634 e626, doi:10.1016/j.stem.2022.02.004 (2022).<br>635 finn, Y.-L., Yuan, Y. & Tian, L. Microglial regional heterog 635 6 Tan, Y.-L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the<br>636 Molecular Psychiatry 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).<br>637 1 Liddelow, S. A. & Barres, B. A. Reactive Astroc
- 
- 636 *Molecular Psychiatry* 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).<br>637 1 Liddelow, S. A. & Barres, B. A. Reactive Astrocytes: Production, Function, and Therapeutic<br>638 Potential. *Immunity* 46, 957-967, doi:10.1 For the Psychiatry 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).<br>
Molecular Psychiatry 25, 351-367, doi:10.1016/j.immuni.2017.06.006 (2017)<br>

Bennett, M. L. & Viaene, A. N. What are activated and reactive glia and w<br> Formula *Call Deadlyting* Call Deadlyting Cal
- 
- 639 8 Bennett, M. L. & Viaene, A. N. What are activated and reactive glia and wh<br>640 neurodegeneration? *Neurobiol Dis* 148, 105172, doi:10.1016/j.nbd.2020.105<br>641 9 Tan, Y. L., Yuan, Y. & Tian, L. Microglial regional het For Figure 1. Control of Microsofter and Reaction 2.020.105172 (2021).<br>
640 neurodegeneration? Neurobiol Dis 148, 105172, doi:10.1016/j.nbd.2020.105172 (2021).<br>
642 Psychiatry 25, 351-367, doi:10.1038/s41380-019-0609-8 (20 641 9 Tan, Y. L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the brain.<br>642 *Psychiatry* 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).<br>643 10 Mathys, H. *et al.* Temporal Tracking of Microgl Fan, Y. L., Yuan, Y. & Tian, L. Microglial regional neterogeneity and its role in the brain. More Psychiatry 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).<br>
643 10 Mathys, H. *et al.* Temporal Tracking of Microglia Act 643 10 Mathys, H. *et al.* Temporal Tracking of Microglia Activation in M<br>644 Cell Resolution. Cell Rep 21, 366-380, doi:10.1016/j.celrep.2017.<br>645 11 Schwartz, H. *et al.* Incipient Melanoma Brain Metastases<br>646 Neuroinf
- 644 Cell Resolution. *Cell Rep* 21, 366-380, doi:10.1016/j.celrep.2017.09.039 (2017).<br>645 11 Schwartz, H. *et al.* Incipient Melanoma Brain Metastases Instigate Astrogliosis and<br>646 Neuroinflammation. Cancer Res 76, 4359-4 645 11 Schwartz, H. *et al.* Incipient Melanoma Brain Metastases Instigate Ast<br>646 Neuroinflammation. Cancer Res 76, 4359-4371, doi:10.1158/0008-5472.CAN-16<br>647 12 Colombo, E. & Farina, C. Astrocytes: Key Regulators of Neu
- 
- 646 Neuroinflammation. Cancer Res 76, 4359-4371, doi:10.1158/0008-5472.CAN-16-0485 (2016).<br>647 12 Colombo, E. & Farina, C. Astrocytes: Key Regulators of Neuroinflammation. Trends Immunol<br>648 37, 608-620, doi:10.1016/j.it.2
- 647 12 Colombo, E. & Farina, C. Astrocytes: Key Regulators of Neuroinflammation. Trends Immunol<br>648 37, 608-620, doi:10.1016/j.it.2016.06.006 (2016).<br>649 13 Rehman, R. *et al.* Met/HGFR triggers detrimental reactive microg 648<br> **37**, 608-620, doi:10.1016/j.it.2016.06.006 (2016).<br> **649**<br> **13** Rehman, R. *et al.* Met/HGFR triggers detrimental reactive microglia in TBI. *Cell Rep* **41**,<br> **111867**, doi:10.1016/j.celrep.2022.111867 (2022).<br> **14** 649 13 Rehman, R. *et al.* Met/HGFR triggers detriment<br>650 111867, doi:10.1016/j.celrep.2022.111867 (2022)<br>651 14 Yamagata, T. *et al.* Hepatocyte growth factor spec<br>652 in the neurons, similar to the action of neurotr-<br>6 650<br>
111867, doi:10.1016/j.celrep.2022.111867 (2022).<br>
651 14 Yamagata, T. *et al.* Hepatocyte growth factor specifically expressed in microglia activated Ras<br>
in the neurons, similar to the action of neurotrophic factors. 14 Yamagata, T. *et al.* Hepatocyte growth factor speci<br>
652 in the neurons, similar to the action of neurotro<br>
653 *research communications* **210**, 231-237, doi:10.100<br>
654 15 Nicoleau, C. *et al.* Endogenous Hepatocyte G
- France Contracts Specifically expressed in intereglia activated Ras<br>
in the neurons, similar to the action of neurotrophic factors. *Biochemical and biophysical*<br>
research communications 210, 231-237, doi:10.1006/bbrc.1995 France II and Table 1913.<br>
653 *research communications* 210, 231-237, doi:10.1006/bbrc.1995.1651 (1995).<br>
654 15 Nicoleau, C. *et al.* Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular<br>
7 Zone Neura Fesearch communications 210, 251-257, doi:10.1000/bbrc.1999.1691 (1999).<br>
654 15 Nicoleau, C. *et al.* Endogenous Hepatocyte Growth Factor Is a Niche Signal fo<br>
655 2008 Neural Stem Cell Amplification and Self-Renewal. *St*
- For 15 Nicoleau, C. et al. Entogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular<br>
1655 2008 Neural Stem Cell Amplification and Self-Renewal. *Stem Cells* 27, 408-419,<br>
16 Schetters, S. T. T., Gomez-Nicol Example Neural Stem Cell Amplification and Self-Renewal. Stem Cells 21, 400-413,<br>656 doi:10.1634/stemcells.2008-0226 (2009).<br>657 16 Schetters, S. T. T., Gomez-Nicola, D., Garcia-Vallejo, J. J. & Van Kooyk, Y. Neuroinflamma
- 657 16 Schetters, S. T. T., Gomez-Nicola, D., Garc<br>
658 Microglia and T Cells Get Rea<br>
659 doi:10.3389/fimmu.2017.01905 (2017).<br>
660 17 Colonna, M. & Butovsky, O. Microglia Fur<br>
661 and Neurodegeneration. Annu Rev Imm<br>
662 Microglia and T Cells Get Ready to Tango. *Front Immunol* 8, 1905,<br>659 doi:10.3389/fimmu.2017.01905 (2017).<br>660 17 Colonna, M. & Butovsky, O. Microglia-Function in the Central Nervous System During Health<br>661 and Neurodege Microglia and T Cells Get Ready to Tango. Tront Immanor 6, 1505,<br>659 doi:10.3389/fimmu.2017.01905 (2017).<br>660 17 Colonna, M. & Butovsky, O. Microglia Function in the Central Nervous System During Health<br>661 and Neurodegene 660 17 Colonna, M. & Butovsky, O. Microglia F<br>661 and Neurodegeneration. Annu Rev Im<br>662 051116-052358 (2017).<br>663 18 Caffarel, M. M. & Braza, M. S. Microg<br>664 victim, ravager, or something else? J Ex<br>665 02535-7 (2022).
- 661 and Neurodegeneration. Annu Rev Immunol 35, 441-468, doi:10.1146/annurev-immunol-<br>662 051116-052358 (2017).<br>663 18 Caffarel, M. M. & Braza, M. S. Microglia and metastases to the central nervous system:<br>664 victim, rava 662 051116-052358 (2017).<br>663 18 Caffarel, M. M. & Braza, M. S. Microglia and metastases to the central nervous system:<br>664 victim, ravager, or something else? *J Exp Clin Cancer Res* 41, 327, doi:10.1186/s13046-022-<br>665 0 663 18 Caffarel, M. M. & Braz<br>664 victim, ravager, or some<br>665 02535-7 (2022).<br>666 19 Wang, G. *et al.* Tumor-<br>667 insights to thera<br>668 doi:10.3389/fimmu.202
- 664 victim, ravager, or something else? *J Exp Clin Cancer Res* 41, 327, doi:10.1186/s13046-022-<br>665 02535-7 (2022).<br>666 19 Wang, G. *et al.* Tumor-associated microglia and macrophages in glioblastoma: From basic<br>667 insig 665<br>
665 02535-7 (2022).<br>
666 19 Wang, G. *et al.* Tumor-associated microglia and macrophages in glioblastoma: From basic<br>
insights to therapeutic opportunities. *Front Immunol* 13, 964898,<br>
669 20 Blitz, S. E. *et al.* Tu 666 19 Wang, G. *et al.*<br>667 insights to<br>668 doi:10.3389/fimi<br>669 20 Blitz, S. E. *et*<br>670 Virotherapy: A D<br>671 21 Urbantat, R. M. wang, G. et al. Tumor-associated microgia and macrophages in glioblastoma. Trom basic<br>667 insights to therapeutic opportunities. *Front Immunol* 13, 964898,<br>668 doi:10.3389/fimmu.2022.964898 (2022).<br>670 Dirtherapy: A Doubl
- magnts to therapeutic opportunities. From immunor 13, 964898,<br>668 doi:10.3389/fimmu.2022.964898 (2022).<br>669 20 Blitz, S. E. *et al.* Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic<br>670 Virotherapy: A Doubl 669 20 Blitz, S. E. *et al.* Tumor-Associated N<br>670 Virotherapy: A Double-Edged Sword. *Int J*<br>671 21 Urbantat, R. M. *et al.* Tumor-Associated N<br>672 Glioblastoma and Temozolomide-Induced
- 670 Blitz, S. E. et al. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic<br>671 21 Urbantat, R. M. et al. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in<br>672 Glioblastoma and Temozolomide 670 Virotherapy: A Double-Edged Sword. *Int 3 Mol Sci* 23, doi:10.339071jins23031808 (2022).<br>671 21 Urbantat, R. M. *et al.* Tumor-Associated Microglia/Macrophages as a Predictor for Survive Glioblastoma and Temozolomide-I 672 Grisantat, R. M. et al. Tumor Associated Microglia/Macrophages as a Predictor for Survival in<br>672 Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance<br>24 672 Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance

Overcoming Strategy by Combination Therapy. *Int J Mol Sci* 22, doi:10.3390/ijms222011180<br>
674 (2021).<br>
675 22 Andersen, R. S., Anand, A., Harwood, D. S. L. & Kristensen, B. W. Tumor-Associated Microglia<br>
676 and Macrophag 675 22 Anderse<br>
676 and Ma<br>
677 Cancers<br>
678 23 Radke,<br>
680 24 Köhler,<br>
680 24 Köhler, and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy.<br>
677 *Cancers (Basel)* 13, doi:10.3390/cancers13174255 (2021).<br>
678 23 Radke, J. *et al.* Decoding molecular programs in melanoma bra Cancers (Basel) 13, doi:10.3390/cancers13174255 (2021).<br>
678 23 Radke, J. et al. Decoding molecular programs in melanoma brain metastases. Nature<br>
679 Communications 13, 7304, doi:10.1038/s41467-022-34899-x (2022).<br>
680 24 678 23 Radke, J. et al. Decoding molecular programs in mel<br>679 *Communications* 13, 7304, doi:10.1038/s41467-022-34899<br>680 24 Köhler, C. Allograft inflammatory factor-1/lonized calcit<br>681 specifically expressed by most su 679 Communications 13, 7304, doi:10.1038/s41467-022-34899-x (2022).<br>680 24 Köhler, C. Allograft inflammatory factor-1/lonized calcium-binding adapter molecule 1 is<br>681 specifically expressed by most subpopulations of macro 680 24 Köhler, C. Allograft inflammatory factor-1/lonized calcium-binding<br>681 specifically expressed by most subpopulations of macrophages and<br>682 and Tissue Research 330, 291-302, doi:10.1007/s00441-007-0474-7 (<br>683 25 Y 681 specifically expressed by most subpopulations of macrophages and spermatids in testis. *Cell*<br>682 and Tissue Research 330, 291-302, doi:10.1007/s00441-007-0474-7 (2007).<br>683 25 Yoshihara, K. et al. Inferring tumour pur specifically expressed by most subpopulations of macrophages and spermatids in testis. Cell<br>
and Tissue Research 330, 291-302, doi:10.1007/s00441-007-0474-7 (2007).<br>
683 25 Yoshihara, K. et al. Inferring tumour purity and 683 25 Yoshihara, K. *et al.* Inferring tumour purity and stromal and immune cel<br>684 expression data. *Nat Commun 4*, 2612, doi:10.1038/ncomms3612 (2013).<br>685 26 Ros-Martinez, S., Navas-Carrillo, D., Alonso-Romero, J. L. Froshmana, K. et al. Inferring tumour purity and stromal and immune cell admixture from<br>
expression data. Nat Commun 4, 2612, doi:10.1038/ncomms3612 (2013).<br>
Ros-Martinez, S., Navas-Carrillo, D., Alonso-Romero, J. L. & Ore Expression data. Not Commun 4, 2012, doi:10.1038/ncomms3612 (2013).<br>
685 26 Ros-Martinez, S., Navas-Carrillo, D., Alonso-Romero, J. L. & Orenes-Pinero,<br>
novel prognostic tool. Association with clinical outcome, response to Frame is the prognostic tool. Association with clinical outcome, response to treatment and survival<br>
in several malignancies. *Crit Rev Clin Lab Sci* 57, 432-443,<br>
doi:10.1080/10408363.2020.1729692 (2020).<br>
Zhang, Y. *et a* 687 in several malignancies. Crit Rev Clin Lab Sci 57, 432-443,<br>688 doi:10.1080/10408363.2020.1729692 (2020).<br>689 27 Zhang, Y. *et al.* Integrin beta7 Inhibits Colorectal Cancer Pathogenesis via Maintaining<br>690 Antitumor 688 doi:10.1080/10408363.2020.1729692 (2020).<br>689 27 Zhang, Y. *et al.* Integrin beta7 Inhibits Colorectal Cancer Pathogenesis via Maintaining<br>690 Antitumor Immunity. *Cancer Immunol Res* 9, 967-980, doi:10.1158/2326-6066. 689 27 Zhang, Y. *et al.* Integrin beta7 Inhibits Col<br>690 Antitumor Immunity. Cancer Immunol Res 9,<br>691 (2021).<br>692 28 Ge, Q. *et al.* Immunological Role and Prognos<br>693 *Cancer* 12, 595-610, doi:10.7150/jca.50785 (20<br>694 Example 12 Zhang, Y. et al. Imegini beta7 Inhibits Colorectal cancer Tathogenesis via Maintaining<br>
680 Antitumor Immunity. Cancer Immunol Res 9, 967-980, doi:10.1158/2326-6066.CIR-20-0879<br>
692 28 Ge, Q. et al. Immunologica Finitumor Immunity. Cancer *Immunor Res 9, 967-960*, doi:10.1158/2326-6060.CIR-20-0873<br>
692 28 Ge, Q. *et al.* Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis. J<br> *Cancer* 12, 595-610, doi:10.7150 692 28 Ge, Q. e<br>
693 Cancer:<br>
694 29 Geirsdo<br>
695 Microgl<br>
696 30 Lafuent<br>
697 Heilate 692 28 Ge, Q. et al. Immunological Role and Prognosite value of APBB11 in Pan-Cancer Analysis. 3<br>693 *Cancer* 12, 595-610, doi:10.7150/jca.50785 (2021).<br>694 29 Geirsdottir, L. *et al.* Cross-Species Single-Cell Analysis Re 694 29 Geirsdottir, L. et al. Cross-Species Single-Cell Ana<br>695 Microglia Program. Cell 179, 1609-1622 e1616, doi:<br>696 30 Lafuente, E. M. et al. RIAM, an Ena/VASP and Pro<br>697 mediates Rap1-induced adhesion. De<br>698 doi:10. Microglia Program. Cell 179, 1609-1622 e1616, doi:10.1016/j.cell.2019.11.010 (2019).<br>
Experiment and Cell 179, 1609-1622 e1616, doi:10.1016/j.cell.2019.11.010 (2019).<br>
Lafuente, E. M. et al. RIAM, an Ena/VASP and Profilin 696 30 Lafuente, E. M. *et al.* RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-G<br>697 mediates Rap1-induced adhesion. *Developmental cell* 7, 5:<br>698 doi:10.1016/j.devcel.2004.07.021 (2004).<br>700 methods and T. *e* Example 1. M. et al. NAM, an Enayvase and Profilm ligand, interacts with Rap1-GTP and<br>
697 mediates Rap1-induced adhesion. Developmental cell 7, 585-595,<br>
doi:10.1016/j.devcel.2004.07.021 (2004).<br>
1 magaki, T. et al. The r 698 doi:10.1016/j.devcel.2004.07.021 (2004).<br>699 31 Inagaki, T. *et al.* The retinoic acid-responsive proline-rich protein is identified in<br>699 31 Inagaki, T. *et al.* The retinoic acid-responsive proline-rich protein is i 699 31 Inagaki, T. et al. The retinoic acid-<br>
700 promyeloleukemic HL-60 cells. *J Biol Cher*<br>
702 32 Hoffmann, F. et al. Prognostic and predi<br>
703 expression in melanoma. *Clin Epigenetics*<br>
704 33 Chen, S. et al. Integr 699 31 Inagaki, T. et al. The Tethlote acid-responsive prome herr procent is identified in<br>
700 promyeloleukemic HL-60 cells. *J Biol Chem* 278, 51685-51692, doi:10.1074/jbc.M308016200<br>
702 32 Hoffmann, F. et al. Prognosti From Promyeloleukemic HL-60 cens. J Biol Chem 278, 51685-51692, doi:10.1074/jbc.M308016200<br>
702 32 Hoffmann, F. et al. Prognostic and predictive value of PD-L2 DNA methylation and mRNA<br>
expression in melanoma. *Clin Epigen* 702 32 Hoffma<br>
703 express<br>
704 33 Chen, S<br>
705 adhesio<br>
706 34 Zhang,<br>
707 Colon C 22 Frommann, F. et al. Prognostic and predictive value of PD-L2 DNA methylation and mNNA<br>
2020 expression in melanoma. Clin Epigenetics 12, 94, doi:10.1186/s13148-020-00883-9 (2020).<br>
2021 2021 2021 2021 2021 2021 2021 202 Expression in melanoma. Clin Epigenetics 12, 94, doi:10.1100/313140-020-00883-9 (2020).<br>
704 33 Chen, S. et al. Integrin alphaEbeta7(+) T cells direct intestinal stem cell fate decisions<br>
adhesion signaling. Cell research 204 33 Chen, S. et al. Integrin alphaEbeta7(+) T cells direct intestinal stem cell rate decisions via<br>
2006 34 Zhang, L. *et al.* Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in<br>
2006 Colon Cancer. 205 addition signaling. Cell research 31, 1291-1307, doi:10.1038/s41422-021-00501-2 (2021).<br>
206 34 Zhang, L. et al. Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies<br>
207 Colon Cancer. Cell 181, 442-459 2123<br>
2707 Colon Cancer. Cell 181, 442-459 e429, doi:10.1016/j.cell.2020.03.048 (2020).<br>
2708 35 Schmiedel, B. J. *et al.* Single-cell eQTL analysis of activated T cell subsets reveals activation<br>
2709 and cell type-depend 271<br>
27 Colon Cancer. Cell 181, 442-459 e429, doi:10.1016/j.cell.2020.03.048 (2020).<br>
27 Colon Cancer. Cell 181, 442-459 e429, doi:10.1016/j.cell.2020.03.048 (2020).<br>
27 Colon Cancer of also and cell type-dependent effects 35 Schmiedel, B. J. et al. Single-cell eQTL analysis of activated T cell subsets reveals activation<br>
36 aloi:10.1126/sciimmunol.abm2508 (2022).<br>
711 36 Weiss, S. A. *et al.* Melanoma brain metastases have lower T-cell cont 20910)<br>710 doi:10.1126/sciimmunol.abm2508 (2022).<br>711 36 Weiss, S. A. *et al.* Melanoma brain metastases have lower T-cell content and microvessel<br>712 density compared to matched extracranial metastases. *J Neurooncol* 152 711 36 Weiss, S. A. *et al.* Melanoma brain meta<br>
712 density compared to matched extrac<br>
713 doi:10.1007/s11060-020-03619-0 (2021).<br>
714 37 Griss, J. *et al.* B cells sustain inflammati<br>
715 blockade in human melanoma. 712 Weiss, S. A. et al. Melanoma brain metastases have lower T-cell content and microvesser<br>
712 density compared to matched extracranial metastases. *J Neurooncol* 152, 15-25,<br>
713 doi:10.1007/s11060-020-03619-0 (2021).<br> 212 density compared to matched extracramal metastases. J Neurooncol 132, 13-25,<br>
133 doi:10.1007/s11060-020-03619-0 (2021).<br>
714 37 Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint<br> 714 37 Griss, J. *et al.* B cells sustain inflammat<br>715 blockade in human melanoma. *Nat Con*<br>716 (2019).<br>717 38 Huang, L. *et al.* Correlation of tumor-in<br>718 survival by immunogenomic analysis. *Can*<br>719 (2020). 2714 37 Griss, J. et al. B cells sustain inflammation and predict response to immune energybric<br>
2715 blockade in human melanoma. Nat Commun 10, 4186, doi:10.1038/s41467-019-12160-2<br>
2717 38 Huang, L. et al. Correlation of 2020).<br>
715 blockade in human melanoma. Nut Commun 10, 4186, doi:10.1038/s41467-015-12160-2<br>
717 38 Huang, L. et al. Correlation of tumor-infiltrating immune cells of melanoma with overall<br>
2020).<br>
720 39 Saul, D. et al. 717 38 Huang,<br>
718 survival<br>
719 (2020).<br>
720 39 Saul, D.<br>
721 pathwar<br>
722 40 Pais Fer Fraction of tumor-infiltrating immune cells of melanoma with overall<br>
1718 survival by immunogenomic analysis. Cancer medicine 9, 8444-8456, doi:10.1002/cam4.3466<br>
1720 39 Saul, D. et al. A new gene set identifies senescen 319 survival by immunogenomic analysis. Cancer medicine 9, 0444-0450, doi:10.1002/cam4.3466<br>
720 39 Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated<br>
pathways across tissues. Na (1994)<br>
1995 - Saul, D.<br>
1997 - Saul, D.<br>
1997 - Pais Fer<br>
1997 - Pais Fer<br>
1998 - Cells in<br>
1998 - Cells in<br>
1998 - Cells in<br>
1998 - Cells in 35 Saul, D. et al. A new gene set identifies senescent cells and predicts senescente-associated<br>
721 pathways across tissues. Nat Commun 13, 4827, doi:10.1038/s41467-022-32552-1 (2022).<br>
722 10 Pais Ferreira, D. et al. Cen 721 pathways across tissues. Nat Commun 13, 4827, doi:10.1038/s41467-022-32532-1 (2022).<br>
722 40 Pais Ferreira, D. *et al.* Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effec<br>
cells in the absence of cytot 722 40 Pais Ferreira, D. et al. Central memory CD8(+) Pleasance from stem-like Terry (iii) effector<br>723 cells in the absence of cytotoxic differentiation. Immunity 53, 985-1000 e1011,<br>80i:10.1016/j.immuni.2020.09.005 (202  $723$  cells in the absence of cytotoxic differentiation. Immunity 33, 985-1000 e1011,<br>  $10(10.1016/j.)$  mmuni.2020.09.005 (2020).

724 doi:10.1016/j.immuni.2020.09.005 (2020).

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297080;](https://doi.org/10.1101/2023.10.16.23297080) this version posted October 16, 2023. The copyright holder for this preprint

- 
- 725 41 Sade Feldman, W. et al. Defining T Cell States Associated with Response to Checkpoint<br>726 Immunotherapy in Melanoma. Cell 176, 404, doi:10.1016/j.cell.2018.12.034 (2019).<br>727 42 Connolly, K. A. *et al.* A reservoir
- 226 Immunotherapy in Melanoma. Centry 2004, doi:10.1016/j.cell.2010.12.034 (2013).<br>
228 Connolly, K. A. *et al.* A reservoir of stem-like CD8(+) T cells in the tumor-draining lyr<br>
229 doi:10.1126/sciimmunol.abg7836 (2021). 227 42 Connolly, K. A. et al. A reservoir of stem-like CD0(+) T cells in the tumor-driaming lymph node<br>
228 preserves the ongoing antitumor immune response. *Sci Immunol* 6, eabg7836,<br>
229 doi:10.1126/sciimmunol.abg7836 (2 Fresh Constitution in the ongoing antituding the ongoing term in the original of the original dots.<br>
1730 43 Fischer, G. M. *et al.* Molecular Profiling Reveals Unique Immune and Metabolic Features of<br>
1731 Melanoma Brain 43 Fischer, G. M. *et al.* Molecular Profiling R<br>731 Melanoma Brain Metastases. Cancer Disc<br>732 (2019).<br>733 44 Desole, C. *et al.* HGF and MET: From Brain<br>734 *Dev Biol* 9, 683609, doi:10.3389/fcell.2021<br>735 45 Zhang, Y.
- 
- 730 43 Fischer, G. M. et al. Molecular Fromming Reveals Online and Metabolic Features of<br>731 Melanoma Brain Metastases. *Cancer Discov* 9, 628-645, doi:10.1158/2159-8290.CD-18-1489<br>732 (2019).<br>733 44 Desole, C. *et al.* HG For Melanoma Brain Metastases. Cancer Discov 9, 026-045, doi:10.1158/2159-8290.CD-16-1489<br>
732 (2019).<br>
733 44 Desole, C. et al. HGF and MET: From Brain Development to Neurological Disorders. *Front Cell*<br> *Dev Biol* 9, 68 733 44 Desole,<br>
733 44 Desole,<br>
735 45 Zhang,<br>
736 Reveals<br>
737 doi:10.1<br>
738 46 Zhang, 233 44 Desole, C. et al. HGF and MET: From Brain Development to Neurological Disorders. From Cell<br>
2734 Dev Biol 9, 683609, doi:10.3389/fcell.2021.683609 (2021).<br>
2735 2737 doi:10.1016/j.neuron.2015.11.013 (2016).<br>
2737 do *Pev Biol 9, 683609, doi:10.3389/fcell.2021.083609 (2021).*<br>
735 45 Zhang, Y. *et al.* Purification and Characterization of Progeni<br>
737 doi:10.1016/j.neuron.2015.11.013 (2016).<br>
738 46 Zhang, Y., Jain, R. K. & Zhu, M. Rec
- 2135 45 Zhang, Y. et al. Purification and Characterization of Progress and Mature Human Astrocytes<br>
736 Reveals Transcriptional and Functional Differences with Mouse. *Neuron* 89, 37-53,<br>
737 doi:10.1016/j.neuron.2015.11.0 Frances Manuscriptional and Functional Birecrees with Mouse. Neuron 89, 37-53,<br>
1737 doi:10.1016/j.neuron.2015.11.013 (2016).<br>
738 46 Zhang, Y., Jain, R. K. & Zhu, M. Recent Progress and Advances in HGF/MET-Targeted<br>
Thera 738 46 Zhang, Y., Jain, R. K. & Zhu, M. Recentral<br>739 Therapeutic Agents for Cancer<br>740 doi:10.3390/biomedicines3010149 (2015).<br>741 47 Ramani, N. S., Morani, A. C. &<br>742 (Amplification/Polysomy) Identified in Me<br>743 *Patho*
- Therapeutic Agents for Cancer Treatment. *Biomedicines* 3, 149-181,<br>
740 doi:10.3390/biomedicines3010149 (2015).<br>
741 47 Ramani, N. S., Morani, A. C. & Zhang, S. MET Gene High Copy Number<br>
742 (Amplification/Polysomy) Iden Therapeutic Agents for Cancer Treatment. Biometicines 3, 143-181,<br>
1740 doi:10.3390/biomedicines3010149 (2015).<br>
741 47 Ramani, N. S., Morani, A. C. & Zhang, S. MET Gene High Copy Number<br>
742 (Amplification/Polysomy) Ident 741 47 Ramani, N. S., Morani, A. C. &<br>
742 (Amplification/Polysomy) Identified in Mel<br>
743 *Pathol* 157, 502-505, doi:10.1093/ajcp/aqa<br>
744 48 Rozeman, E. A. *et al.* Survival and bioma<br>
745 neoadjuvant immunotherapy tria
- (Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy. Am J Clin<br>
743 Pathol 157, 502-505, doi:10.1093/ajcp/aqab171 (2022).<br>
744 48 Rozeman, E. A. *et al.* Survival and biomarker analyses from the *Partial Targeted History)* Internet in Melanoma for Fotential Targeted History). Am J cm<br> *Pathol* **157**, 502-505, doi:10.1093/ajcp/aqab171 (2022).<br> **Reconditional Transform in Melanoma** *Nat Med* **27**, 256-263,<br> **Recond**
- 243 Pathol 157, 502-505, doi:10.1095/ajep/aqab171 (2022).<br>
244 48 Rozeman, E. A. *et al.* Survival and biomarker analyses<br>
245 neoadjuvant immunotherapy trials in stage III m<br>
247 49 Reijers, I. L. M. *et al.* The interfe 1944 48 Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-heo and OpACIN-<br>
195 neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27, 256-263,<br>
196 doi:10.1038/s41591-020-01211-7 (2021).<br>
1 reoadjuvant immunotherapy trials in stage in inerational. Nut Med 27, 250-263,<br>
doi:10.1038/s41591-020-01211-7 (2021).<br>
747 49 Reijers, I. L. M. et al. The interferon-gamma (IFN-y) signature from baseline tumor material<br>
p 747 49 Reijers, I. L. M. *et al.* The interferon-gam<br>748 predicts pathologic response after neoad<br>749 III melanoma. *Journal of*<br>750 doi:10.1200/JCO.2022.40.16\_suppl.9539 (<br>751 50 Subramanian, A. *et al.* Gene set enrich<br>7 Reijers, I. L. M. *et al.* The interferon-gamma (IFN-y) signature from baseline tumor material<br>
748 predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage<br>
179 III melanoma. Journal of
- 749 III melanoma. Journal of Clinical Oncology 40, 9539-9539,<br>
750 doi:10.1200/JCO.2022.40.16\_suppl.9539 (2022).<br>
751 50 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for<br>
752 interpret 1999 III melanoma. Journal of China Oncology 40, 9539-9539,<br>1990 III melanoma. A. et al. Gene set enrichment analysis: a knowledge-based approach for<br>1990 III subtramanian, A. et al. Gene set enrichment analysis: a knowled 751 50 Subramanian, A. *et al.* Gene set enrichment<br>752 interpreting genome-wide expression profiles. *F*<br>753 doi:10.1073/pnas.0506580102 (2005).<br>754 51 Gonzalez, H. *et al.* Cellular architecture of huma<br>755 doi:10.1016/j
- 
- 751 50 Subramanian, A. et al. Gene set emfemment analysis. a knowledge-based approach for<br>
1752 interpreting genome-wide expression profiles. *Proc Notl Acod Sci U S A* **102**, 15545-15550,<br>
1754 51 Gonzalez, H. *et al.* Ce merpreting genome-wide expression profiles. Proc Natl Acad Sci O 3 A 102, 13343-13350,<br>
doi:10.1073/pnas.0506580102 (2005).<br>
754 51 Gonzalez, H. *et al.* Cellular architecture of human brain metastases. Cell 185, 729-745 e 754 51 Gonzalez, H. *et al.* Cellular architecture<br>
755 doi:10.1016/j.cell.2021.12.043 (2022).<br>
756 52 Dufner, A., Andjelkovic, M., Burgering,<br>
757 localization and activation differentiall<br>
758 initiation factor 4E-bindin 254 51 Gonzalez, H. et al. Cellular architecture of human brain metastases. Cell 185, 725-745 e720,<br>
255 doi:10.1016/j.cell.2021.12.043 (2022).<br>
256 52 Dufner, A., Andjelkovic, M., Burgering, B. M., Hemmings, B. A. & Thoma 756 52 Dufner, A., Andjelkovic, M., Burgering,<br>757 localization and activation differentiall<br>758 initiation factor 4E-binding protein<br>759 doi:10.1128/MCB.19.6.4525 (1999).<br>760 53 Seip, K. *et al.* Fibroblast-induced s<br>761 20015, doi:10.18632/oncotarget.7671 (2016)<br>
756 Samma activation differentially affect S6 kinase 1 activity and eukaryotic translation<br>
758 initiation factor 4E-binding protein 1 phosphorylation. *Mol Cell Biol* 19, 4525-4
- 758 initiation factor 4E-binding protein 1 phosphorylation. *Mol* Cell Biol 19, 4525-4534,<br>
759 doi:10.1128/MCB.19.6.4525 (1999).<br>
760 53 Seip, K. *et al.* Fibroblast-induced switching to the mesenchymal-like phenotype an mination factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 19, 4323-4334,<br>
1759 doi:10.1128/MCB.19.6.4525 (1999).<br>
760 53 Seip, K. *et al.* Fibroblast-induced switching to the mesenchymal-like phenotype and<br>
761 P 760 53 Seip, K. *et al.* Fibroblast-induced<br>761 PI3K/mTOR signaling protects mela<br>762 20015, doi:10.18632/oncotarget.767<br>763 54 Yan, Y. *et al.* Vemurafenib and C<br>764 Mutation&#x2013;Positive Locally<br>765 *Annals of Oncolog*
- 760 53 Seip, K. et al. Fibroblast-induced switching to the mesenchymal-like phenotype and<br>
761 PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget 7, 19997-<br>
20015, doi:10.18632/oncotarget.7671 (20 20015, doi:10.18632/oncotarget.7671 (2016).<br>
762 20015, doi:10.18632/oncotarget.7671 (2016).<br>
763 54 Yan, Y. *et al.* Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600<br>
764 Mutation&#x2013;Positive Loc 763 54 Yan, Y. *et al.* Vemurafenib and Cobimetini<br>
764 Mutation&#x2013;Positive Locally Advanced<br>
765 *Annals of Oncology* 25, iv378, doi:10.1093/ann<br>
766 55 Zhao, S. *et al.* Selective Inhibitor of the c<br>
767 Hepatocellu
- 763 54 Tan, T. et al. Vemaration and Cobimetinio Potently immote Pso Signaling in Brafvood<br>764 Mutation&#x2013;Positive Locally Advanced or Metastatic Melanoma from Brim7 Study.<br>765 Zhao, S. et al. Selective Inhibitor of t Annals of Oncology 25, iv378, doi:10.1093/annonc/mdu344.9 (2014).<br>
766 55 Zhao, S. et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced<br>
767 Hepatocellular Carcinoma: No Beneficial Effect With the U 765 55 Zhao, S. *et al.* Selective Inhibitor of the c-Met Receptor Tyrosir<br>
767 Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tiva<br>
768 12, 731527, doi:10.3389/fimmu.2021.731527 (2021).<br>
769 56 Quail, D. F
- 
- 206 35 Zhao, S. et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced<br>
167 Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol<br>
12, 731527, doi:10.3389/fimmu.2021 12, 731527, doi:10.3389/fimmu.2021.731527 (2021).<br>
769 56 Quail, D. F. & Joyce, J. A. The Microenvironmental Landscape of Brain Tumors. Cancer cell 31,<br>
770 326-341, doi:10.1016/j.ccell.2017.02.009 (2017).<br>
771 57 Roesler, 768 12, 731527, doi:10.3389/fimmu.2021.731527 (2021). 276 56 Quail, D. F. & Joyce, J. A. The Microenvironmental Landscape of Brain Tumors. Cancer cent 31,<br>
276 326-341, doi:10.1016/j.ccell.2017.02.009 (2017).<br>
271 57 Roesler, R., Dini, S. A. & Isolan, G. R. Neuroinflammation 120 57 Roesler, R., Dini, S. A. & Isolan, G. R. Neur<br>
1772 glioblastoma and brain metastases: Recent dev<br>
1773 *Immunol* 206, 314-324, doi:10.1111/cei.13668 (20<br>
1775 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Ep<br>
1775
- 272 glioblastoma and brain metastases: Recent developments in imaging approaches. Clin Exp<br>
1773 Immunol 206, 314-324, doi:10.1111/cei.13668 (2021).<br>
274 58 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelial-mesenchy Free Biloblastoma and brain metastases. Recent developments in imaging approaches. Clin Exp<br>
173 Immunol 206, 314-324, doi:10.1111/cei.13668 (2021).<br>
774 58 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelial-mesenchy 773 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelii<br>775 He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelii<br>775 *Immunol* 14, 1097880, doi:10.3389/fimmu.2023.10978 way in which glioma-associated microglia/macrophages promote glioma progression. Front<br>
1776 11.1097880, doi:10.3389/fimmu.2023.1097880 (2023).<br>
26 way in which glioma-associated microglia/macrophages promote glioma progression. Front<br>1776 Immunol 14, 1097880, doi:10.3389/fimmu.2023.1097880 (2023).<br>26 776 Immunol 14, 1097880, doi:10.3389/fimmu.2023.1097880 (2023).

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.16.23297080;](https://doi.org/10.1101/2023.10.16.23297080) this version posted October 16, 2023. The copyright holder for this preprint

- 
- 
- 277 59 Zhai, H., Heppner, F. L. & Tsirka, S. E. Microglia/macrophages promote glioma progression.<br>
2778 Glia 59, 472-485, doi:10.1002/glia.21117 (2011).<br>
279 60 Sofroniew, M. V. Astrogliosis. Cold Spring Harbor perspective
- 60 Glia 59, 472-485, doi:10.1002/glia.21117 (2011).<br>
779 60 Sofroniew, M. V. Astrogliosis. Cold Spring Hd<br>
781 61 Herrmann, J. E. et al. STAT3 is a critical regula<br>
782 spinal cord injury. J Neurosci 28, 7231-7243, doi:1<br> 279 60 Sofroniew, M. V. Astrogiosis. Cold Spring Harbor perspectives in biology 7, a020420,<br>
2781 61 Herrmann, J. E. et al. STAT3 is a critical regulator of astrogliosis and scar formation after<br>
2782 spinal cord injury. J
- 781 61 Herrmann, J. E. *et al.* STAT3 is a critical<br>
1782 spinal cord injury. J Neurosci 28, 7231-724:<br>
783 62 Priego, N. *et al.* STAT3 labels a subpop<br>
784 metastasis. Nat Med 24, 1024-1035, doi:10<br>
785 63 Maina, F., Hil France of the means of a critical regulator of astroghosts and scar formation after<br>
1782 spinal cord injury J Neurosci 28, 7231-7243, doi:10.1523/JNEUROSCI.1709-08.2008 (2008).<br>
1784 metastasis. Nat Med 24, 1024-1035, doi Fraggo, N. et al. STAT3 labels a subpopulation of reactive astrocytes required for brametastasis. Nat Med 24, 1024-1035, doi:10.1038/s41591-018-0044-4 (2018).<br>
785 63 Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & 783 62 Priego, N. et al. STAT3 labels a subpopulation of reactive astrocytes required for brain<br>784 metastasis. Nat Med 24, 1024-1035, doi:10.1038/s41591-018-0044-4 (2018).<br>785 63 Maina, F., Hilton, M. C., Ponzetto, C., Da Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is<br>
786 required for sensory nerve development and HGF promotes axonal growth and survival of<br>
787 sensory neurons. *Genes Dev* 11, 3
- 
- France of the second and HGF promotes axonal growth and survival of<br>
required for sensory nerve development and HGF promotes axonal growth and survival of<br>
sensory neurons. *Genes Dev* 11, 3341-3350, doi:10.1101/gad.11.24. 787 sensory neurons. Genes Dev 11, 3341-3350, doi:10.1101/gad.11.24.3341 (1997).<br>
788 64 Garcia-Diaz, A. et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2<br>
Expression. Cell Rep 29, 3766, doi:10.1016/ 39788<br>
54 Garcia-Diaz, A. et al. Interferon Receptor Signaling Pathways Regulating PD-L:<br>
Expression. Cell Rep 29, 3766, doi:10.1016/j.celrep.2019.11.113 (2019).<br>
790 65 Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. 789<br>
Expression. *Cell Rep* 29, 3766, doi:10.1016/j.celrep.2019.11.113 (2019).<br>
790 65 Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. & Saelens, X. Interferon-inducible protein<br>
791 Mx1 inhibits influenza virus by in Expression. Cell Rep 29, 3766, doi:10.1016/j.cellep.2019.11.113 (2019).<br>
790 65 Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. & Saelens, X. Interfe<br>
791 Mx1 inhibits influenza virus by interfering with functional vi
- 
- Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex<br>
The sasembly. J. Virol 86, 13445-13455, doi:10.1128/JVI.01682-12 (2012).<br>
Acker, G. et al. The CXCR2/CXCL2 signalling pathway A For a ssembly. *J Virol* **86**, 13445-13455, doi:10.1128/JVI.01682-12 (2012).<br>
792 assembly. *J Virol* **86**, 13445-13455, doi:10.1128/JVI.01682-12 (2012).<br>
794 high-grade glioma. *Eur J Cancer* **126**, 106-115, doi:10.1016/j 2792 assembly. J Virol 86, 13445-13455, doi:10.1128/JVI.01082-12 (2012).<br>
793 66 Acker, G. *et al.* The CXCR2/CXCL2 signalling pathway - An alternative<br>
794 high-grade glioma. *Eur J Cancer* **126**, 106-115, doi:10.1016/j. 2793 67 Acker, G. et al. The CXCR2/CXCL2 signalling pathway An alternative therapeute approach in<br>
1794 high-grade glioma. *Eur J Cancer* 126, 106-115, doi:10.1016/j.ejca.2019.12.005 (2020).<br>
1795 67 Jiang, H., Lei, R., Di 194 high-grade glioma. Eur J Cancer 126, 100-115, aon.10.1016/j.ejca.2015.12.005 (2020).<br>
195 67 liang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for<br>
197 2105-15-182 (2014).<br>
198 68 Lo
- 
- 801 coordinately downregulated in human diabetes. Nat Genet 34, 267-273, doi:10.1038/ng1180<br>802 (2003). For generation sequencing paired end reads. *BMC Bioinformatics* 15, 182, doi:10.1186/1471<br>
798 68 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for<br>
RNA-seq data with DESeq2. *Geno* 798 68 Love, M. I., Huber, W.<br>
799 RNA-seq data with DI<br>
800 69 Mootha, V. K. *et al.*<br>
801 coordinately downre<br>
802 (2003).<br>
803 70 Hanzelmann, S., Cast RNA-seq data with DESeq2. *Genome Biol* 15, 550, doi:10.1186/s13059-014-0550-8 (2014).<br>
800 69 Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are<br>
801 coordinately downregulated in 799 RNA-seq data with DESeq2. Genome Biol 15, 350, doi:10.1186/s13059-014-0550-0 (2014).<br>
800 69 Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation<br>
801 coordinately downregulated in 801 coordinately downregulated in human diabetes. Nat Genet 34, 267-273, doi:10.1038/ng1180 (2003).<br>802 (2003).<br>803 70 Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray<br>804 and RNA-
- 
- 802 (2003).<br>
802 (2003).<br>
803 70 Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray<br>
804 and RNA-seq data. *BMC Bioinformatics* 14, 7, doi:10.1186/1471-2105-14-7 (2013).<br>
805 71 Bier
- 803 70 Hanzeln<br>
804 and RN<br>
805 71 Bierman<br>
806 metasta<br>
807 72 Schildha<br>
808 carcinol 804<br>
and RNA-seq data. *BMC Bioinformatics* **14**, 7, doi:10.1186/1471-2105-14-7 (2013).<br>
805 71 Biermann, J. *et al.* Dissecting the treatment-naive ecosystem of human melanoma brain<br>
metastasis. *Cell* **185**, 2591-2608 e2 805 71 Biermann, J. *et al.* Dissecting the treatment-naive ecosystem of human melan metastasis. *Cell* 185, 2591-2608 e2530, doi:10.1016/j.cell.2022.06.007 (2022).<br>807 72 Schildhaus, H. U. *et al.* MET amplification statu 806<br>
metastasis. Cell 185, 2591-2608 e2530, doi:10.1016/j.cell.2022.06.007 (2022).<br>
807 72 Schildhaus, H. U. *et al. MET amplification status in therapy-naive adeno- and squamous cell*<br>
carcinomas of the lung. *Clin Cancer* Electronics Cell 185, 2551-2608 e2530, doi:10.1016/j.cell.2022.06.007 (2022).<br>
807 72 Schildhaus, H. U. et al. MET amplification status in therapy-naive adeno- and<br>
808 (2015).<br>
810 73 Livak, K. J. & Schmittgen, T. D. Anal
- 808 carcinomas of the lung. Clin Cancer Res 21, 907-915, doi:10.1158/1078-0432.CCR-14-0450<br>809 (2015).<br>810 73 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time<br>811 quantitative PCR 809 (2015).<br>810 73 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time<br>811 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402-408,<br>812 doi:10.1006/meth.2001.1262 810 73 Livak, K<br>811 quantita<br>812 doi:10.1<br>813 811 9 quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408,<br>812 doi:10.1006/meth.2001.1262 (2001).<br>813  $\frac{1}{812}$  doi:10.1006/meth.2001.1262 (2001).<br>813<br>814 813<br>813<br>814
- 
- 
- 813<br>814<br>815 815<br>816
- ---<br>816<br>817
- ---<br>817

818 **Figure legends**<br>819 Figure 1: Transcript<br>820 **identification of sult<br>821 MBM of indicated pa** Figure 1: Transcriptome and methylome profiling of Iba1<sup>high</sup> and Iba1<sup>neg</sup> Figure 1: Transcriptome and methylome profiling of Iba1<sup>nigh</sup> and Iba1<sup>neg</sup> MBM revealed<br>identification of subset-specific genes. a.) Immunohistochemistry (IHC) for Iba1 (red) of<br>MBM of indicated patients. b.) Representati **identification of subset-specific genes**. a.) Immunohistochemistry (IHC) for Iba1 (red) of<br>821 MBM of indicated patients. b.) Representative IHC for levels of CD3 in Iba1<sup>high</sup> (Pat 4) and<br>822 Iba1<sup>neg</sup> (Pat 1) MBM. c.) I MBM of indicated patients. b.) Representative IHC for levels of CD3 in Iba1<sup>high</sup> MBM of indicated patients. b.) Representative IHC for levels of CD3 in Iba1<sup>nigh</sup> (Pat 4) and<br>822 Iba1<sup>neg</sup> (Pat 1) MBM. c.) Immune score of MBM (study EGAS00001005976, n=16) indicating<br>823 different immunologic (color cod  $\beta$ lba1<sup>neg</sup> (Pat 1) MBM. c.) Immune score of MBM (study EGAS00001005976, n=16) indicating 822 Iba1<sup>neg</sup> (Pat 1) MBM. c.) Immune score of MBM (study EGAS00001005976, n=16) indicating<br>823 different immunologic (color coded) subsets of tumors. d.) Dot plot showing the significant<br>824 correlation of Iba1/AIF1 expr different immunologic (color coded) subsets of tumors. d.) Dot plot showing the significant<br>824 correlation of Iba1/AIF1 expression and immune score of brain metastases (BM, R=0.86,<br>825 p<2.2e-16) and extracranial metastas 824 correlation of Iba1/AIF1 expression and immune score of brain metastases (BM, R=0.86,<br>825 p<2.2e-16) and extracranial metastases (EM, R=0.78, p=5.5e-13). e.) Survival analysis of<br>826 patients with MBM (study, EGAS00001 9<2.2e-16) and extracranial metastases (EM, R=0.78, p=5.5e-13). e.) Survival analysis of<br>826 patients with MBM (study, EGAS00001003672), featuring high or low level of Iba1/AlF1<br>827 expression revealed no significant diffe patients with MBM (study, EGAS00001003672), featuring high or low level of Iba1/AIF1<br>827 expression revealed no significant difference (p=0.11). f.) Survival analysis of TCGA<br>828 melanoma patients (n=459), featuring high o expression revealed no significant difference (p=0.11). f.) Survival analysis of TCGA<br>828 melanoma patients (n=459), featuring high or low level of lba1/AIF1 expression revealed<br>829 significant difference (logrank p=1.3e-0 melanoma patients (n=459), featuring high or low level of Iba1/AIF1 expression revealed<br>829 significant difference (logrank p=1.3e-07) and Cox-regression analysis showed association<br>830 with favorable disease course (HR=0. significant difference (logrank p=1.3e-07) and Cox-regression analysis showed association<br>830 with favorable disease course (HR=0.46). g.) Schematic representation of candidate<br>831 identification by methylome and transcri with favorable disease course (HR=0.46). g.) Schematic representation of candidate<br>831 identification by methylome and transcriptome profiling of n=16 MBM of study. Methylome<br>832 (850k) profiling of Iba1<sup>high</sup> (n=5) or Ib 831 identification by methylome and transcriptome profiling of n=16 MBM of study. Methylome<br>832 (850k) profiling of Iba1<sup>high</sup> (n=5) or Iba1<sup>neg</sup> (n=2) identified 416 differentially methylated<br>833 regions (DMRs), within t (850k) profiling of Iba1<sup>high</sup> (n=5) or Iba1<sup>neg</sup> (n=2) identified 416 differentially methylated<br>
regions (DMRs), within the 5´-UTR of 316 corresponding genes of which 296 were<br>
expressed in MBM with 56 genes (77 DMRs), s regions (DMRs), within the 5´-UTR of 316 corresponding genes of which 296 were<br>834 expressed in MBM with 56 genes (77 DMRs), significantly (p≤0.05) discriminating lba1<sup>high</sup><br>835 and lba1<sup>low/neg</sup> MBM. h.) Heat map represe expressed in MBM with 56 genes (77 DMRs), significantly (p≤0.05) discriminating Iba1<sup>high</sup> 834<br>835<br>836<br>837 and Iba1<sup>low/neg</sup> MBM. h.) Heat map representation of 77 DMRs (left panel) and top expressed and Iba1<sup>lowmeg</sup> MBM. h.) Heat map representation of 77 DMRs (left panel) and top expressed<br>836 (right panel) genes (n=31). Analysis identified a panel of 12 genes that clustered with<br>837 expression of microglia/TAM-associ (right panel) genes (n=31). Analysis identified a panel of 12 genes that clustered with<br>expression of microglia/TAM-associated genes AIF1, SYK and HCK. i.) Correlation analysis<br>of cluster genes with association to immune/T expression of microglia/TAM-associated genes AIF1, SYK and HCK. i.) Correlation analysis<br>838 of cluster genes with association to immune/TAM regulated processes, strength of<br>839 correlation is color coded. j.) Comparative 838 of cluster genes with association to immune/TAM regulated processes, strength of<br>839 correlation is color coded. j.) Comparative t-SNE representation of brain cell subclasses<br>840 microglia, neurons and oligodendrocytes correlation is color coded. j.) Comparative t-SNE representation of brain cell subclasses<br>
microglia, neurons and oligodendrocytes (left) and expression of *APBB1IP* (Amyloid Beta<br>
841 Precursor Protein Binding Family B Me microglia, neurons and oligodendrocytes (left) and expression of *APBB1IP* (Amyloid Beta<br>841 Precursor Protein Binding Family B Member 1 Interacting Protein), expression level (log2<br>842 RPKM) is color coded. k.) Dot plot s 841 Precursor Protein Binding Family B Member 1 Interacting Protein), expression level (log2<br>842 RPKM) is color coded. k.) Dot plot showing the significant correlation of *APBB1IP* expression<br>843 and immune score of brain RPKM) is color coded. k.) Dot plot showing the significant correlation of *APBB1IP* expression<br>and immune score of brain metastases (BM, R=0.86, p<2.2e-16) and extracranial<br>28 843 and immune score of brain metastases (BM, R=0.86, p<2.2e-16) and extracranial<br>
28

metastases (EM, R=0.92, p<2.2e-16). Significance was determined by unpaired, two-sided t-<br>test (d, g, k).<br>**Figure 2: Expression of ITGB7 serves as indicator of lymphocyte infiltration.** a.) Box<br>plot representation of level 845 test (d, g, k).<br>846 **Figure 2: Ex**<br>847 plot represen<br>848 immune cell Figure 2: Expression of ITGB7 serves as indicator of lymphocyte infiltration. a.) Box<br>plot representation of levels of ITGB7 indicates a wide pattern of expression among indicated<br>immune cell populations. Monocytes and neu plot representation of levels of ITGB7 indicates a wide pattern of expression among indicated<br>
848 immune cell populations. Monocytes and neutrophil granulocytes show low levels of ITGB7.<br>
849 b.) IHC of a representative M immune cell populations. Monocytes and neutrophil granulocytes show low levels of ITGB7.<br>
849 b.) IHC of a representative MBM of a patient with refractory intracranial disease for Iba1 (red,<br>
850 first column) and CD3 (bro b.) IHC of a representative MBM of a patient with refractory intracranial disease for Iba1 (red,<br>850 first column) and CD3 (brown, second column) indicating focal enrichment of<br>851 microglia/macrophages and CD3<sup>+</sup> T cells 850 first column) and CD3 (brown, second column) indicating focal enrichment of<br>851 microglia/macrophages and CD3<sup>+</sup> T cells within ITGB7 positive areas (red, second column).<br>852 Hematoxylin and eosin (H&E) staining shows microglia/macrophages and CD3<sup>+</sup> microglia/macrophages and CD3<sup>+</sup> T cells within ITGB7 positive areas (red, second column).<br>852 Hematoxylin and eosin (H&E) staining shows discrimination of tumor cells and tumor-<br>853 infiltrating lymphocytes (TILs) c.) Exp B52 Hematoxylin and eosin (H&E) staining shows discrimination of tumor cells and tumor-<br>
B53 infiltrating lymphocytes (TILs) c.) Expression (FPKM, log2) of CD4, PD-L1 (CD274) and<br>
B54 SUSD3 in MBM with high or low level o 853 infiltrating lymphocytes (TILs) c.) Expression (FPKM, log2) of CD4, PD-L1 (CD274) and<br>854 SUSD3 in MBM with high or low level of ITGB7, indicating cellular co-occurrence. d.) Dot plot<br>855 showing the significant inver 854 SUSD3 in MBM with high or low level of ITGB7, indicating cellular co-occurrence. d.) Dot plot<br>855 showing the significant inverse correlation (R=-0.87, p=5.2e-05) of β-values (probe<br>856 cg26689077) indicating the met 855 showing the significant inverse correlation (R=-0.87, p=5.2e-05) of β-values (probe<br>856 cg26689077) indicating the methylation level at a side located within the proximal enhancer-<br>857 like structure of the ITGB7 gene eg26689077) indicating the methylation level at a side located within the proximal enhancer-<br>857 like structure of the ITGB7 gene and immune score of MBM (n=14) of study<br>858 EGAS00001005976 (first panel). Box plots represe 857 like structure of the ITGB7 gene and immune score of MBM  $(n=14)$  of study<br>858 EGAS00001005976 (first panel). Box plots represent a significant (p=4.5e-04) or non-<br>859 significant (p=0.86) association of ITGB7 methylat 858 EGAS00001005976 (first panel). Box plots represent a significant (p=4.5e-04) or non-<br>859 significant (p=0.86) association of ITGB7 methylation (probe cg26689077) or BRAF mutation<br>860 status (center and right panels) of significant (p=0.86) association of ITGB7 methylation (probe cg26689077) or BRAF mutation<br>860 status (center and right panels) of all MBM investigated (n=21). e.) Dot plot showing the<br>861 significant correlation of ITGB7 e status (center and right panels) of all MBM investigated (n=21). e.) Dot plot showing the<br>861 significant correlation of ITGB7 expression and immune score of MBM (R=0.51, p=1.8e-06)<br>862 and EM (R=0.61, p=1.1e-09) indicatin significant correlation of ITGB7 expression and immune score of MBM (R=0.51, p=1.8e-06)<br>and EM (R=0.61, p=1.1e-09) indicating immune-related expression of ITGB7 irrespective of<br>the side of metastasis. f.) Correlation map s and EM (R=0.61, p=1.1e-09) indicating immune-related expression of ITGB7 irrespective of<br>863 the side of metastasis. f.) Correlation map showing high association (p<0.05) of ITGB7 with<br>864 relevant immune cell markers such the side of metastasis. f.) Correlation map showing high association (p<0.05) of ITGB7 with<br>relevant immune cell markers such as PD-1 (PDCD1), PD-L1 (CD274), PD-L2 (PDCD1LG2)<br>but low correlation with tumor cell markers NGF relevant immune cell markers such as PD-1 (PDCD1), PD-L1 (CD274), PD-L2 (PDCD1LG2)<br>865 but low correlation with tumor cell markers NGFR, MITF, MLANA or SLC45A2. g.) Dot plot<br>866 showing the significant correlation of ITGB7 but low correlation with tumor cell markers NGFR, MITF, MLANA or SLC45A2. g.) Dot plot<br>866 showing the significant correlation of ITGB7 and expression of PD-L2 (BM: R=0.45, p=3.4e-<br>967 05; EM: R=0.42, p=1.1e-03) and SUSD3 866 showing the significant correlation of ITGB7 and expression of PD-L2 (BM: R=0.45, p=3.4e-<br>867 05; EM: R=0.42, p=1.1e-03) and SUSD3 (BM: R=0.44, p=5.2e-05; EM: R=0.61, p=2.6e-07).<br>868 h.) Dot plot showing the correlatio 05; EM: R=0.42, p=1.1e-03) and SUSD3 (BM: R=0.44, p=5.2e-05; EM: R=0.61, p=2.6e-07).<br>868 h.) Dot plot showing the correlation of ITGB7 expression and immune score of primary (PT;<br>869 R=0.59, p=9.4e-16), metastatic (EM; R=0 h.) Dot plot showing the correlation of ITGB7 expression and immune score of primary (PT;<br>
869 R=0.59, p=9.4e-16), metastatic (EM; R=0.78, p=2.2e-16) and brain metastatic (BM; R=0.2,<br>
870 p=0.61) melanoma (TCGA-SKCM), indi R=0.59, p=9.4e-16), metastatic (EM; R=0.78, p=2.2e-16) and brain metastatic (BM; R=0.2,<br>
870 p=0.61) melanoma (TCGA-SKCM), indicating that expression of ITGB7 is independent from<br>
871 melanoma progression stages. i.) Survi 970 p=0.61) melanoma (TCGA-SKCM), indicating that expression of ITGB7 is independent from<br>871 melanoma progression stages. i.) Survival analysis of TCGA melanoma patients (n=459),<br>29 871 melanoma progression stages. i.) Survival analysis of TCGA melanoma patients (n=459),<br>29<br>29 872 featuring high or low level of ITGB7 and SUSD3 expression revealed significant difference<br>873 (logrank p=4.0e-04 and p=6.6e-08) and Cox-regression analysis showed association with<br>874 favorable disease course (HR=0.60 873 (logrank p=4.0e-04 and p=6.6e-08) and Cox-regression analysis showed association with<br>874 favorable disease course (HR=0.60 and HR=0.48). Box and whisker plots show median<br>875 (center line), the upper and lower quarti 874 favorable disease course (HR=0.60 and HR=0.48). Box and whisker plots show median<br>875 (center line), the upper and lower quartiles (the box), and the range of the data (the<br>876 whiskers), including outliers (a, c, d). center line), the upper and lower quartiles (the box), and the range of the data (the<br>whiskers), including outliers (a, c, d). Significance was determined by unpaired, two-sided t-<br>test (c, d) or one-way ANOVA (a).<br>878 **Fi** whiskers), including outliers (a, c, d). Significance was determined by unpaired, two-sided t-<br>877 test (c, d) or one-way ANOVA (a).<br>878 **Figure 3: Signature-based deconvolution identified parameter of MBM featuring a**<br>879

877 test (c, d) or one-way ANOVA (a).<br>878 **Figure 3: Signature-based dec<br>879 favorable disease course and<br>880 GSEA (ssGSEA)-based deconv** Figure 3: Signature-based deconvolution identified parameter of MBM featuring a<br>1879 favorable disease course and identified a role of MET signaling. a.) Single-sample<br>1880 GSEA (ssGSEA)-based deconvolution of MBM of study 879 **favorable disease course and identified a role of MET signaling**. a.) Single-sample<br>880 GSEA (ssGSEA)-based deconvolution of MBM of study EGAS00001005976 using<br>881 customized gene signatures indicating "Signaling" pro 880 GSEA (ssGSEA)-based deconvolution of MBM of study EGAS00001005976 using<br>881 customized gene signatures indicating "Signaling" processes, cellular subsets and stages of<br>882 microglia and astrocyte and immune cell subset customized gene signatures indicating "Signaling" processes, cellular subsets and stages of<br>
microglia and astrocyte and immune cell subsets. ssGSEA demonstrated distinct separation<br>
of MBM with high, median or low immune microglia and astrocyte and immune cell subsets. ssGSEA demonstrated distinct separation<br>of MBM with high, median or low immune score regarding expression levels of signature<br>genes, BMCs served as controls. ssGSEA uncovere 883 of MBM with high, median or low immune score regarding expression levels of signature<br>884 genes, BMCs served as controls. ssGSEA uncovered differentially activated pathways and<br>885 processes such as MET and STAT3 and i genes, BMCs served as controls. ssGSEA uncovered differentially activated pathways and<br>885 processes such as MET and STAT3 and interferon signaling, senescence (SenMayo), stress<br>886 response and tumor inflammation in tumor processes such as MET and STAT3 and interferon signaling, senescence (SenMayo), stress<br>response and tumor inflammation in tumors enriched for reactive microglia and astrocytes<br>and innate and acquired immune cells subsets. response and tumor inflammation in tumors enriched for reactive microglia and astrocytes<br>and innate and acquired immune cells subsets. b.) Confocal microscopy images of orthotopic<br>tumors established by stereotactic injecti and innate and acquired immune cells subsets. b.) Confocal microscopy images of orthotopic<br>888 tumors established by stereotactic injection of BMC1-M4 or BMC2 cells into brains of<br>889 Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup>, stained fo tumors established by stereotactic injection of BMC1-M4 or BMC2 cells into brains of<br>889 Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup>, stained for Iba1 (green, microglia) or Iba1, GFAP (red, astrocytes)<br>890 and KBA.62 (turquoise, pan-melano Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup> Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup>, stained for Iba1 (green, microglia) or Iba1, GFAP (red, astrocytes)<br>and KBA.62 (turquoise, pan-melanoma cell marker). DAPI served as nuclear dye. Markers<br>show distinct areas of tumor (MBM) and and KBA.62 (turquoise, pan-melanoma cell marker). DAPI served as nuclear dye. Markers<br>
891 show distinct areas of tumor (MBM) and microenvironment (TME) and regions of microglia<br>
892 infiltration, 21 days after intracrania 891 show distinct areas of tumor (MBM) and microenvironment (TME) and regions of microglia<br>892 infiltration, 21 days after intracranial injection<sup>23</sup>. MBM-TME boarders are indicated by white,<br>893 dashed lines. c.) IHC of t infiltration, 21 days after intracranial injection $^{23}$ infiltration, 21 days after intracranial injection<sup>23</sup>. MBM-TME boarders are indicated by white,<br>dashed lines. c.) IHC of tumors investigated in (a) for activation and tyrosine phosphorylation<br>(residue Y705) of STAT3. pST dashed lines. c.) IHC of tumors investigated in (a) for activation and tyrosine phosphorylation<br>894 (residue Y705) of STAT3. pSTAT3<sup>Y705</sup> is particularly present in microenvironmental cells<br>895 (astrocytes). Black, dashed (residue Y705) of STAT3. pSTAT3<sup>Y705</sup> (residue Y705) of STAT3. pSTAT3<sup>Y705</sup> is particularly present in microenvironmental cells<br>
(astrocytes). Black, dashed lines indicate MBM-TME boarders. In b, c, bars indicate 50 µm.<br>
d-e.) Expression levels of hepatocyte g (astrocytes). Black, dashed lines indicate MBM-TME boarders. In b, c, bars indicate 50 µm.<br>
896 d-e.) Expression levels of hepatocyte growth factor (HGF) in tumors of studies<br>
897 EGAS00001005976, TCGA-SKCM and EGAS0000100 896 d-e.) Expression levels of hepatocyte growth factor (HGF) in tumors of studies<br>897 EGAS00001005976, TCGA-SKCM and EGAS00001003672 demonstrating HGF expression<br>898 in all tumor subsets. f-g.) Investigation of HGF expres EGAS00001005976, TCGA-SKCM and EGAS00001003672 demonstrating HGF expression<br>
898 in all tumor subsets. f-g.) Investigation of HGF expression in immune cell subsets (DICE<br>
899 database<sup>35</sup>) and brain cells (study GSE73721) 898 in all tumor subsets. f-g.) Investigation of HGF expression in immune cell subsets (DICE<br>899 database<sup>35</sup>) and brain cells (study GSE73721) revealed highest levels in basophil<br>30 database $^{\rm 35}$ 899 database<sup>35</sup>) and brain cells (study GSE73721) revealed highest levels in basophil<br>30<br>30 granulocytes and monocytes (f) and in astrocytes and microglia (g). h.) UMAP projection of<br>901 expression profiles from nuclei isolated from 5 neurotypical donors as provided by Seattle<br>902 Alzheimer's disease brain cell a expression profiles from nuclei isolated from 5 neurotypical donors as provided by Seattle<br>902 Alzheimer's disease brain cell atlas (https://portal.brain-map.org/explore/seattle-alzheimers-<br>903 disease), cellular subtypes Alzheimer's disease brain cell atlas (https://portal.brain-map.org/explore/seattle-alzheimers-<br>903 disease), cellular subtypes are color coded (left panel). Log-normalized expression levels of<br>904 HGF in nuclei isolated fr disease), cellular subtypes are color coded (left panel). Log-normalized expression levels of<br>904 HGF in nuclei isolated from 5 neurotypical donors (center panel). Log-normalized expression<br>905 levels of HGF in nuclei isol 904 HGF in nuclei isolated from 5 neurotypical donors (center panel). Log-normalized expression<br>905 levels of HGF in nuclei isolated from 84 aged donors (42 cognitively normal and 42 with<br>906 dementia), right panel, demons levels of HGF in nuclei isolated from 84 aged donors (42 cognitively normal and 42 with<br>906 dementia), right panel, demonstrating increased number of HGF expressing microglia and<br>907 astrocytes as triggered by inflammatory dementia), right panel, demonstrating increased number of HGF expressing microglia and<br>astrocytes as triggered by inflammatory processes. i.) Dot plot showing the correlation of<br>HGF expression and immune score of BM (R=0.4 astrocytes as triggered by inflammatory processes. i.) Dot plot showing the correlation of<br>908 HGF expression and immune score of BM (R=0.49, p=5.3e-06) and EM (R=0.41, p=1.5e-03)<br>909 indicating a potential role of HGF in 908 HGF expression and immune score of BM (R=0.49, p=5.3e-06) and EM (R=0.41, p=1.5e-03)<br>909 indicating a potential role of HGF in immune cell-related processes. Box and whisker plots<br>910 show median (center line), the upp 909 indicating a potential role of HGF in immune cell-related processes. Box and whisker plots<br>910 show median (center line), the upper and lower quartiles (the box), and the range of the data<br>911 (the whiskers), including 910 show median (center line), the upper and lower quartiles (the box), and the range of the data<br>911 (the whiskers), including outliers (d-g). Significance was determined by unpaired, two-sided t-<br>912 figure 4: Ecad<sup>+</sup> MB

911 (the whiskers), including outliers (d-g). Significance was determined by unpaired, two-sided t-<br>912 test (e) or one-way ANOVA (g).<br>913 **Figure 4: Ecad<sup>+</sup> MBM are defined by expression of MET receptor.** a.) Schematic<br>91 912 test (e) or one-way ANOVA (g).<br>913 **Figure 4: Ecad<sup>+</sup> MBM are d**<br>914 summary of the initial scre<br>915 (EGAS00001005976; n=16 MBI **Figure 4: Ecad<sup>+</sup> MBM are defined by expression of MET receptor.** a.) Schematic 913 **Figure 4: Ecad<sup>+</sup> MBM are defined by expression of MET receptor.** a.) Schematic<br>914 summary of the initial screen of MBM expression data of our recent study<br>915 (EGAS00001005976; n=16 MBM) for subset expressed recepto 914 summary of the initial screen of MBM expression data of our recent study<br>915 (EGAS00001005976; n=16 MBM) for subset expressed receptors. MBM contain Ecad<sup>+</sup> and<br>916 NGFR<sup>+</sup> subsets and admixed cells such reactive micro (EGAS00001005976; n=16 MBM) for subset expressed receptors. MBM contain Ecad<sup>+</sup> (EGAS00001005976; n=16 MBM) for subset expressed receptors. MBM contain Ecad<sup>+</sup> and<br>916 NGFR<sup>+</sup> subsets and admixed cells such reactive microglia, labeled by expression of<br>917 Iba1/AIF1 and or P2RY12. The initial survey yi NGFR<sup>+</sup> subsets and admixed cells such reactive microglia, labeled by expression of 916 NGFR<sup>+</sup> subsets and admixed cells such reactive microglia, labeled by expression of<br>917 Iba1/AIF1 and or P2RY12. The initial survey yielded 24 receptors that potentially establish<br>918 cell survival/growth of MBM. b.) C 917 Iba1/AIF1 and or P2RY12. The initial survey yielded 24 receptors that potentially establish<br>918 cell survival/growth of MBM. b.) Correlation map (Spearman, p<0.05) showing the<br>919 relationship of identified receptors e ell survival/growth of MBM. b.) Correlation map (Spearman, p<0.05) showing the<br>919 relationship of identified receptors expressed in MBM of our previous study, emphasizing the<br>920 distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> mo relationship of identified receptors expressed in MBM of our previous study, emphasizing the<br>920 distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> molecular subsets. The value of the correlation<br>921 coefficient is color coded. c.) B distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> molecular subsets. The value of the correlation<br>
921 coefficient is color coded. c.) Box plots depicting the levels of most relevant receptors that<br>
922 significantly separated Ecad coefficient is color coded. c.) Box plots depicting the levels of most relevant receptors that<br>922 significantly separated Ecad<sup>high</sup> and Ecad<sup>low</sup> subsets of MBM and extracerebral metastases<br>923 (EM) of study EGAS00001003 significantly separated Ecad<sup>high</sup> and Ecad<sup>low</sup> 922 significantly separated Ecad<sup>nigh</sup> and Ecad<sup>low</sup> subsets of MBM and extracerebral metastases<br>
923 (EM) of study EGAS00001003672, providing MBM = 79, EM = 59 (ADIPOR1, Adiponectin<br>
924 Receptor 1, p=0.019/7.9e-05; SIRP 923 (EM) of study EGAS00001003672, providing MBM = 79, EM = 59 (ADIPOR1, Adiponectin<br>924 Receptor 1, p=0.019/7.9e-05; SIRPA, Signal Regulatory Protein Alpha, p=1.1e-05/0.0046;<br>925 PLXNC1, Plexin C1, p=4.6e-06/3e-04). d.) 924 Receptor 1, p=0.019/7.9e-05; SIRPA, Signal Regulatory Protein Alpha, p=1.1e-05/0.0046;<br>925 PLXNC1, Plexin C1, p=4.6e-06/3e-04). d.) Box plots depicting the levels of MET in Ecad<sup>high</sup><br>926 and Ecad<sup>low</sup> subsets of MBM PLXNC1, Plexin C1, p=4.6e-06/3e-04). d.) Box plots depicting the levels of MET in Ecad<sup>high</sup> 925<br>926<br>927 and Ecad<sup>low</sup> subsets of MBM and EM (left panel,  $p=1.4e-04/p=0.41$ ) or in all subtypes of MBM and EM ( $p=2.7e-05$ ) in high and low proliferating tumor cell subsets (right panel, 31 927 MBM and EM (p=2.7e-05) in high and low proliferating tumor cell subsets (right panel,<br>31<br>31

928 p=9.1e-03). e.) IHC of selected MBM for MET and MITF validated the two subsets. f-g.)<br>929 Expression and activation status of MET in BRAF wildtype (wt; Pts 14, 39) and BRAF<sup>V600E/R</sup><br>930 mutated MBM (Pts 28, 29, 31). P Expression and activation status of MET in BRAF wildtype (wt; Pts 14, 39) and BRAF<sup>V600E/R</sup> 929<br>930<br>931<br>932 mutated MBM (Pts 28, 29, 31). Phosphorylation of MET at residues Y1234/1235 is critical for<br>931 kinase activation. h.) IHC of indicated tumors for co-localization of pMET<sup>Y1234/1235</sup> (brown) and<br>932 Iba1 (red) demonstratin kinase activation. h.) IHC of indicated tumors for co-localization of pMET<sup>Y1234/1235</sup> (brown) and<br>1932 Iba1 (red) demonstrating potential activation of MET receptor signaling tumor cells by stromal<br>1933 cell-secreted HGF. 932 Iba1 (red) demonstrating potential activation of MET receptor signaling tumor cells by stromal<br>933 cell-secreted HGF. i.) Heat map representing expression levels of regulators and targets of<br>934 interferon signaling an ell-secreted HGF. i.) Heat map representing expression levels of regulators and targets of<br>934 interferon signaling and immune related genes showing clustering according to the level of<br>935 ITGB7 expression. Box and whiske 934 interferon signaling and immune related genes showing clustering according to the level of<br>935 ITGB7 expression. Box and whisker plots show median (center line), the upper and lower<br>936 quartiles (the box), and the ran 935 ITGB7 expression. Box and whisker plots show median (center line), the upper and lower<br>936 quartiles (the box), and the range of the data (the whiskers), including outliers (c, d).<br>937 Significance was determined by un

quartiles (the box), and the range of the data (the whiskers), including outliers (c, d).<br>937 Significance was determined by unpaired, two-sided t-test (c, d).<br>938 Figure 5: Inhibitors of MET receptor decrease growth of br 937 Significance was determined by unpaired, two-sided t-test (c, d).<br>938 **Figure 5: Inhibitors of MET receptor decrease growth<br>039 conventional melanoma cell lines.** a.) Comparative IHC of<br>940 phosphorylated and activated Figure 5: Inhibitors of MET receptor decrease growth of brain metastatic and<br>939 conventional melanoma cell lines. a.) Comparative IHC of selected MBM for levels of<br>940 phosphorylated and activated MET receptor (pMET<sup>Y1234</sup> conventional melanoma cell lines. a.) Comparative IHC of selected MBM for levels of<br>940 phosphorylated and activated MET receptor (pMET<sup>Y1234/1235</sup>) and ribosomal protein S6<br>941 (pS6<sup>235/236</sup>) of consecutive sections sugge phosphorylated and activated MET receptor (pMET<sup>Y1234/1235</sup> phosphorylated and activated MET receptor (pMET<sup>Y1234/1235</sup>) and ribosomal protein S6<br>(pS6<sup>235/236</sup>) of consecutive sections suggesting MET-associated activation of mTOR<br>signaling. b.) Immunofluorescence microscopy of lymp  $(pS6^{235/236})$  of consecutive sections suggesting MET-associated activation of mTOR 941 ( $pS6^{235/236}$ ) of consecutive sections suggesting MET-associated activation of mTOR<br>942 signaling. b.) Immunofluorescence microscopy of lymph node-metastatic (T2002) and brain<br>943 metastatic (BMC53) patient-derived 942 signaling. b.) Immunofluorescence microscopy of lymph node-metastatic (T2002) and brain<br>943 metastatic (BMC53) patient-derived melanoma cell lines for co-occurrence of MET (red) and<br>944 pS6<sup>235/236</sup> (green). DAPI serve metastatic (BMC53) patient-derived melanoma cell lines for co-occurrence of MET (red) and<br>944 pS6<sup>235/236</sup> (green). DAPI served as nuclear dye. c.) qPCR analysis of BMCs for expression of<br>945 MET receptor, bars indicate me  $\mathsf{pS6}^{235/236}$ pS6<sup>235/236</sup> (green). DAPI served as nuclear dye. c.) qPCR analysis of BMCs for expression of<br>945 MET receptor, bars indicate median levels ±SD of three biological replicates. d.) Gross initial<br>946 ARQ197 sensitivity test MET receptor, bars indicate median levels ±SD of three biological replicates. d.) Gross initial<br>946 ARQ197 sensitivity test of BMC53 and BMC1-M1 cells showing high and low levels of MET<br>947 expression. Cell density was det 946 ARQ197 sensitivity test of BMC53 and BMC1-M1 cells showing high and low levels of MET<br>947 expression. Cell density was determined by crystal violet staining. e.) Broad range<br>948 determination of sensitivity of BMCs, T2 947 expression. Cell density was determined by crystal violet staining. e.) Broad range<br>
948 determination of sensitivity of BMCs, T2002 and conventional melanoma cell lines (A375,<br>
949 A2058, MeWo) to METi PHA-665752 and 948 determination of sensitivity of BMCs, T2002 and conventional melanoma cell lines (A375,<br>949 A2058, MeWo) to METi PHA-665752 and ARQ197. Cell density and BRAF mutation status<br>950 are indicated. Dotted line depicts the 949 A2058, MeWo) to METi PHA-665752 and ARQ197. Cell density and BRAF mutation status<br>950 are indicated. Dotted line depicts the estimated range of  $IC_{50}$ . f.) PHA-665752 dose-response<br>951 fit curve-based calculation of 950 are indicated. Dotted line depicts the estimated range of  $IC_{50}$ . f.) PHA-665752 dose-response<br>951 fit curve-based calculation of  $IC_{50}$  values of A375 cells with overexpression of NGFR or RFP<br>952 control cells and 951 fit curve-based calculation of IC<sub>50</sub> values of A375 cells with overexpression of NGFR or RFP<br>952 control cells and MeWo cells. g.) Dabrafenib dose-response fit curve-based calculation of<br>953 IC<sub>50</sub> values of BMCs exh 952 control cells and MeWo cells. g.) Dabrafenib dose-response fit curve-based calculation of<br>953 IC<sub>50</sub> values of BMCs exhibiting different BRAF mutations (BMC2<sup>p.N581Y</sup>, BMC4<sup>p.V600K</sup>) and<br>954 A375<sup>p.V600E</sup>, A2058<sup>p.V60</sup>  $IC_{50}$  values of BMCs exhibiting different BRAF mutations (BMC2<sup>p.N581Y</sup>, BMC4<sup>p.V600K</sup> 953 IC<sub>50</sub> values of BMCs exhibiting different BRAF mutations (BMC2<sup>p.N5811</sup>, BMC4<sup>p.v600K</sup>) and<br>954 A375<sup>p.V600E</sup>, A2058<sup>p.V600E</sup> cells. h-i.) Live cell imaging-based tracking of confluence (%) of<br>955 BMC2 and BMC4 cells A375<sup>p.V600E</sup>, A2058<sup>p.V600E</sup>  $4375^{p.9600E}$ , A2058<sup>p.V600E</sup> cells. h-i.) Live cell imaging-based tracking of confluence (%) of<br>955 BMC2 and BMC4 cells in dependence of increasing doses of ARQ197. Shown are median<br>32 955 BMC2 and BMC4 cells in dependence of increasing doses of ARQ197. Shown are median 32

values±SD of eight technical replicates. A representative out of two experiments is shown. j.)<br>957 ARQ197 dose-response fit curves of BMCs, T2002 and conventional cell lines. Calculated<br>958 IC<sub>50</sub> values are indicated, su 957 ARQ197 dose-response fit curves of BMCs, T2002 and conventional cell lines. Calculated<br>958 IC<sub>50</sub> values are indicated, suggesting response of dabrafenib resistant cell lines to METi. k.)<br>959 Bar diagram summarizing I 958 IC<sub>50</sub> values are indicated, suggesting response of dabrafenib resistant cell lines to METi. k.)<br>959 Bar diagram summarizing IC<sub>50</sub> values (nM) indicating the response of indicated cell lines to<br>960 ARQ197. The BRAF s 959 Bar diagram summarizing IC<sub>50</sub> values (nM) indicating the response of indicated cell lines to<br>960 ARQ197. The BRAF status is color coded. I.) Working model suggesting the activation of<br>961 MET receptor signaling in ad 960 ARQ197. The BRAF status is color coded. I.) Working model suggesting the activation of<br>961 MET receptor signaling in adjacent tumor cells and in (reactive) microglia (RM) by microglia<br>962 released HGF. IRF-mediated HGF 961 MET receptor signaling in adjacent tumor cells and in (reactive) microglia (RM) by microglia<br>962 released HGF. IRF-mediated HGF expression in turn is triggered by immune cell<br>963 (monocytes/macrophages, M) released int released HGF. IRF-mediated HGF expression in turn is triggered by immune cell<br>963 (monocytes/macrophages, M) released interferon-gamma. HGF binding to tumor cell (TC)<br>964 expressed MET receptor directs downstream activatio 963 (monocytes/macrophages, M) released interferon-gamma. HGF binding to tumor cell (TC)<br>964 expressed MET receptor directs downstream activation of the RAS/RAF/MEK/ERK and the<br>965 PI3K/AKT/mTOR/p70S6K branch. The latter i expressed MET receptor directs downstream activation of the RAS/RAF/MEK/ERK and the<br>965 PI3K/AKT/mTOR/p70S6K branch. The latter is leading to phosphorylation and activation of<br>966 the ribosomal protein S6. Box and whisker PI3K/AKT/mTOR/p70S6K branch. The latter is leading to phosphorylation and activation of<br>966 the ribosomal protein S6. Box and whisker plots show median (center line), the upper and<br>967 lower quartiles (the box), and the ra

the ribosomal protein S6. Box and whisker plots show median (center line), the upper and<br>967 bower quartiles (the box), and the range of the data (the whiskers), including outliers (c).<br>968 **Figure 6: HGF/MET receptor sign** 967 lower quartiles (the box), and the range of the data (the whiskers), including outliers (c).<br>968 **Figure 6: HGF/MET receptor signaling might be activated in tumor cells at imr<br>969 <b>cell/TAM dense areas.** Schematic repr Figure 6: HGF/MET receptor signaling might be activated in tumor cells at immune<br>
cell/TAM dense areas. Schematic representation of our working model suggesting the<br>
interaction of tumor cells with stromal cells, particula **cell/TAM dense areas.** Schematic representation of our working model suggesting the<br>970 interaction of tumor cells with stromal cells, particularly microglia and immune cells,<br>971 consequentially leading to activation of 970 interaction of tumor cells with stromal cells, particularly microglia and immune cells,<br>971 consequentially leading to activation of MET signaling in tumor cells via stromal cell-released<br>972 HGF. Expression of HGF in 971 consequentially leading to activation of MET signaling in tumor cells via stromal cell-released<br>972 HGF. Expression of HGF in turn and ITGB7 and PD-L1 is likely triggered by T cell provided<br>973 interferon-gamma. Increa 972 HGF. Expression of HGF in turn and ITGB7 and PD-L1 is likely triggered by T cell provided<br>1973 interferon-gamma. Increased levels of ITGB7 may foster recruitment of immune cells.<br>1974 973 interferon-gamma. Increased levels of ITGB7 may foster recruitment of immune cells.<br>974<br>975

975

975

- 977<br>978
- 

978<br>979 979<br>980

980

981 **Supplementary figure legends<br>982 Supplementary figure 1: Iba1/AIF1 exp<br>983 (IF) for Iba1 (red) and GFAP (labeling<br>984 mutated MBM (Pat 15) that progressed of Supplementary figure 1: Iba1/AIF1 expression separates MBM** a.) Immunofluorescence<br>983 (IF) for Iba1 (red) and GFAP (labeling of reactive and normal astrocytes) of a NRAS<sup>Q61R</sup><br>984 mutated MBM (Pat 15) that progressed on (IF) for Iba1 (red) and GFAP (labeling of reactive and normal astrocytes) of a NRAS $^{Q61R}$ 983<br>984<br>985<br>986 mutated MBM (Pat 15) that progressed on treatment with immune checkpoint inhibitors (ICi;<br>ipilimumab) showed strong infiltration of tumor-associated microglia/macrophages (TAMs)<br>and the presence of aggregates of microglia ipilimumab) showed strong infiltration of tumor-associated microglia/macrophages (TAMs)<br>and the presence of aggregates of microglia and reactive astrocytes. MBM (without adjacent<br>stromal cells) of Pat 3 showed high infiltr 986 and the presence of aggregates of microglia and reactive astrocytes. MBM (without adjacent<br>987 stromal cells) of Pat 3 showed high infiltration of TAMs. DAPI served as nuclear dye. b.) Box<br>988 plots representing the le 987 stromal cells) of Pat 3 showed high infiltration of TAMs. DAPI served as nuclear dye. b.) Box<br>988 plots representing the levels (FPKM, log2) of Iba1/AIF1 in MBM and BMC of study<br>989 EGAS00001005976 and MBM and EM of st 988 plots representing the levels (FPKM, log2) of Iba1/AIF1 in MBM and BMC of study<br>989 EGAS00001005976 and MBM and EM of study EGAS00001003672. c.) Per sample<br>990 representation of expression levels (FPKM, log2) of Iba1/A 989 EGAS00001005976 and MBM and EM of study EGAS00001003672. c.) Per sample<br>990 representation of expression levels (FPKM, log2) of Iba1/AlF1 in MBM, brain metastases-<br>991 derived cell lines (BMCs) and brain controls (BC) 990 representation of expression levels (FPKM, log2) of Iba1/AIF1 in MBM, brain metastases-<br>991 derived cell lines (BMCs) and brain controls (BC) of studies mentioned in (b). d-f.) Survival<br>992 analyses of MBM patients (n= 994 Analysis revealed a significant (logrank p=5.5e-07) favorable disease course (HR=0.50, Coxanalyses of MBM patients (n=67) of study EGAS00001003672 or of TCGA-SKCM study<br>
993 (n=459), featuring high or low level of APBB1IP (d, e) or PD-L2 (PDCD1LG2) expression.<br>
994 Analysis revealed a significant (logrank p=5.5 (n=459), featuring high or low level of APBB1IP (d, e) or PD-L2 (PDCD1LG2) expression.<br>994 Analysis revealed a significant (logrank p=5.5e-07) favorable disease course (HR=0.50, Cox-<br>995 regression analysis) of *APBB1IP*<sup>h</sup> 994 Analysis revealed a significant (logrank p=5.5e-07) favorable disease course (HR=0.50, Cox-<br>995 regression analysis) of *APBB1IP*<sup>high</sup> melanoma (e) and favorable outcome associated with<br>996 high levels of PD-L2 expres regression analysis) of *APBB1IP*high regression analysis) of *APBB1IP*<sup>nigh</sup> melanoma (e) and favorable outcome associated with<br>
996 high levels of PD-L2 expression in MBM (f). Survival of MBM patients was not significantly<br>
997 affected by *APBB1IP* levels 996 high levels of PD-L2 expression in MBM (f). Survival of MBM patients was not significantly<br>997 affected by *APBB1IP* levels (d). g.-m.) Correlation and cell type-specificity of microglia<br>998 markers SYK, HCK, P2RY12 an 997 affected by *APBB1IP* levels (d). g.-m.) Correlation and cell type-specificity of microglia<br>998 markers SYK, HCK, P2RY12 and *AIF1*. n.) Dot plot shows significant (R=0.85, p=1.3e-04)<br>999 correlation of *ITGB7* express 998 markers *SYK, HCK, P2RY12* and *AIF1.* n.) Dot plot shows significant (R=0.85, p=1.3e-04)<br>
999 correlation of *ITGB7* expression of MBM (n=16, study EGAS00001005976) and immune<br>
900 score. Box and whisker plots show me orrelation of *ITGB7* expression of MBM (n=16, study EGAS00001005976) and immune<br>000 score. Box and whisker plots show median (center line), the upper and lower quartiles (the<br>001 box), and the range of the data (the whisk score. Box and whisker plots show median (center line), the upper and lower quartiles (the<br>1001 box), and the range of the data (the whiskers), including outliers (b).<br>1002 **Supplementary figure 2: The indicators of favora** 

box), and the range of the data (the whiskers), including outliers (b).<br>1002<br>Supplementary figure 2: The indicators of favorable disease cou<br>1004 APBB1IP are broadly expressed among immune cell subsets 1002<br>1003<br>1004<br>1005 **Supplementary figure 2: The indicators of favorable disease course ITGB7, SUSD3 and**<br>1004 **APBB1IP are broadly expressed among immune cell subsets.** a.) Box plots showing<br>1005 expression levels of ITGB7 among T cell subse **APBB1IP are broadly expressed among immune cell subsets.** a.) Box plots showing<br>
1005 expression levels of ITGB7 among T cell subsets (CD4, T helper cells), CD8 (cytotoxic T<br>
1006 cells), NK cells (natural killer cells), expression levels of ITGB7 among T cell subsets (CD4, T helper cells), CD8 (cytotoxic T<br>1006 cells), NK cells (natural killer cells), cDC (conventional dendritic cells), pDC (plasmacytoid<br>1007 dendritic cells) lymphoid fol 1006 cells), NK cells (natural killer cells), cDC (conventional dendritic cells), pDC (plasmacytoid<br>1007 dendritic cells) lymphoid follicle-residing B cells (FollicularB cell subsets), innate lymphoid<br>34 1007 dendritic cells) lymphoid follicle-residing B cells (FollicularB cell subsets), innate lymphoid<br>34

cells, type 3 (ILC3), mast cells, macrophages (Macro), monocyte subsets (Mono), myofibrils<br>1009 (non-immune related cells), plasma cells (PlasmaB) and tumor-associated macrophages<br>1010 (TAMs) as provided by study GSE146771 (non-immune related cells), plasma cells (PlasmaB) and tumor-associated macrophages<br>1010 (TAMs) as provided by study GSE146771. b.) IHC of MBM of indicated patients for ITGB7.<br>1011 ITGB7 expression is evident in lymphocyte 1010 (TAMs) as provided by study GSE146771. b.) IHC of MBM of indicated patients for ITGB7.<br>1011 ITGB7 expression is evident in lymphocyte-enriched areas. c.-d.) Boxplot showing<br>1012 expression levels of SUSD3 in immune ce 1011 ITGB7 expression is evident in lymphocyte-enriched areas. c.-d.) Boxplot showing<br>1012 expression levels of SUSD3 in immune cell subsets of (a), and shows levels obtained from<br>1013 DICE (Database of Immune Cell Express expression levels of SUSD3 in immune cell subsets of (a), and shows levels obtained from<br>1013 DICE (Database of Immune Cell Expression, Expression quantitative trait loci (eQTLs) and<br>1014 Epigenomics), suggesting broad but DICE (Database of Immune Cell Expression, Expression quantitative trait loci (eQTLs) and<br>1014 Epigenomics), suggesting broad but variable expression among immune cell subsets. e.)<br>1015 Comparative illustration of levels of Epigenomics), suggesting broad but variable expression among immune cell subsets. e.)<br>1015 Comparative illustration of levels of ITGB7 and SUSD3 as requested from DICE. f.) Box plot<br>1016 showing expression levels of APBB1I 1015 Comparative illustration of levels of ITGB7 and SUSD3 as requested from DICE. f.) Box plot<br>1016 showing expression levels of APBB1IP among immune cell subsets of the aforementioned<br>1017 GEO study, suggesting a broad e 1016 showing expression levels of APBB1IP among immune cell subsets of the aforementioned<br>1017 GEO study, suggesting a broad expression among immune cell types. Box and whisker plots<br>1018 show median (center line), the upp 1017 GEO study, suggesting a broad expression among immune cell types. Box and whisker plots<br>1018 show median (center line), the upper and lower quartiles (the box), and the range of the data<br>1019 (the whiskers), including 1018 show median (center line), the upper and lower quartiles (the box), and the range of the data<br>
1019 (the whiskers), including outliers (a, c, d, f).<br>
1020

1019 (the whiskers), including outliers (a, c, d, f).<br>1020<br>1021 **Supplementary figure 3: Methylome prof** 1020<br>1021<br>1022<br>1023 **Supplementary figure 3: Methylome profiling uncovered epigenetic regulatory sites in**<br>1022 **the ITGB7 gene.** a.) Schematic representation of the ITGB7 gene, showing exons, intronic<br>1023 regions and sites of epigenetic mar the ITGB7 gene. a.) Schematic representation of the ITGB7 gene, showing exons, intronic<br>1023 regions and sites of epigenetic marks as depicted by indicated probes. ITGB7 expression<br>1024 levels are associated with methylati regions and sites of epigenetic marks as depicted by indicated probes. ITGB7 expression<br>1024 levels are associated with methylation at sites covered by probes cg26689077 and<br>1025 cg01033299 located within a proximal enhanc levels are associated with methylation at sites covered by probes cg26689077 and<br>1025 cg01033299 located within a proximal enhancer-like signature and intronic region close to 5<sup>2</sup><br>1026 UTR. Additional regions as covered b cg01033299 located within a proximal enhancer-like signature and intronic region close to 5<sup>2</sup><br>1026 UTR. Additional regions as covered by probes cg18320160 and cg11510999 are associated<br>1027 with the BRAF mutation status 1026 UTR. Additional regions as covered by probes cg18320160 and cg11510999 are associated<br>1027 with the BRAF mutation status of tumors. b.-c.) Dot plots showing no significant correlation<br>1028 of methylation status (ind 1027 with the BRAF mutation status of tumors. b.-c.) Dot plots showing no significant correlation of methylation status (indicated by β-values) at sites covered by probes cg18320160 and cg11510999 and immune score. d.-e.) Box pots indicating a significant association of β-values, determined by aforementioned probes (cg11510999, <math display="inline">p = 3e-06</math>; cg18320160, <math display="inline">p = 10e-06</math> 1028 of methylation status (indicated by β-values) at sites covered by probes cg18320160 and<br>1029 cg11510999 and immune score. d.-e.) Box pots indicating a significant association of β-<br>1030 values, determined by aforeme 1029 cg11510999 and immune score. d.-e.) Box pots indicating a significant association of β-<br>1030 values, determined by aforementioned probes (cg11510999, p = 3e-06; cg18320160, p=<br>1031 0.003) and BRAF status (BRAF<sup>V600</sup> values, determined by aforementioned probes (cg11510999, p = 3e-06; cg18320160, p=<br>1031 0.003) and BRAF status (BRAF<sup>V600</sup> vs. wt/NRAS<sup>Q61</sup>) of MBM. Box and whisker plots show<br>1032 median (center line), the upper and lowe 0.003) and BRAF status (BRAF<sup>V600</sup> vs. wt/NRAS<sup>Q61</sup> 1031 0.003) and BRAF status (BRAF<sup>V600</sup> vs. wt/NRAS<sup>Q61</sup>) of MBM. Box and whisker plots show<br>1032 median (center line), the upper and lower quartiles (the box), and the range of the<br>1033 data (the whiskers), including out median (center line), the upper and lower quartiles (the box), and the range of the<br>
1033 data (the whiskers), including outliers (d, e).<br>
1034 1033 data (the whiskers), including outliers (d, e).<br>1034<br>**Algeria** 

Supplementary figure 4: Single sample GSEA revealed classification of immune<br>1036 molecular subtypes of MBM. a.) Single-sample GSEA (ssGSEA)-based deconvolution of<br>1037 MBM (n=79) of study EGAS00001003672 using customized molecular subtypes of MBM. a.) Single-sample GSEA (ssGSEA)-based deconvolution of<br>1037 MBM (n=79) of study EGAS00001003672 using customized gene signatures indicating<br>1038 "Signaling" processes, cellular subsets and stages 1037 MBM (n=79) of study EGAS00001003672 using customized gene signatures indicating<br>1038 "Signaling" processes, cellular subsets and stages of microglia and astrocyte and immune<br>1039 cell subsets. ssGSEA demonstrated dist "1038 "Signaling" processes, cellular subsets and stages of microglia and astrocyte and immune<br>1039 cell subsets. ssGSEA demonstrated distinct separation of MBM with high, median or low<br>1040 immunescore regarding expressio cell subsets. ssGSEA demonstrated distinct separation of MBM with high, median or low<br>1040 immunescore regarding expression levels of signature genes, BMCs served as controls.<br>1041 ssGSEA uncovered differentially activated 1040 immunescore regarding expression levels of signature genes, BMCs served as controls.<br>1041 ssGSEA uncovered differentially activated pathways and processes such as MET and<br>1042 STAT3 and interferon signaling, senescenc 1041 ssGSEA uncovered differentially activated pathways and processes such as MET and<br>1042 STAT3 and interferon signaling, senescence (SenMayo), stress response and tumor<br>1043 inflammation in tumors enriched for reactive m 1042 STAT3 and interferon signaling, senescence (SenMayo), stress response and tumor<br>1043 inflammation in tumors enriched for reactive microglia and astrocytes and innate and<br>1044 acquired immune cells subsets. b.) Boxplot 1043 inflammation in tumors enriched for reactive microglia and astrocytes and innate and<br>1044 acquired immune cells subsets. b.) Boxplot showing expression levels of HGF in indicated<br>1045 immune cell subsets obtained from acquired immune cells subsets. b.) Boxplot showing expression levels of HGF in indicated<br>1045 immune cell subsets obtained from DICE. c.-e.) Expression of MET receptor pathway genes<br>1046 in MBM of study EGAS00001003672 sho immune cell subsets obtained from DICE. c.-e.) Expression of MET receptor pathway genes<br>1046 in MBM of study EGAS00001003672 showing high or low enrichment of microglia, as<br>1047 determined by levels of microglia-specific g in MBM of study EGAS00001003672 showing high or low enrichment of microglia, as<br>1047 determined by levels of microglia-specific genes (SYK, HCK, AlF1/lba1= microglia score<br>1048 suggests a significant correlation of microgl determined by levels of microglia-specific genes (SYK, HCK, AlF1/lba1= microglia score<br>1048 suggests a significant correlation of microglia infiltration and activation of MET receptor<br>1049 signaling. HGF, hepatocyte growth suggests a significant correlation of microglia infiltration and activation of MET receptor<br>1049 signaling. HGF, hepatocyte growth factor (p=1.8e-09); PIK3CG, Phosphatidylinositol-4,5-<br>1050 Bisphosphate 3-Kinase Catalytic signaling. HGF, hepatocyte growth factor (p=1.8e-09); PIK3CG, Phosphatidylinositol-4,5-<br>1050 Bisphosphate 3-Kinase Catalytic Subunit Gamma (p<2.2e-16); PTK2B, Protein Tyrosine<br>1051 Kinase 2 Beta (p<2.2e-16); STAT3, Signal 1050 Bisphosphate 3-Kinase Catalytic Subunit Gamma (p<2.2e-16); PTK2B, Protein Tyrosine<br>1051 Kinase 2 Beta (p<2.2e-16); STAT3, Signal Transducer And Activator Of Transcription 3<br>1052 (p=5.3e-11); MAP4K1; Mitogen-Activated Kinase 2 Beta (p<2.2e-16); STAT3, Signal Transducer And Activator Of Transcription 3<br>1052 (p=5.3e-11); MAP4K1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (p=3.4e-<br>1053 12). Box and whisker plots show median (c (p=5.3e-11); MAP4K1; Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (p=3.4e-<br>1053 12). Box and whisker plots show median (center line), the upper and lower quartiles (the<br>1054 box), and the range of the data (the

1053 12). Box and whisker plots show median (center line), the upper and lower quartiles (the<br>1054 box), and the range of the data (the whiskers), including outliers (b-e).<br>1055 **Supplementary figure 5: MET-FISH analysis r** box), and the range of the data (the whiskers), including outliers (b-e).<br>1055 **Supplementary figure 5: MET-FISH analysis revealed absen<br>1056 <b>amplifications in MBM.** a.) Hematoxylin and eosin (H&E) stair<br>1057 histology (u **Supplementary figure 5: MET-FISH analysis revealed absence of MET receptor**<br>1056 **amplifications in MBM.** a.) Hematoxylin and eosin (H&E) staining shows tumor cell<br>1057 histology (upper row). Fluorescence in-situ hybridiz amplifications in MBM. a.) Hematoxylin and eosin (H&E) staining shows tumor cell<br>1057 histology (upper row). Fluorescence in-situ hybridization with a MET-specific probe (red)<br>1058 revealed no specific amplifications of th histology (upper row). Fluorescence in-situ hybridization with a MET-specific probe (red)<br>1058 revealed no specific amplifications of the MET gene in MBM (n=7) as compared with<br>1059 centromere control (green) and irrespect 1058 revealed no specific amplifications of the MET gene in MBM (n=7) as compared with<br>1059 centromere control (green) and irrespective of the BRAF/NRAS mutation status. DAPI served<br>1060 as nuclear dye, bars indicate 50 µm centromere control (green) and irrespective of the BRAF/NRAS mutation status. DAPI served<br>1060 as nuclear dye, bars indicate 50 µm. b.) Quantitative representation of FISH analysis,<br>1061 indicating the number of MET copies 1060 as nuclear dye, bars indicate 50  $\mu$ m. b.) Quantitative representation of FISH analysis,<br>1061 indicating the number of MET copies per nucleus and ratio of MET and CEP7 (Centromer 7).<br>1062 c.) IHC for Iba1 (red) and indicating the number of MET copies per nucleus and ratio of MET and CEP7 (Centromer 7).<br>1062 c.) IHC for Iba1 (red) and pMET<sup>Y1234/1235</sup> (brown) revealed absence of activated MET in<br>36 c.) IHC for Iba1 (red) and  $\text{pMET}^{\text{Y1234/1235}}$ 1062 c.) IHC for Iba1 (red) and  $pMET^{\gamma_12,34/12,35}$  (brown) revealed absence of activated MET in 36

Iba1<sup>high</sup> microglia residing in adjacent tissue (upper panel) and MET activation in tumor cells 1063 lba1<sup>nigh</sup> microglia residing in adjacent tissue (upper panel) and MET activation in tumor cells<br>1064 without neighboring TAMs. d.) HGF expression in brain cells residing within the different<br>1065 lobes (FL, frontal; without neighboring TAMs. d.) HGF expression in brain cells residing within the different<br>1065 lobes (FL, frontal; PL, parietal; TL, temporal; OL, occipital lobe) and pons as retrieved from<br>1066 the Allan Brain Atlas (http 1065 lobes (FL, frontal; PL, parietal; TL, temporal; OL, occipital lobe) and pons as retrieved from<br>1066 the Allan Brain Atlas (https://portal.brain-map.org/). Box and whisker plots show median<br>1067 (center line), the uppe the Allan Brain Atlas (https://portal.brain-map.org/). Box and whisker plots show median<br>1067 (center line), the upper and lower quartiles (the box), and the range of the data (the<br>1068 whiskers), including outliers (d).<br>1 1067 (center line), the upper and lower quartiles (the box), and the range of the data (the<br>1068 whiskers), including outliers (d).<br>1069 Supplementary figure 6: Expression of interferon-related genes is enriched in MBM of

1068 whiskers), including outliers (d).<br>1069<br>1070 **Supplementary figure 6: Expre**<br>1071 **ITGB7<sup>high</sup>/IScore<sup>high</sup> phenotype** 1069<br>1070<br>1071<br>1072 **Supplementary figure 6: Expression of interferon-related genes is enriched in MBM of<br>1071 ITGB7<sup>high</sup>/IScore<sup>high</sup> phenotype. a.) Heat map indicating expression levels and subset-<br>1072 association of interferon-inducible ITGB7high/IScorehigh** 1071 **ITGB7<sup>nign</sup>/IScore<sup>nign</sup> phenotype.** a.) Heat map indicating expression levels and subset-<br>1072 association of interferon-inducible genes, mediators of interferon signaling and relevant<br>1073 immune cell-expressed mar association of interferon-inducible genes, mediators of interferon signaling and relevant<br>1073 immune cell-expressed markers such as CD3E, CD4, CD8A in MBM (n=79) of study<br>1074 EGAS00001003672. Molecular subsets, category 1073 immune cell-expressed markers such as CD3E, CD4, CD8A in MBM (n=79) of study<br>1074 EGAS00001003672. Molecular subsets, category of genes and strength of expression are<br>1075 color coded. b.-d.) Dot plots indicating the EGAS00001003672. Molecular subsets, category of genes and strength of expression are<br>
1075 color coded. b.-d.) Dot plots indicating the significant correlation of *ITGB7*, *IRF1* (Interferon<br>
1076 Regulatory Factor 1), *IR* color coded. b.-d.) Dot plots indicating the significant correlation of *ITGB7*, *IRF1* (Interferon<br>1076 Regulatory Factor 1), *IRF8* and *IFNG* in MBM and EM of the aforementioned study. e.) Dot<br>1077 plots indicating the 1076 Regulatory Factor 1), *IRF8* and *IFNG* in MBM and EM of the aforementioned study. e.) Dot<br>1077 plots indicating the significant correlation of expression of *HGF*, *IRF1* and *IRF8* in MBM and<br>1078 EM of the aforemen plots indicating the significant correlation of expression of *HGF*, *IRF1* and *IRF8* in MBM and<br>1078 EM of the aforementioned study. f.-g.) Investigation of expression data of murine BV2<br>1079 microglia cells (study GSE13 EM of the aforementioned study. f.-g.) Investigation of expression data of murine BV2<br>1079 microglia cells (study GSE132739) following interferon (1 U/mL IFNy, 24h) or control<br>1080 treatment revealed interferon-responsible microglia cells (study GSE132739) following interferon (1 U/mL IFNγ, 24h) or control<br>1080 treatment revealed interferon-responsible genes. Interferon treatment significantly increased<br>1081 levels of ltgb7 (p=2.9e-03), Hgf treatment revealed interferon-responsible genes. Interferon treatment significantly increased<br>
1081 levels of ltgb7 (p=2.9e-03), Hgf (p=4.4e-02), Mx1 (p=1.2e-02), Cd274 (p=3.6e-02), Irf1<br>
1082 (p=3.1e-02), Cxcl9 (p=4.0e-03 1081 levels of Itgb7 (p=2.9e-03), Hgf (p=4.4e-02), Mx1 (p=1.2e-02), Cd274 (p=3.6e-02), Irf1<br>1082 (p=3.1e-02), Cxcl9 (p=4.0e-03) and Aif1 (p=4.0e-03). However, Susd3 was significantly<br>1083 downregulated upon interferon trea 1082 (p=3.1e-02), Cxcl9 (p=4.0e-03) and Aif1 (p=4.0e-03). However, Susd3 was significantly<br>1083 downregulated upon interferon treatment (p=4.0e-02). h.) ssGSEA analysis of MBM with<br>1084 defined signatures showing enrichmen 1083 downregulated upon interferon treatment (p=4.0e-02). h.) ssGSEA analysis of MBM with<br>1084 defined signatures showing enrichment of interferon-related signaling among other indicated<br>1085 processes. Box and whisker plo defined signatures showing enrichment of interferon-related signaling among other indicated<br>1085 processes. Box and whisker plots show median (center line), the upper and lower quartiles<br>1086 (the box), and the range of th processes. Box and whisker plots show median (center line), the upper and lower quartiles<br>1086 (the box), and the range of the data (the whiskers), including outliers (f, g).<br>1087 **Supplementary figure 7: The mTOR/pS6 sign** 

(the box), and the range of the data (the whiskers), including outliers (f, g).<br>1087<br>**Supplementary figure 7: The mTOR/pS6 signaling is activated in MBM**<br>1089 (Pat 14) for levels of activated/phosphorylated MET receptor (p 1087<br>1088<br>1089<br>1090 **Supplementary figure 7: The mTOR/pS6 signaling is activated in MBM.** a.) IHC of MBM<br>1089 (Pat 14) for levels of activated/phosphorylated MET receptor (pMET<sup>Y1234/1235</sup>) and mTOR/pS6<br>1090 (pS6<sup>S235/236</sup>) signaling revealed (Pat 14) for levels of activated/phosphorylated MET receptor (pMET<sup>Y1234/1235</sup> (Pat 14) for levels of activated/phosphorylated MET receptor (pMET<sup>Y1234/1235</sup>) and mTOR/pS6<br>1090 (pS6<sup>S235/236</sup>) signaling revealed co-occurrence of both. b.) Co-occurrence of pS6<sup>S235/236</sup> and<br>37 (pS6<sup>S235/236</sup>) signaling revealed co-occurrence of both. b.) Co-occurrence of pS6<sup>S235/236</sup>  $($ pS6<sup>S235/236</sup>) signaling revealed co-occurrence of both. b.) Co-occurrence of pS6<sup>S235/236</sup> and<br>37

- 
- 
- 1091 MITF. Bars indicate 50 μm. c.) Confocal microscopy imaging of BMC1-M1 and BMC53 cells<br>1092 for levels of NGFR and MET showing a mutually exclusive expression pattern or low level of<br>1093 MET in NGFR<sup>+</sup> cells. d.) Liv 1092 for levels of NGFR and MET showing a mutually exclusive expression pattern or low level of<br>1093 MET in NGFR<sup>+</sup> cells. d.) Live cell imaging tracked dose-response of BMC1-M1 cells to<br>1094 increasing doses of ARQ197. MET in NGFR<sup>+</sup> cells. d.) Live cell imaging tracked dose-response of BMC1-M1 cells to<br>1094 increasing doses of ARQ197.
- 1094 increasing doses of ARQ197.



Redmer et al., Figure 1







Redmer et al., Figure 2



Redmer et al., Figure 3















# Interferon-induced HGF stimulates MET signaling in MBM

